



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 607 439 B1

(12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
09.01.2002 Bulletin 2002/02

(51) Int Cl.7: C07D 215/00, C07D 235/00,
C07D 239/72, C07D 239/84,
C07D 239/94, C07D 239/95,
A61K 31/47, A61K 31/505

(21) Application number: 92920913.8

(22) Date of filing: 30.09.1992

(86) International application number:
PCT/JP92/01258

(87) International publication number:
WO 93/07124 (15.04.1993 Gazette 1993/10)

(54) NITROGENOUS HETEROCYCLIC COMPOUND

STICKSTOFF ENTHALTENDE HYDROCYCLISCHE VERBINDUNGEN
COMPOSE HETEROCYCLIQUE AZOTE

(84) Designated Contracting States:
AT BE CH DE DK FR GB IE IT LI LU NL SE

(30) Priority: 30.09.1991 JP 32085391

(43) Date of publication of application:
27.07.1994 Bulletin 1994/30

(73) Proprietor: Eisai Co., Ltd.
Tokyo 112-88 (JP)

(72) Inventors:

- TAKASE, Yasutaka
Tsukuba-shi, Ibaraki 305 (JP)
- WATANABE, Nobuhisa
Tsukuba-shi, Ibaraki 305 (JP)
- MATSUI, Makoto
Nagoya-shi, Aichi 466 (JP)
- IKUTA, Hironori
Ushiku-shi, Ibaraki 300-12 (JP)
- KIMURA, Teiji
Tsukuba-shi, Ibaraki 305 (JP)
- SAEKI, Takao
Kitasouma-gun, Ibaraki 302-01 (JP)
- ADACHI, Hideyuki
Inashiki-gun, Ibaraki 300-03 (JP)
- TOKUMURA, Tadakazu
Tsuchiura-shi, Ibaraki 300 (JP)
- MOCHIDA, Hisatoshi
Konan-shi, Aichi 483 (JP)
- AKITA, Yasunori
Tsukuba-gun, Ibaraki 300-24 (JP)
- SOUDA, Shigeru
Ushiku-shi, Ibaraki 300-12 (JP)

(74) Representative:

Hansen, Bernd, Dr. Dipl.-Chem. et al
Hoffmann Eitle, Patent- und Rechtsanwälte,
Postfach 81 04 20
81904 München (DE)

(56) References cited:

WO-A-93/12095	WO-A-94/05661
JP-A- 3 017 068	JP-A- 53 071 088
JP-A- 55 160 776	JP-A- 57 171 973
JP-A- 58 079 983	JP-A- 59 033 264
JP-A- 61 033 185	JP-A- 61 140 568
JP-A- 61 167 688	JP-A- 63 096 174
JP-A- 63 216 884	JP-A- 64 000 074

- CHEMICAL ABSTRACTS, vol. 94, no. 9, 2 March 1981, Columbus, Ohio, US; abstract no. 65554u, TIWARI, S.S. ET AL. 'Search for new anthelmintics- Part II: Synthesis ...' & ACTA CIENC. INDICA, (SER) J. CHEM. 1980, 6(2), 108-11
- CHEMICAL ABSTRACTS, vol. 101, no. 5, 30 July 1984, Columbus, Ohio, US; abstract no. 35051y, D. CRAIG W. ET AL. '1-(4-Aminophenyl)isoquinoline derivatives. Potent inhibitors of calcium-independent and calcium-dependent phosphodiesterases from rat cerebral cortex.' & BIOCHEM. PHARMACOL. 1984, 33(8), 1205-12
- J. Med. Chem., 28(1), 12-17 (1985).

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

EP 0 607 439 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[Field of the Invention]

5 [0001] The present invention relates to a nitrogeous heterocyclic compound having an excellent activity as a drug.

[Background of the Invention and Prior Art]

10 [0002] Angina pectoris which is one of ischemic heart diseases has been known as a disease which often attacks the aged. Although nitric and nitrous acid compounds, calcium antagonists and β -blocker have been used as therapeutic agents therefor, the effect of such a therapeutic agent is far insufficient to treat angina pectoris or to prevent the evolution thereof into myocardial infarction. Recently, the age of a patient with angina pectoris has lowered and the symptom thereof has become complicated owing to change in the style of living, stress increased by the complication of society and so forth, so that a new type of more excellent drug has been desired eagerly.

15 [0003] It is believed that cyclic GMP (hereinafter abbreviated to "cGMP") which is one of cyclic nucleotides and is known as an intracellular second messenger participates in the action of the nitric and nitrous acid compounds among the above drugs which are now used. The relaxing effect of cGMP on the smooth muscle of vessel and bronchus is well known. Although the mechanism of action of these drugs are not always apparent, it is generally presumed that the activity of this cGMP results from the acceleration of the synthesis of cGMP which is caused by the activation of guanylate cyclase. However, the above-mentioned drugs exhibit a low bioavailability and a relatively short time of action. Further, it is reported that the drug resistance is induced, which is a problem in a clinical field.

[0004] Under these circumstances, the present inventors have started studies to develop a new type of more excellent drug.


25 [0005] That is, the present inventors have paid their attention to cGMP phosphodiesterase (hereinafter abbreviated to "cGMP-PDE")-inhibiting activity and have made extensive studies on compounds having such an activity for many years. As a result of the studies, they have found that a nitrogenous heterocyclic compound which will be described below has such an activity to be efficacious for various ischemic heart diseases and have accomplished the present invention.

30 [0006] Although quinazoline derivatives useful as drugs are included in, e.g., Publication of International Patent Application by Japanese No. 502462/1990, they are different from the compounds of the present invention in respect of both structure and activity.

[0007] EP-A-404 322 discloses quinazoline compounds of the general formula

35

40




45 wherein the substituents R²-R⁵ represent hydrogen, C₁-C₄ alkyl or $-(CH_2)_nAr$ wherein Ar is an optionally substituted phenyl ring. These compounds are disclosed to be useful in therapy as inhibitors of gastric acid secretion.

[0008] EP-A-168 151 discloses dihydropyridine cardiovascular agents of the general formula


50

55



wherein R^2 and R^3 represent H or C_1 - C_4 alkyl or may, taken together with the nitrogen atom to which they are bonded, be hetero cyclic ring. These compounds are described to be calcium antagonists and α_1 -antagonists which are useful for the treatment of hypertension, heart failure and angina.


[0009] US 4,734,418 discloses an antihypertensive preparation containing, as an active component, a quinazoline derivative of the following general formula:



wherein R^1 is a hydrogen atom or methoxy group, R^2 and R^3 represent H or a lower alkoxy group and R^4 is a hydrogen atom or an amino group. The index i is 2 or 3, and Het represents a specific heterocyclic ring.

[Disclosure of the invention]

[0010] The present invention provides a nitrogenous heterocyclic compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof:



R^1 , R^2 , R^3 and R^4 , which may be the same or different from one another, represent H, halogen, $-C\equiv N$, C_{1-8} -alkyl or C_{1-8} -hydroxyalkyl (in both of which a terminal C-atom may be replaced by $-ONO_2$ or $-SO_3X$, with $X = H, Na$ or K), acylamino (wherein one or two acyl groups are bonded to the N-atom selected from aliphatic C_{1-5} -acyl, benzoyl, toluoyl, naphthoyl, furoyl, nicotinoyl and isonicotinoyl), optionally protected carboxyl, C_{1-8} -alkoxy,

a group $-S(=O)_n-R^7$, wherein R^7 is C_{1-8} -alkyl (wherein a terminal C-atom may be replaced by $-ONO_2$ or $-SO_3X$, with $X = H, Na$ or K), and $n = 0, 1$ or 2 , or two of R^1 , R^2 , R^3 and R^4 may together form methylenedioxy, ethylenedioxy or a phenyl ring;

R^5 is H, halogen, $-OH$, hydrazino, C_{1-8} -alkyl, C_{1-8} -hydroxyalkyl, C_{2-8} -alkenyl, optionally protected carboxyl- C_{1-8} -alkyl or carboxyl- C_{2-8} -alkenyl (in each of which a terminal C-atom of the alkyl or alkenyl moiety may be replaced by $-ONO_2$ or $-SO_3X$, with $X = H, Na$ or K), optionally protected carboxyl, or C_{1-8} -alkoxy,

a group $-S(=O)_m-R^8$, wherein R^8 is C_{1-8} -alkyl (wherein a terminal C-atom may be replaced by $-ONO_2$ or $-SO_3X$, with $X = H, Na$ or K), and $m = 0, 1$ or 2 ,

a group $-O-R^9$, wherein R^9 is optionally protected C_{1-8} -hydroxyalkyl or carboxy- C_{1-8} -alkyl (in each of which a terminal C-atom may be replaced by $-ONO_2$ or $-SO_3X$, with $X = H, Na$ or K), or benzyl which may optionally be substituted with $-OH$, nitro, halogen, C_{1-4} -alkyl, C_{1-4} -alkoxy, optionally protected carboxyl, C_{1-4} -hydroxyalkyl, carboxyl- C_{1-4} -alkyl or tetrazolyl, a phenyl group substituted with a group R^{23} , R^{23} is

-OH, or C₁₋₈-alkyl, C₁₋₈-hydroxyalkyl or C₁₋₈-hydroxyalkyloxy (in each of which a terminal C-atom may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K), or C₁₋₈-alkoxy,


a 5- to 7-membered monocyclic or condensed heteroaryl group containing one or two O-, N-, or S-atom(s) as heteroatom(s) or a 1,3-benzodioxolyl, 1,4-benzodioxyl, 1,3-benzodioxolylalkyl or 1,4-benzodioxylalkyl group, which each may optionally be substituted with -OH, nitro, halogen, C₁₋₄-alkyl, C₁₋₄-alkoxy, optionally protected carboxyl, C₁₋₄-hydroxyalkyl, carboxyl-C₁₋₄-alkyl or tetrazolyl,

a group -C(R²⁴)=O or -C(R²⁴)=N-R¹⁰, wherein R²⁴ is H or C₁₋₈-alkyl (wherein in the alkyl moiety a terminal C-atom may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K) and R¹⁰ is -OH or an optionally protected carboxyl-C₁₋₈-alkyloxy group (wherein in the alkyl moiety a terminal C-atom may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K),

a group -NR¹¹R¹² (wherein R¹¹ and R¹², which may be the same or different from each other, each represent H, C₁₋₈-alkyl, C₁₋₈-hydroxyalkyl, C₁₋₈-aminoalkyl optionally protected carboxyl-C₁₋₈-alkyl, or (C₁₋₈-alkyl)carbamoyl (in each of which a terminal C-atom of the alkyl moiety may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K), 1,3-benzoxolylalkyl or 1,4-benzodioxylalkyl,

or R¹¹ and R¹², together with the nitrogen to which they are bonded, can form a ring which may contain another nitrogen or oxygen, and which may optionally be substituted with one or two substituents selected from optionally protected -OH, -C≡N, halogen, C₁₋₄-alkyl, C₁₋₄-alkoxy, optionally protected carboxyl, C₁₋₄-hydroxyalkyl, carboxyl-C₁₋₄-alkyl or tetrazolyl;

R6 is a group of the formula



wherein R¹⁹ is H, C₁₋₈-alkyl, C₁₋₈-hydroxyalkyl, C₁₋₂-alkoxy-C₁₋₈-alkyl, optionally protected carboxyl-C₁₋₈-alkyl (in each of which a terminal C-atom of the alkyl moiety may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K) or an acyl group selected from aliphatic C₁₋₅-acyl, benzoyl, toluoyl, naphthoyl, furoyl, nicotinoyl and isonicotinoyl;

R²⁰, R²¹ and R²², which may be the same or different each represent H, halogen, -OH, -NO₂, amino, C₁₋₈-alkyl, C₁₋₂-alkoxy-C₁₋₈-alkyl, C₂₋₈-alkenyl C₁₋₈-alkylsulfonylamino, hydroxyimino-C₁₋₈-alkyl, mono- or di-((C₁₋₈-alkyl)oxycarbonyl)amino, (C₁₋₈-alkyl)oxycarbonyloxy (in each of which a terminal C-atom of the alkyl or alkenyl moiety may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K) or C₁₋₈-alkoxy,

an acyl group selected from aliphatic C₁₋₅-acyl, benzoyl, toluoyl, naphthoyl, furoyl, nicotinoyl and isonicotinoyl; an acylamino group, wherein one or two acyl groups as defined above are bonded to the N-atom of the amino group,

a 5- to 7-membered monocyclic or condensed heteroaryl group containing one or two O-, N-, or S-atom(s) as heteroatom(s), which may optionally be substituted with -OH, nitro, halogen, C₁₋₄-alkyl, C₁₋₄-alkoxy, optionally protected carboxyl, C₁₋₄-hydroxyalkyl, carboxyl-C₁₋₄-alkyl or tetrazolyl,

or two of R²⁰, R²¹ and R²², together with the carbon atoms to which they are bonded, may form a saturated or unsaturated ring which may contain one or two heteroatom(s) independently selected from O and N, or an S-atom,

and r is 0 or an integer of 1 to 8.

[0011] The present invention also provides a preventive or therapeutic agent for diseases for which phosphodiesterase-inhibiting action is efficacious, especially for which cyclic-GMP phosphodiesterase-inhibiting action is efficacious, which contains a nitrogenous heterocyclic compound or a pharmacologically acceptable salt thereof described above as the active ingredient.

[0012] As diseases described above, ischemic heart diseases, concretely angina pectoris, hypertension, heart failure and asthma, are cited.

[0013] Furthermore, the present invention provides a drug composition comprising a nitrogenous heterocyclic compound and/or a pharmacologically acceptable salt thereof described above and a pharmacologically acceptable filler.

[0014] The present invention provides a use of a nitrogenous heterocyclic compound or a pharmacologically acceptable salt thereof to prepare a therapeutic agent for diseases for which phosphodiesterase-inhibiting action is efficacious, and a treating method for a disease which comprises administering a therapeutic effective amount of a nitrogenous heterocyclic compound and/or a pharmacologically acceptable salt thereof to a patient suffering from a disease for which phosphodiesterase-inhibiting action is efficacious.

[0015] The C₁₋₈-alkyl group defined with respect to R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R¹¹, R¹², R¹⁹, R²⁰, R²¹, R²², R²³, and R²⁴ in the above definition of the compound (1) according to the present invention is a straight-chain or branched alkyl group having 1 to 8 carbon atoms and examples thereof include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group (amyl group), neopentyl group, tert-pentyl group, 2-methylbutyl group, 3-methylbutyl group, 1,2-dimethylpropyl group, hexyl group, isohexyl group, 1-methylpentyl group, 2-methylpentyl group, 3-methylpentyl group, 2,2-dimethylbutyl group, 2,3-dimethylbutyl group, 3,3-dimethylbutyl group, 2-ethylbutyl group, 1,1,2-trimethylpropyl group, 1,2,2-trimethylpropyl group, 1-ethyl-1-methylpropyl group, 1-ethyl-2-methylpropyl group, heptyl group and octyl group. Among these groups, methyl group, ethyl group, propyl group and isopropyl group are cited as preferable ones. Among these groups, methyl group and ethyl group are cited as still preferable ones.

[0016] In these C₁₋₈-alkyl groups, a carbon atom at its terminal may be represented by a sulfonic acid group (-SO₃H) or a group represented by the formula -ONO₂. Furthermore, the sulfonic acid group may form a salt such as groups represented by the formulas -SO₃Na and -SO₃K.

[0017] The C₁₋₈-alkyl group which may be substituted with a halogen atom used in the definition of R¹, R², R³ and R⁴ refers to a C₁₋₈-alkyl group described above in which one or two or more hydrogen atoms may be replaced by halogen atom(s).

[0018] The C₁₋₈-alkoxy group defined with respect to R¹, R², R³, R⁴, R⁵, R⁶, R²⁰, R²¹, R²², and R²³ is a straight-chain or branched alkoxy group having 1 to 8 carbon atoms and examples thereof include methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, 2-methylbutoxy group, 2,3-dimethylbutoxy group and hexyloxy group. Among these groups, methoxy group and ethoxy group are cited as preferable ones.

[0019] The C₂₋₈-alkenyl group defined with respect to R⁵, R⁶, R²⁰, R²¹ and R²² is one derived from the above-mentioned C₁₋₈-alkyl group and examples thereof include ethylene group, propylene group, butylene group and isobutylene group.

[0020] The hydroxyalkyl group defined with respect to R¹, R², R³, R⁴, R⁵, R¹¹, R¹², R¹⁹, and R²³ is one derived from the above-mentioned C₁₋₈-alkyl group.

[0021] The hydroxyalkyl group which may be protected used in the definition of R⁹ refers to a hydroxyalkyl group wherein the hydroxyl group is protected with, for example, nitro group, a C₁₋₈-alkyl group as described above such as methyl group and ethyl group, an acyl group such as acetyl group, propionyl group, butyryl group, pivaloyl group and nicotinoyl group or other group which may have a c-GMP PDE-inhibitory activity. The nitrogenous heterocyclic compound thus protected according to the present invention exhibits an effect as a drug after being deprotected the protective group in vivo or as such.

[0022] The acyl group defined with respect to R¹⁹, R²⁰, R²¹ and R²² is one derived from an aliphatic one, an aromatic one or a heterocycle and examples thereof include C₁₋₅ alkanoyl groups such as formyl group, acetyl group, propionyl group, butyryl group, valeryl group, isovaleryl group and pivaloyl group; aroyl groups such as benzoyl group, toluoyl group and naphthoyl group; and heteroaroyl groups such as furoyl group, nicotinoyl group and isonicotinoyl group. Among these groups, formyl group, acetyl group and benzoyl group are cited as preferable ones.

[0023] The carboxyl-protective group defined with respect to R¹, R², R³, R⁴, R⁵, and R⁵ includes lower alkyl groups such as methyl group, ethyl group and t-butyl group; lower alkyl groups substituted with a phenyl group which may have a substituent, such as p-methoxybenzyl group, p-nitrobenzyl group, 3,4-dimethoxybenzyl group, diphenylmethyl group, trityl group and phenethyl group; halogenated lower alkyl groups such as 2,2,2-trichloroethyl group and 2-iodoethyl group; lower alkanoyloxy lower alkyl groups such as pivaloyloxymethyl group, acetoxymethyl group, propionyloxymethyl group, butyryloxymethyl group, valeryloxymethyl group, 1-acetoxyethyl group, 2-acetoxyethyl group, 1-pivaloyloxyethyl group and 2-pivaloyloxyethyl group; higher alkanoyloxy lower alkyl groups such as palmitoyloxyethyl group, heptadecanoyloxymethyl group and 1-palmitoyloxyethyl group; lower alkoxy-carbonyloxy lower alkyl groups such as methoxycarbonyloxymethyl group, 1-butoxycarbonyloxyethyl group and 1-(isopropoxycarbonyloxy)ethyl group; ethyl group; carboxy lower alkyl groups such as carboxymethyl group and 2-carboxyethyl group; heterocyclic groups such as 3-phthalidyl group; benzoyloxy lower alkyl groups which may have a substituent, such as 4-glycyloxybenzoyloxymethyl group and 4-[N-(t-butoxycarbonyl)glycyloxy]benzoyloxymethyl group; (substituted dioxolene) lower alkyl groups such as (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group; cycloalkyl-substituted lower alkanoyloxy lower alkyl groups such as 1-cyclohexylacetyloxyethyl group; and cycloalkyloxycarbonyloxy lower alkyl groups such as 1-cyclohex-

ylloxycarbonyloxyethyl group.

[0024] Further, the protected carboxyl group also includes various acid amides groups. That is, the protected carboxyl group may be any one, so far as it can be deprotected in vivo to give a carboxyl group. The nitrogenous heterocyclic compound thus protected according to the present invention exhibits an effect as a drug after being deprotected the protective group in vivo or as such.

[0025] Although the cycloalkyl group which may be substituted used in the definition of R¹, R², R³, R⁴, and R⁵ refers to one having 3 to 8 carbon atoms, those having 3 to 6 carbon atoms are preferable.

[0026] The heteroaryl group constituting the heteroaryl group which may be substituted defined with respect to R⁵, R²⁰, R²¹ and R²² is a 5- to 7-membered monocyclic group or a condensed heterocyclic group each containing one to two oxygen atom(s), nitrogen atom(s) or sulfur atom(s) as the heteroatom(s) and examples thereof include furyl group, pyridyl group, thienyl group, imidazolyl group, quinazolyl group and benzimidazolyl group.

[0027] The heteroaryl group constituting the heteroarylalkyl group which may be substituted defined with respect to R¹¹ and R¹² refers to any of the heteroaryl groups described above. Further, the alkyl group constituting the heteroaryl group refers to any of the C₁₋₈-alkyl groups described above.

[0028] "R¹¹ and R¹² and the nitrogen atom to which both groups are bonded may together form a ring which may contain another nitrogen atom or an oxygen atom" described in the definition of R¹¹ and R¹²

refers to piperidino group, piperazino group and morpholino group as specific examples. Further, the substituent with which the ring may be substituted includes hydroxyl group; halogen atoms such as chlorine atom, fluorine atom, bromine atom and iodine atom; C₁₋₄-alkyl groups such as methyl, ethyl and t-butyl; C₁₋₄-alkoxy groups such as methoxy, ethoxy and t-butoxy; cyano groups; carboxyl groups which may be protected; hydroxyalkyl groups; carboxyalkyl groups; heteroaryl groups such as tetrazolyl group; and so on. The ring may have one to two substituents described above.

[0029] The substituent constituting the "heteroaryl group which may be substituted" contained in the definition of R⁵, R²⁰, R²¹ and R²², the "phenylalkyloxy group which may be substituted" contained in the definition of R⁶, the "1,3-benzodioxolyl group which may be substituted, 1,4-benzodioxyl group which may be substituted, 1,3-benzodioxylalkyl group which may be substituted or 1,4-benzodioxylalkyl group which may be substituted" contained in the definition of R⁵, the "benzyl group which may be substituted" defined with respect to R⁹ and the "heteroarylalkyl group which may be substituted" defined with respect to R¹¹ and R¹² includes, for example, hydroxyl group; nitro group; halogen atoms such as chlorine atom, fluorine atom, bromine atom and iodine atom; C₁₋₄-alkyl groups such as methyl, ethyl and t-butyl; C₁₋₄-alkoxy groups such as methoxy, ethoxy and t-butoxy; carboxyl groups which may be protected; hydroxyalkyl groups; carboxyalkyl groups; tetrazolyl group; and so on. Although the acylamino group defined with respect to R¹, R², R³, R⁴, R²⁰, R²¹ and R²² refers to an amino group wherein an acyl group(s) as described above is(are) bonded to the nitrogen atom of the amino group, i.e., monoacylamino group or diacylamino group, the monoacylamino group is preferred.

[0030] The halogen atom defined with respect to R¹, R², R³, R⁴, R⁵, R⁶, R²⁰, R²¹, R²² and R⁵⁰ includes fluorine atom, chlorine atom, bromine atom and iodine atom.

[0031] The carboxylalkyl group which may be protected defined with respect to R⁵, R⁹, R¹⁰, R¹¹, R¹² and R¹⁹ is a carboxyalkyl group wherein the carboxyl group may be protected with the carboxyl-protective group described above. Further, the carboxy group(s) in this carboxyalkyl group may be bonded to any and one to two carbon atom(s) of the C₁₋₈-alkyl group as described above.

[0032] The carboxyalkenyl group which may be protected defined with respect to R⁵ refers to a carboxyalkenyl group wherein the carboxyl group is protected with the carboxyl-protective group described above. Further, the carboxy group(s) in this carboxyalkenyl group may be bonded to any and one to two carbon atom(s) of the C₁₋₈-alkyl group as described above.

[0033] The C₁₋₂-alkoxy-C₁₋₈-alkyl group defined with respect to R¹⁹, R²⁰, R²¹ and R²² is one derived from the above-mentioned C₁₋₈-alkyl group and examples thereof include methoxymethyl group, methoxyethyl group, methoxybutyl group and ethoxyethyl group.

[0034] The aminoalkyl group defined with respect to R¹¹ and R¹² refers to a C₁₋₈-alkyl group as described above wherein an amino group is bonded to any of the carbon atoms constituting the C₁₋₈-alkyl group.

[0035] The alkylcarbamoyl group defined with respect to R¹¹ and R¹² refers to one derived from the above-mentioned C₁₋₈-alkyl group.

[0036] The carboxyalkylcarbamoyl group which may be protected used in the definition of R¹¹ and R¹² refers to any of the alkylcarbamoyl groups described above which has a carboxyl group, which may be protected, bonded to any carbon atom of the alkyl.

[0037] The alkylsulfonylamino group defined with respect to R²⁰, R²¹ and R²² refers to one derived from the above-mentioned C₁₋₈-alkyl group.

[0038] The hydroxyiminoalkyl group defined with respect to R²⁰, R²¹ and R²² is a C₁₋₈-alkyl group as described above wherein a hydroxyimino group is bonded to any of the carbon atoms constituting the C₁₋₈-alkyl group.

[0039] Although the alkylloxycarbonylamino group defined with respect to R²⁰, R²¹ and R²² is an amino group wherein

the nitrogen atom of the amino group is mono- or disubstituted with an alkyloxycarbonyl derived from the above-mentioned C₁₋₈-alkyl group, the monosubstituted alkyloxycarbonylamino group is preferable.

[0040] The alkyloxycarbonyloxy group defined with respect to R²⁰, R²¹ and R²² refers to a group wherein an alkyloxycarbonyl derived from the above-mentioned C₁₋₈-alkyl group is bonded to an oxygen atom.


5 [0041] The hydroxyalkyloxy group defined with respect to R²³ refers to one derived from the hydroxyalkyl group described above.

[0042] The pharmacologically acceptable salt includes inorganic acid salts such as hydrochloride, hydrobromide, sulfate and phosphate; organic acid salts such as acetate, maleate, tartrate, methanesulfonate, benzenesulfonate and toluenesulfonate; and amino acid salts such as arginine, aspartate and glutamate. Further, some of the compounds
10 may form metal salts such as Na, K, Ca or Mg, and the pharmacologically acceptable salt of the present invention also includes these metal salts.

[0043] Although the compound of the present invention may be present as various isomers including geometrical isomers, i.e., cis-isomer and trans-isomer, and optical isomers, i.e., d-isomer and l-isomer depending upon the kinds and combination of the substituents, it is needless to say that the compounds of the present invention includes all of
15 the isomers.

[0044] Preferable specific examples of the compound of the present invention will now be described in order to facilitate the understanding of the present invention, though it is needless to say that the compounds of the present invention are not limited to these examples.

20 [0045] The most desirable specific examples of the compound include compounds represented by the following general formula (A) and pharmacologically acceptable salts thereof:



[in general formula (A), R¹, R², R³, R⁴, R¹¹, R¹², R¹⁹, R²⁰, R²¹, R²² and r are the same as those in general formula (1)].

35 [0046] As R¹, R², R³ and R⁴, each of which may be the same or different from one another, hydrogen atom, a halogen atom and cyano group are preferable and, among them, hydrogen atom, cyano group and chlorine atom are still preferable.

[0047] To enter into details with respect to the combination of R¹, R², R³ and R⁴, it is desirable that one of R¹, R², R³ and R⁴ is cyano group or chlorine atom and the others are hydrogen atoms and, among them, it is most desirable
40 that R² is cyano group or chlorine atom and R¹, R³ and R⁴ are hydrogen atoms.

[0048] As R¹¹ and R¹², each of which may be the same or different from each other, hydrogen atom, a C₁₋₈-alkyl group and a carboxyalkyl group which may be protected are preferable and, among these, hydrogen atom, methyl group and 3-carboxypropyl group are preferable.

[0049] Further, it is most desirable that R¹¹ and R¹², together with the nitrogen atom to which they are bonded, form
45 a ring which may be substituted, and among them, a piperidine ring is most desirable. It is still preferable that this ring is substituted with a C₁₋₄-alkyl group, a C₁₋₄-alkoxy group, a carboxyl group which may be protected, a hydroxyl group, a halogen atom, a hydroxyalkyl group or a carboxyalkyl group, and among them, a carboxyl group which may be protected is most preferable.

50 [0050] R¹⁹ is preferably a hydrogen atom or a C₁₋₈-alkyl group such as methyl group and ethyl group, particularly preferably a hydrogen atom.

[0051] r is desirably 0, 1 or 2, most desirably 1.


[0052] As R²⁰, R²¹ and R²², a hydrogen atom, a C₁₋₈-alkyl group, a C₁₋₈-alkoxy group and a halogen atom are preferable, or it is preferable that two of R²⁰, R²¹ and R²² together form methylenedioxy or ethylenedioxy.

55 [Preparation process]

[0053] Representative processes for the preparation of the compound according to the present invention will now be described below.

Preparation process 1

[0054] When R^5 is a hydrogen atom, a halogen atom or a group selected from among those which are directly bonded to the quinazoline skeleton through a carbon atom in the general formula (I), a compound represented by the general formula (I) can also be prepared by the following process:



15

20

phosphorus oxychloride or
phosphorus oxychloride + phosphorus
pentachloride / heating



(in a series of formulas, R^5 is a hydrogen atom, a halogen atom or a group selected from among those which are directly bonded to the quinazoline skeleton through a carbon atom in R^5 described above; and R^1 , R^2 , R^3 and R^4 are each as defined above.




[0055] That is, this process is one for preparing a quinazoline derivative represented by the general formula (III) by reacting a quinazoline derivative represented by the general formula (II) with phosphorus oxychloride or by reacting it with phosphorus oxychloride in the presence of phosphorus pentachloride under heating.

Preparation process 2

[0056] When R^5 is a group selected from among a hydrogen atom, a halogen atom, a group represented by the formula



(wherein R^8 and m are each as defined above), a group represented by the formula $-O-R^9$ (wherein R^9 is as defined above), a heteroaryl group which may be substituted and a group which is directly bonded to the ring through a carbon atom (for example, a C_{1-6} -alkyl group, a carboxyl group which may be protected, a 1,3-benzodioxolyl group which may be substituted, a 1,4-benzodioxyl group which may be substituted, a 1,3-benzodioxylalkyl group which may be substituted and a 1,4-benzodioxylalkyl group which may be substituted), a compound represented by the general formula (I) can be prepared by the following process:



[in a series of formulas, R^1 , R^2 , R^3 and R^4 are each as defined above; $\text{R}^{\text{E}}_{\text{b}}$ represents a group selected from among a hydrogen atom, a halogen atom, a group represented by the formula



35 (wherein R^{E} and m are each as defined above), a group represented by the formula $-\text{O}-\text{R}^{\text{E}}$ (wherein R^{E} is as defined above), a heteroaryl group which may be substituted and a group which is directly bonded to the ring through a carbon atom (for example, a C_{1-6} -alkyl group, a carboxyl group which may be protected, a 1,3-benzodioxolyl group which may be substituted, a 1,4-benzodioxyl group which may be substituted, a 1,3-benzodioxolylalkyl group which may be substituted and a 1,4-benzodioxylalkyl group which may be substituted); $\text{R}^{\text{E}}_{\text{a}}$ represents a group selected from among those defined above with respect to R^{E} ; and E represents an eliminable group].

40 [0057] That is, this process is one for preparing an objective compound (V) by condensing a quinazoline derivative represented by the general formula (IV) with a compound represented by the general formula (VI).

[0058] The eliminable group represented by E in the formula includes halogen atoms and alkoxy groups.

[0059] This process may be conducted in the presence of a base at need.


45 [0060] The base includes organic bases such as triethylamine, pyridine and diisopropylethylamine; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, sodium hydroxide and sodium hydride; and alkoxides such as sodium methoxide and potassium t-butoxide.

[0061] As the reaction solvent, every solvent which is inert to the reaction can be used and examples thereof include ethanol, isopropyl alcohol, tetrahydrofuran, dimethylformamide and dimethyl sulfoxide. This process can be conducted even in the absence of any solvent in some cases.


50 [0062] The reaction temperature preferably ranges from -20 to 300°C .

Preparation process 3

55 [0063] When R^{E} is a group selected from among those defined above with respect to R^{E} except a hydrogen atom, halogen atoms and groups which are directly bonded to the quinazoline skeleton through a carbon atom, a compound represented by the general formula (I) can be prepared by the following process:



(VII)

$$\downarrow \text{H}-\text{R}^5_{\text{c}} \text{ or its salt} \quad (\text{IX})$$


(VIII)

(in a series of formulas, R^1 , R^2 , R^3 and R^4 are each as defined above; R^5_{c} is a group selected from among those defined above with respect to R^5 except a hydrogen atom, halogen atoms and groups which are directly bonded to the quinazoline skeleton through a carbon atom;

R^6_{b} is a group selected from among those defined above with respect to R^6 ; and
F represents an eliminable group).

[0064] That is, this process is one for preparing an objective compound (VIII) by condensing a compound represented by the general formula (VII) with a compound represented by the general formula (IX).

[0065] The eliminable group represented by F in the formula includes, for example, halogen atoms, alkylthio groups and so forth.

[0066] This process may be conducted in the presence of a base at need.

[0067] The base includes organic bases such as triethylamine, pyridine and diisopropylethylamine; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, sodium hydroxide and sodium hydride; and alkoxides such as sodium methoxide and potassium t-butoxide.

[0068] As the reaction solvent, every solvent which is inert to the reaction can be used and examples thereof include ethanol, isopropanol, tetrahydrofuran, dimethylformamide and dimethyl sulfoxide.


[0069] The reaction temperature preferably ranges from 0 to 300°C.

Preparation process 4

[0070] When R^5 is a group represented by the formula



(wherein R^{24} is a hydrogen atom or a C_{1-8} -alkyl group in the general formula (I), a compound represented by the general formula (I) can also be prepared by the following process:



(in a series of formulas, R^1 , R^2 , R^3 , R^4 and R^6 are each as defined above; and R^{24} and R^{25} , each of which may be the same or different from each other, represent each a hydrogen atom or a C_{1-8} -alkyl group).

[0071] That is, this process is one for preparing an objective compound (XI) by reacting a compound represented by the general formula (X) with an ordinary reducing agent or an ordinary nucleophilic reagent, either directly or through the oxidation of an alcohol (XII).

[0072] The reducing agent includes lithium aluminum hydride, sodium borohydride, diisobutylaluminum hydride and so forth.

[0073] The nucleophilic reagent includes lower alkyl metals such as methyl lithium, methylmagnesium bromide and so forth.


[0074] The oxidizing agent to be used when the reaction is conducted through the alcohol (XII) includes potassium bichromate/sulfuric acid, dimethyl sulfoxide/oxalyl chloride and so forth.

[0075] As the reaction solvent, every solvent which is inert to the reaction can be used.




[0076] The reaction temperature ranges from 0°C to the refluxing temperature of the solvent.

Preparation process 5

[0077] When R^5 is a group represented by the formula



(wherein R^{10} and R^{24} are each as defined above) in the general formula (I), a compound represented by the general formula (I) can also be prepared by the following process:



25 (in a series of formulas, R¹, R², R³, R⁴, R⁶, R¹⁰ and R²⁴ are each as defined above).


[0078] That is, this process is one for preparing a compound represented by the formula (XIII) by reacting a compound represented by the general formula (XI) with hydroxylamine.

[0079] As the reaction solvent, every solvent which is inert to the reaction can be used.



[0080] The reaction temperature ranges from 0°C to the refluxing temperature of the solvent.

30 Preparation process 8

[0081] When R⁶ is a group represented by the formula



(wherein R¹⁹, R²⁰, R²¹ and r are each as defined above) in the general formula (I), a compound represented by the general formula (I) can also be prepared by the following process:



(in a series of formulas, R^1 , R^2 , R^3 , R^4 , R^5 , R^{13} , R^{20} , R^{21} and r are each as defined above).

30 [0082] That is, this process is one for preparing an objective compound (XX) by reducing a compound represented by the general formula (XIX).


[0083] The reduction is conducted by conventional means, e.g., catalytic reduction using palladium/carbon or platinum catalyst or reduction with iron or tin.

35 [0084] As the reaction solvent, every solvent which is inert to the reaction can be used.

Preparation process 9


40 [0085] When R^5 is a group represented by the formula $-O-R^9$ (wherein R^9 is a carboxyl group which may be protected) in the general formula (I), a compound represented by the formula (I) can be prepared by the following process:

(The first step)



55

Oxidation



10 (in a series of formulas, R¹, R², R³, R⁴ and R⁵ are each as defined above; and m represents 0 or an integer of 1 to 2).


[0086] That is, this process is one for preparing a compound represented by the general formula (XXII) by oxidizing a compound represented by the general formula (XXI) by conventional means.


15 [0087] As the oxidizing agent, everyone can be used so far as it is conventionally used and examples thereof include chromium (VI), dimethyl sulfoxide and oxalyl chloride.

[0088] As the reaction solvent, every solvent which is inert to the reaction can be used.

[0089] The reaction temperature ranges from 0°C to the refluxing temperature of the solvent.

20 (The second step)






or



↓ Wittig reaction




(in a series of formulas, R^1 , R^2 , R^3 , R^4 , R^6 and m are each as defined above; and R^{28} , R^{29} and R^{30} , each of which may be the same or different from one another, represent each a hydrogen atom or a lower alkyl group).

[0090] That is, this process is one for preparing a compound represented by the general formula (XXIV) by reacting the compound (XXII) prepared in the first step with the Wittig reagents (XXIII) or (XXIII)'.

[0091] As the reaction solvent, everyone which is inert to the reaction can be used.


[0092] The reaction temperature ranges from 0°C to the refluxing temperature of the solvent.

(The third step)



15

reduction



30

(in a series of formulas, R^1 , R^2 , R^3 , R^4 , R^6 , R^{29} , R^{30} and m are each as defined above).


[0093] That is, this process is one for preparing the objective compound (XXV) by reducing the compound (XXIV) prepared in the second step.

[0094] The reduction may be conducted by conventional means, and examples thereof include catalytic reduction using palladium/carbon or platinum catalyst.

35


Preparation process 10

[0095] When R^6 is a group represented by the formula



50


(wherein R^{19} , R^{20} , R^{21} and r are each as defined above; and R^{31} represents an acyl group, a lower alkylsulfonyl group or a lower alkyloxycarbonyl group) in the general formula (I), a compound represented by the general formula (I) can also be prepared by the following process:



15

acylation or
sulfonylation or
alkoxycarbonylation

base



30

(in a series of formulas, R^1 , R^2 , R^3 , R^4 , R^5 , R^{19} ,
 R^{20} , R^{21} , R^{31} and r are each as defined above).

35

[0096] That is, this process is one for preparing an objective compound (XXVI) by subjecting the compound represented by the general formula (XX) prepared in the Preparative process 8 to the conventional acylation, sulfonylation or alkoxycarbonylation in the presence of a base.

[0097] As the acylating agent, every acylating agent which is conventionally used, for example, activated derivatives of carboxylic acids such as acid chloride, acid anhydride and mixed acid anhydride; and condensing agents such as dicyclohexylcarbodiimide is used.

40

[0098] As the sulfonylating agent, every sulfonylating agent which is conventionally used can be used and examples thereof include a lower alkylsulfonyl chloride and a lower alkylsulfonic anhydride.

[0099] The alkoxycarbonylating agent includes every alkoxycarbonylating agent which is conventionally used, for example, a lower alkylloxycarbonyl chloride and a lower alkyl pyrocarbonate.

45


[0100] As the base, every base can be used and examples thereof include organic bases such as pyridine and triethylamine; and inorganic bases such as sodium carbonate, potassium carbonate, sodium hydroxide and sodium hydride.

Preparation process 13

50

[0101] The compound of the present invention can also be prepared by the following process:

(The first step)



R¹, R², R³ and R⁴ are each as defined above; R⁶_d represents a group selected from among those defined above with respect to R⁶;


and Q and Q' represent halogen atoms).

[0102] The first step is a condensation reaction according to a conventional process.

[0103] It is preferred that the reaction is proceeded by heating under reflux in the presence of an organic base such as triethylamine, pyridine and diisopropylethylamine, an organic base such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, sodium hydroxide and sodium hydride or an alkoxide such as sodium methoxide and potassium t-butoxide.

[0104] Every solvent which is inert to the reaction can be used as the reaction solvent, and examples thereof include alcohol solvents such as ethanol and isopropyl alcohol, ether solvents such as tetrahydrofuran, dimethylformamide and dimethylsulfoxide. Further, in the present process, the reaction can be proceeded in the absence of a reaction solvent in some cases.

(The second step)



(R¹, R², R³, R⁴, R^{6d} and Q are each as defined above; and R^{5d} represents a group selected from among those defined above with respect to R⁵ except groups which are directly bonded to the ring portion through a carbon atom).

[0105] That is, the second step is a process for preparing an objective compound in which the compound obtained in the first step is condensed with a compound represented by the general formula R^{5d}-H.

[0106] In the present process, the reaction can be proceeded in the presence of a base at need.

[0107] As the base, organic bases such as triethylamine, pyridine and diisopropylethylamine, inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, sodium hydroxide and sodium hydride and alkoxides such as sodium methoxide and potassium t-butoxide can be cited.

[0108] Every solvent which inert to the reaction can be used as the reaction solvent, and examples thereof include alcohol solvents such as ethanol and isopropanol, ether solvents such as tetrahydrofuran, dimethylformamide and dimethylsulfoxide.

[0109] The reaction temperature is preferably 0°C to 300°C.


[0110] In the case where R^{5d} is a group which is bonded to the ring portion through a nitrogen atom, it is preferred that the reaction is proceeded by heating under reflux in the presence of a tertiary amine such as triethylamine. While in the case where R^{5d} is a group which is bonded to the ring portion through an oxygen atom or a sulfur atom, it is preferred that the reaction is proceeded by heating under reflux in the presence of an alkali such as sodium hydroxide and sodium carbonate.

[0111] The compounds thus obtained in the preparation processes 1 to 13 described above can form salts thereof by a conventional process, for example, by adding sodium hydroxide, potassium hydroxide or methanesulfonic chloride.


[0112] Next, the preparation processes for the raw compounds used in the preparation processes will be shown.

Preparation process A


[0113] Among the starting materials used in the preparation process 13, the compound in which the ring portion is a quinazoline ring and Q and Q' are chlorine atoms can also be prepared by the following process:



10 (the first step)



25 (the second step)



35 (in a series of formulas, R¹, R², R³ and R⁴ are each as defined above; and X' represents any group among a hydroxyl group, an alkoxy group and an amino group).

[0114] That is, this process is one for preparing the objective compound (c) by cyclizing the compound (a) by a conventional process to obtain the compound (b) and then chlorinating it by a conventional process.


45 [0115] The first step is a cyclization reaction. It is a step in which urea is reacted with the compound (a) to obtain the compound (b). In this case, the reaction temperature is preferably about 170 to 190°C, and although every solvent can be used as long as it is inert to the reaction, preferable examples thereof include N-methylpyrrolidone and the like. In this step, the reaction can also be proceeded in the absence of the solvent.

[0116] Further, the compound (b) can also be obtained by cyclizing with carbonyldiimidazole or by cyclizing under an acidic or basic condition after converting to urethane with a chloroformic ester when X' is an amino group.

50 [0117] The second step is a chlorination reaction. This step can be carried out by a conventional manner, and examples thereof include a process in which the compound (b) is heated under reflux with phosphorus pentachloride and phosphorus oxychloride, or phosphorus oxychloride while stirring to chlorinate.


55 Preparation process B

[0118] The starting material (II) used in the preparation process 1 can be prepared by the following process:




10 (the first step)

acylating agent such as
acid chloride/base



20 (the second step)

acid or base



30
35
(in a series of formulas, R¹, R², R³ and R⁴ are each as defined above; and R⁵_C represents a halogen atom or a group selected from among groups which are directly bonded to the ring portion through a carbon atom in those defined with respect to above R⁵).

40 [0119] That is, the above process is a reaction in which an amide product is obtained by a conventional process in the first step and a cyclization is carried out in the presence of an acid or a base in the second step.

45 [0120] The amide product (e) can be obtained by a conventional process, and it can be obtained, for example, by reacting the compound (d) with an acylating agent such as an acid chloride represented by R⁵_C-COCl in the presence of a base.

[0121] Tertiary amines such as triethylamine and organic bases such as pyridine are preferably cited as the base.

50 [0122] Specific examples of the acylating agent include acid chlorides such as benzoyl chloride, acetyl chloride, ethyloxalyl chloride and benzyloxyacetyl chloride.

[0123] The reaction temperature is preferably about 0°C to 30°C.


[0124] In the second step, the compound (e) obtained in the first step is heated under reflux in the presence of an acid or a base to obtain the compound (f).

55 [0125] The acid includes acetic anhydride and the like.

[0126] The base includes sodium hydroxide and the like.

Preparation process C

[0127] The starting material (II) can also be prepared by the following process when R⁵_a is a hydrogen atom in the preparation process 1:



(in a series of formulas, R¹, R², R³ and R⁴ are each as defined above; and X^{*} represents a hydroxyl group or a lower alkoxy group).

[0128] That is, the above process is a cyclization reaction by a conventional process.

[0129] The objective compound (h) can be synthesized, for example, by condensing the raw compound (g) with formamide by heating under reflux, or by heating it together with formic acid.

[Effect of the Invention]

[0130] Experimental Examples will now be described to illustrate the effect of the compound of the present invention.

Experimental ExamplesEnzyme inhibiting action with the use of cGMP-PDE prepared from the swine aeorta1. Method of experiment

[0131] The enzymatic activity of the cGMP-PDE prepared from the swine aeorta was determined according to the method of Thompson et al.⁽¹⁾. The enzymatic activity thereof was determined in the presence of 1 mM EGTA by the use of 1 μ M cGMP as a substrate. The compound of the present invention was dissolved in DMSO, added to the reaction liquid and examined for the inhibitory activity. The final concentration of DMSO in the reaction liquid was adjusted to 4% or below. (1) Thompson, W.J. and Strada, S. J., Cyclic Nucleotide Phosphodiesterase (PDE), in Methods of Enzymatic Analysis, vol 4, p.127-234, 1984. Preparation of cGMP-PDE

[0132] The swine aeorta was sliced, followed by the addition of 10 times by volume as much Buffer A (20mM Tris/HCl, 2mM Mg acetate, 1mM Dithiothreitol, 5mM EDTA, 1400TIU/liter aprotinin, 10 mg/liter leupeptin, 1mM benzamidine, 0.2mM PMSF, pH 7.5). The obtained mixture was homogenized and the homogenate was centrifuged at 100000 x g for one hour. The obtained supernatant was supplied a DEAE-Toyopearl 650S (Tosoh, Tokyo, Japan) column. After the column was washed with Buffer B (50mM Tris/HCl, 0.1mM EGTA, 2mM Mg acetate, 1mM Dithiothreitol, 0.2mM PMSF, pH 7.5), gradient elution with 0.05 to 0.4 M NaCl was conducted. Thus, CaM-independent cGMP-PDE fractions were obtained.

2. Results of experiment

[0133] The results of experiment of the compounds of the present invention are given in Tables 1 to 6B.

Table 1

Ex. No.	IC ₅₀ (μ M)
7	1.0
19	0.39
22	0.36
25	0.78
33	0.37
40	0.65
41	0.35
42	0.19
45	0.41
46	0.24
49	0.041
50	0.032
51	0.069
52	0.069
53	0.12
54	0.47
55	0.030
57	0.038
58	0.042
59	0.27
60	0.18

Table 2

Ex. No.	IC ₅₀ (μ M)
64	0.38
65	0.093
67	0.14
68	0.62
69	0.19
70	0.84
71	0.81
72	0.73
73	0.94
74	0.35
78	0.50

EP 0 607 439 B1

Table 2 (continued)

Ex. No.	IC ₅₀ (μM)
81	0.44
82	0.55
83	0.024
84	0.22
86	0.96
87	0.68
89	0.16
91	0.036
92	0.094
93	0.032
95	0.20
97	0.79

Table 3

Ex. No.	IC ₅₀ (μM)
98	0.062
104	0.010
105	0.18
107	0.0040
114	0.0030
112	0.0020
115	0.0020
120	0.0010
121	0.65
122	0.0050
123	0.031
124	0.0080
125	0.0090
126	0.0010
127	0.11
128	0.30
133	0.77
134	0.0050
136	0.93
137	0.38
138	0.81
139	0.021
140	0.68

EP 0 607 439 B1

Table 4

Ex. No.	IC ₅₀ (μM)
146	0.015
150	0.0072
151	0.081
152	0.11
164	0.0080
165	0.016
166	0.026
167	0.56
168	0.011
169	0.011
170	0.029
171	0.00040
172	0.095
174	0.0040
175	0.0060
176	0.0030
177	0.012
178	0.011
179	0.0020
180	0.0090
181	0.0050
182	0.0080
183	0.00040

Table 5

Ex. No.	IC ₅₀ (μM)
184	0.0060
185	0.010
187	0.12
188	0.029
189	0.016
190	0.0050
191	0.019
192	0.020
193	0.00080
194	0.0040
197	0.066

EP 0 607 439 B1

Table 5 (continued)

Ex. No.	IC ₅₀ (μ M)
200	0.064
201	0.049
202	0.0020
203	0.028
204	0.0040
206	0.029
208	0.00019
213	0.023
214	0.0090
216	0.017
220	0.00024
222	0.0065

Table 6A

Ex. No.	IC ₅₀ (μ M)
227	0.0026
228	0.00052
230	0.0058
231	0.41
232	0.044
233	0.013
234	0.0060
235	0.0020
236	0.0060
237	0.014
238	0.0050
239	0.0080
240	0.0040
241	0.18
243	0.00015
244	0.0090
245	0.10

Table 6B

Ex. No.	IC ₅₀ (μ M)
376	0.021

[0134] It became apparent from the above experimental examples that the compounds of the present invention exhibit PDE, particularly cGMP-PDE, inhibiting action. That is, it became obvious that the compounds of the present

invention exhibit the effect to increase the concentration of cGMP in vivo by revealing the cGMP-PDE inhibiting action. Accordingly, the nitrogenous heterocyclic compounds which are the compounds of the present invention are effective in the prevention and medical treatment of diseases for which cGMP-PDE inhibiting action is efficacious. Examples of these diseases include ischemic heart disease such as angina pectoris, myocardial infarction and chronic and acute cardiac failures, lung hypertension which may accompany with cor pulmonale, other hypertension attributable to all causes, peripheral circulatory disturbance, brain circulatory disturbance, brain function disturbance and allergic diseases such as bronchial asthma, atopic dermatitis and allergic rhinitis.

[0135] Those inhibiting a calmodulin-depending type PDE are also included in the compound group of the present invention. There is high possibility that the diseases for which this action is efficacious are the same as the diseases for which cGMP-PDE inhibitory action described above is efficacious, and, also from this point, it can be said that the compounds of the present invention can be used for prevention and medical treatment of the diseases described above.

[0136] Further, the compounds of the present invention are lowly toxic and therefore are extremely safe. Therefore, the present invention is valuable also from this standpoint.

[0137] When the compounds of the present invention are used as drugs for these diseases, they may be each administered orally or parenterally. The dose varies depending upon the extent of symptom; age, sex, weight and sensitivity of a patient; the method of administration; the timing and interval of administration, the properties, dispensing and kind of medical preparation; and the kind of an active ingredient and is not particularly limited.

[0138] In orally administration, the dose thereof per adult a day is generally about 1 to 1000 mg, preferably about 5 to 500 mg, still preferably 10 to 100 mg, which may be generally administered in 1 to 3 portions a day.

[0139] In the case of an injection, the dose thereof is generally 1 µg/kg to 3,000 µg/kg, preferably about 3 µg/kg to 1,000 µg/kg.

[0140] In the preparation of a solid preparation for oral administration, a filler and, if necessary, a binder, disintegrator, lubricant, color and/or corrigent is(are) added to the active ingredient and then there is shaped into a tablet, a coated tablet, granule, powder or a capsule by a conventional manner.

[0141] Examples of the filler to be used include lactose, corn starch, sucrose, glucose, sorbitol, crystalline cellulose and silicon dioxide; those of the binder to be used include polyvinyl alcohol, polyvinyl ether, ethylcellulose, methylcellulose, acacia, tragacanth, gelatin, shellac, hydroxypropylcellulose, hydroxypropylmethylcellulose, calcium citrate, dextrin and pectin; those of the lubricant to be used include magnesium stearate, talc, polyethylene glycol, silica and hardened vegetable oil; those of the color to be used include those authorized as pharmaceutical additives; and those of the corrigent to be used include cocoa powder, mentha herb, aromatic acid, mentha oil, borneol and powdered cinnamon bark. Of course, the tablet and granule may be suitably coated with sugar, gelatin or the like, if necessary.

[0142] In the preparation of an injection, a pH modifier, buffer, suspending agent, solubilizing agent, stabilizer, tonicity agent and/or preservative is(are) added to the active ingredient at need and then there is formulated into an injection for intravenous, subcutaneous or intramuscular administration by a conventional manner. It is also necessary that the injection is freeze-dried according to a conventional method.

[0143] Examples of the suspending agent include methylcellulose, Polysorbate 80, hydroxyethylcellulose, acacia, tragacanth powder, sodium carboxymethylcellulose and polyoxyethylene sorbitan monolaurate.

[0144] Examples of the solubilizing agent include polyoxyethylene hardened castor oil, Polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate, Macrogol and ethyl ester of castor oil fatty acid.


[Example]

[0145] Examples of the present invention will now be described, though it is needless to say that the present invention is not limited to them. In advance of Examples, preparative example of the raw compound for compounds according to the present invention will be described. In the Examples, Me represents a methyl group, Et an ethyl group, Bzl a benzyl group and Ac an acetyl group.

Preparative Example 12-Ethoxycarbonyl-6-chloroquinazolin-4(3H)-one

5 [0146]

10



15

[0147] 2.50 g (0.0147 mol) of 2-amino-5-chlorobenzamide was dissolved in 15 ml of pyridine. 2.0 ml of ethyloxalyl chloride was dropped into the obtained solution under stirring at room temperature. The obtained mixture was stirred for several hours and distilled under a reduced pressure to remove the solvent. The obtained residue was used as such in the subsequent reaction.

20 [0148] The residue was dissolved in 50 ml of acetic acid, followed by the addition of 5 ml of acetic anhydride. The obtained mixture was heated under reflux for 24 hours. The solvent was distilled away under a reduced pressure and ethanol was added to the obtained crystalline residue. The obtained mixture was filtered to recover the crystal. The crystal was washed with ethanol and ether and air-dried to give 2.78 g of the title compound as a pale-yellow crystal.


- 25 • yield(%); 75
 • m.p.(°C); 239 ~ 240
 • Mass; 253 (M+H)⁺
 • NMR δ (DMSO-d₆) ;
 1.36 (3H, t, J=7.2Hz), 4.39 (2H, q, J=7.2Hz), 7.86 (1H, d, J=8.8Hz), 7.92 (1H, dd, J=8.8Hz, 2.4Hz), 8.11 (1H,
 30 d, J=2.4Hz), 12.85 (1H, brs)

Example 44-(3,4-Methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline

35

[0149]

40



45

50 [0150] 21.2 g (0.083 mol) of 4-chloro-6,7,8-trimethoxyquinazoline, 17.0 g (0.112 mol) of piperonylamine and 13.5 g (0.127 mol) of sodium carbonate were mixed with 400 ml of isopropyl alcohol. The obtained mixture was heated under reflux for 24 hours and distilled under a reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (ethyl acetate) and recrystallized from ethyl acetate to give 21.3 g of the title compound as a pale-yellow needle.

55

- molecular formula; C₁₉H₁₉N₃O₅
- yield(%); 69
- m.p.(°C); 197 ~ 198

- Mass; 370 (M+H)⁺
- NMR δ (CDCl₃) ;
3.94 (3H, s), 4.03 (3H, s), 4.12 (3H, s), 4.76 (2H, d, J=8.0Hz), 5.55 (1H, brs), 5.97 (2H, s), 6.64 (1H, s), 6.80 (1H, d, J=8.0Hz), 6.87 (1H, d, J=8.0Hz), 6.91 (1H, s), 8.66 (1H, s)


Examples 5 to 48

[0151] The following compounds were prepared in a similar manner to that of Example 4.

Example 5

4-(3,4-Methylenedioxyphenyl)amino-6,7,8-trimethoxyquinazoline

[0152]




- molecular formula; C₁₈H₁₇N₃O₅
- yield(%); 58
- m.p.(°C); 254 ~ 255 (dec.)
- Mass; 356 (M+H)⁺
- NMR δ (CDCl₃) ;
4.02 (3H, s), 4.05 (3H, s), 4.13 (3H, s), 5.99 (2H, s), 6.83 (1H, d, J=7.6Hz), 7.02 (1H, d, J=7.6Hz), 7.32 (1H, s), 7.33 (1H, s), 8.49 (1H, brs), 8.63 (1H, s)

Example 6

4-Benzylamino-6,7,8-trimethoxyquinazoline

[0153]




- molecular formula; C₁₈H₁₉N₃O₃
- yield(%); 91
- m.p.(°C); 180 ~ 181
- Mass; 326 (M+H)⁺
- NMR δ (CDCl₃) ;

3.94 (3H, s), 4.03 (3H, s), 4.13 (3H, s), 4.87 (2H, d, J=5.2Hz), 5.62 (1H, brs), 6.65 (1H, s), 7.4 (5H, m), 8.67 (1H, s)

Example 7

4-(4-Methoxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0154]




- molecular formula; $C_{19}H_{21}N_3O_4$
- yield(%): 97
- m.p.(°C): 174 ~ 175
- Mass; 356 (M+H)⁺
- NMR δ (CDCl₃);
3.82 (3H, s), 3.93 (3H, s), 4.03 (3H, s), 4.13 (3H, s), 4.79 (2H, d, J=4.8Hz), 5.53 (1H, brs), 6.63 (1H, s), 6.92 (2H, d, J=8.4Hz), 7.35 (2H, d, J=8.4Hz), 8.67 (1H, s)

Example 8

4-(3-Methoxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0155]




- molecular formula; $C_{19}H_{21}N_3O_4$
- yield(%): 89
- m.p. (°C): 142 ~ 143
- Mass; 356 (M+H)⁺
- NMR δ (CDCl₃);
3.80 (3H, s), 3.96 (3H, s), 4.03 (3H, s), 4.12 (3H, s), 4.85 (2H, d, J=4.8Hz), 5.96 (1H, brs), 6.76 (1H, s), 6.86 (1H, d, J=8.0Hz), 6.99 (1H, d, J=8.0Hz), 7.02 (1H, s), 7.29 (1H, t, J=8.0Hz), 8.65 (1H, s)

Example 94-(4-Nitrobenzyl)amino-6,7,8-trimethoxyquinazoline

5 [0156]

10

15



20

25


- molecular formula; $C_{18}H_{18}N_4O_5$
- yield(%); 28
- m.p.(°C); 210 ~ 212
- Mass; 371 (M+H)⁺
- NMR δ (CDCl₃) ;
3.97 (3H, s), 4.05 (3H, s), 4.13 (3H, s), 5.01 (2H, d, J=5.6Hz), 5.96 (1H, brs), 6.76 (1H, s), 7.54 (2H, d, J=8.8Hz), 8.17 (2H, d, J=8.8Hz), 8.62 (1H, s)

Example 104-(3-Nitrobenzyl)amino-6,7,8-trimethoxyquinazoline

30 [0157]

35

40



45


50

- molecular formula; $C_{18}H_{18}N_4O_5$
- yield(%); 30
- m.p.(°C); 159 ~ 160
- Mass; 371 (M+H)⁺
- NMR δ (CDCl₃) ;
3.97 (3H, s), 4.04 (3H, s), 4.12 (3H, s), 4.99 (2H, d, J=5.6Hz), 6.06 (1H, brs), 6.79 (1H, s), 7.51 (1H, t, J=8.0Hz), 7.76 (1H, d, J=8.0Hz), 8.12 (1H, d, J=8.0Hz), 8.22 (1H, s), 8.63 (1H, s)

55

Example 114-(4-Chlorobenzyl)amino-6,7,8-trimethoxyquinazoline


[0158]



- molecular formula; $C_{18}H_{18}N_3O_3Cl$
- yield(%); 61
- m.p.(°C); 181 ~ 182
- Mass; 360 (M+H)⁺
- NMR δ (CDCl₃) ;
3.94 (3H, s), 4.03 (3H, s), 4.12 (3H, s), 4.85 (2H, d, J=5.6Hz), 5.76 (1H, brs), 6.70 (1H, s), 7.32 (4H, brs), 8.64 (1H, s)

Example 124-(3-Chlorobenzyl)amino-6,7,8-trimethoxyquinazoline


[0159]



- molecular formula; $C_{18}H_{18}N_3O_3Cl$
- yield(%); 85
- m.p.(°C) ; 161 ~ 162
- Mass; 360 (M+H)⁺
- NMR δ (CDCl₃) ;
3.97 (3H, s), 4.04 (3H, s), 4.13 (3H, s), 4.87 (2H, d, J=5.2Hz), 5.66 (1H, brs), 6.68 (1H, s), 7.29 (3H, s), 7.39 (1H, s), 8.65 (1H, s)

Example 154-(4-Ethylbenzyl)amino-6,7,8-trimethoxyquinazoline


[0160]



- molecular formula; $C_{20}H_{23}N_3O_3$
- yield(%); 88
- m.p.(°C); 195 ~ 196
- Mass; 354 (M+H)⁺
- NMR δ (CDCl₃):
 1.25 (3H, t, J=7.6Hz), 2.67 (2H, q, J=7.6Hz), 3.94 (3H, s), 4.03 (3H, s), 4.13 (3H, s), 4.83 (2H, d, J=4.8Hz),
 5.56 (1H, brs), 6.63 (1H, s), 7.23 (2H, d, J=8.0Hz), 7.35 (2H, d, J=8.0Hz), 8.67 (1H, s)

Example 164-(Indan-5-ylmethyl)amino-6,7,8-trimethoxyquinazoline


[0161]



- molecular formula; $C_{21}H_{23}N_3O_3$
- yield(%); 61
- m.p.(°C); 198 ~ 199
- Mass; 366 (M+H)⁺
- NMR δ (CDCl₃):
 2.11 (2H, quintet, J=7.2Hz), 2.93 (4H, t, J=7.2Hz), 3.94 (3H, s), 4.04 (3H, s), 4.14 (3H, s), 4.83 (2H, d, J=4.4Hz), 5.55 (1H, brs), 6.64 (1H, s), 7.2 ~ 7.3 (3H, m), 8.68 (1H, s)

Example 18**4-(3-Hydroxymethylbenzyl)amino-6,7,8-trimethoxyquinazoline**


[0162]



- molecular formula; $C_{19}H_{21}N_3O_4$
- yield(%); 86
- m.p.(°C); amorphous
- Mass; 356 (M+H)⁺
- NMR δ ($CDCl_3$) :
3.93 (3H, s), 4.03 (3H, s), 4.12 (3H, s), 4.70 (2H, s), 4.86 (2H, d, J=5.2Hz), 5.82 (1H, brs), 6.72 (1H, s), 7.3 ~ 7.4 (4H, m), 8.63 (1H, s)

Example 19**4-(3,4-Dichlorobenzyl)amino-6,7,8-trimethoxyquinazoline**


[0163]



- molecular formula; $C_{18}H_{17}N_3O_3Cl_2$
- yield(%); 85
- m.p.(°C); 205 ~ 206
- Mass; 394 (M+H)⁺
- NMR δ ($CDCl_3$) :
3.97 (3H, s), 4.04 (3H, s), 4.12 (3H, s), 4.84 (2H, d, J=5.6Hz), 5.88 (1H, brs), 6.74 (1H, s), 7.24 (1H, d, J=8.4Hz), 7.40 (1H, d, J=8.4Hz), 7.47 (1H, s), 8.63 (1H, s)

Example 204-(3-Chloro-4-methoxybenzyl)amino-6,7,8-trimethoxyquinazoline


5 [0164]



- molecular formula; $C_{19}H_{20}N_3O_4Cl$
 - yield(%); 83
 - 20 • m.p.(°C); 164 ~ 165
 - Mass; 390 (M+H)⁺
 - NMR δ (CDCl₃);
- 25 3.90 (3H, s), 3.97 (3H, s), 4.04 (3H, s), 4.13 (3H, s), 4.80 (2H, d, J=5.2Hz), 5.90 (1H, brs), 6.75 (1H, s), 6.91 (1H, d, J=8.8Hz), 7.30 (1H, dd, J=8.8 Hz, 2.0Hz), 7.43 (1H, d, J=2.0Hz), 8.65 (1H, s)

Example 214-(3,4-Difluorobenzyl)amino-6,7,8-trimethoxyquinazoline

30 [0165]




- molecular formula; $C_{18}H_{17}N_3O_3F_2$
 - yield(%); 96
 - 45 • m.p.(°C); 175 ~ 177
 - Mass; 362 (M+H)⁺
 - NMR δ (CDCl₃);
- 50 3.97 (3H, s), 4.04 (3H, s), 4.13 (3H, s), 4.85 (2H, d, J=5.2Hz), 5.73 (1H, brs), 6.69 (1H, s), 7.1 ~ 7.3 (3H, m), 8.64 (1H, s)

55

Example 22**4-(3-Fluoro-4-methoxybenzyl)amino-6,7,8-trimethoxyquinazoline**


[0166]



- molecular formula; $C_{19}H_{20}N_3O_4F$
- yield(%); 82
- m.p.(°C); 171 ~ 172
- Mass; 374 (M+H)⁺
- NMR δ (CDCl₃) ;
 3.89 (3H, s), 3.98 (3H, s), 4.04 (3H, s), 4.12 (3H, s), 4.81 (2H, d, J=5.6Hz), 6.27 (1H, brs), 6.86 (1H, s), 6.94 (1H, m), 7.14 ~ 7.19 (2H, m), 8.64 (1H, s)

Example 23**4-(3,4-Dimethoxybenzyl)amino-6,7,8-trimethoxyquinazoline**

[0167]




- molecular formula; $C_{20}H_{23}N_3O_5$
- yield(%); 32
- m.p.(°C); 171 ~ 172
- Mass; 386 (M+H)⁺
- NMR δ (CDCl₃) ;
 3.87 (3H, s), 3.89 (3H, s), 3.94 (3H, s), 4.03 (3H, s), 4.13 (3H, s), 4.79 (2H, d, J=5.2Hz), 5.67 (1H, brs), 6.69 (1H, s), 6.86 (1H, d, J=8.8Hz), 6.96 (1H, s), 6.98 (1H, d, J=8.8Hz), 8.67 (1H, s)

Example 24

4-(4-Hydroxy-3-methoxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0168]




- molecular formula; $C_{19}H_{21}N_3O_5$
- yield(%); 16
- m.p.(°C); 201 ~ 202 (dec.)
- Mass; 372 (M+H)⁺
- NMR δ (CDCl₃);
 3.88 (3H, s), 3.96 (3H, s), 4.03 (3H, s), 4.12 (3H, s), 4.78 (2H, d, J=5.2Hz), 6.00 (1H, brs), 6.77 (1H, s), 6.91 (1H, s), 6.92 (1H, s), 6.97 (1H, s), 8.65 (1H, s)

Example 25

4-(3,4-Ethylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0169]




- molecular formula; $C_{20}H_{21}N_3O_5$
- yield(%); 92
- m.p.(°C); 217 ~ 219
- Mass; 384 (M+H)⁺
- NMR δ (CDCl₃);
 3.95 (3H, s), 4.03 (3H, s), 4.13 (3H, s), 4.26 (4H, s), 4.75 (2H, d, J=5.2Hz), 5.54 (1H, brs), 6.64 (1H, s), 6.87 (1H, d, J=8.0Hz), 6.90 (1H, d, J=8.0Hz), 6.94 (1H, s), 8.66 (1H, s)

Example 26

4-(3-Allyl-4-methoxymethoxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0170]




- molecular formula; $C_{23}H_{27}N_3O_5$
- yield(%); 49
- m.p.(°C); 120 ~ 121
- Mass; 426 (M+H)⁺
- NMR δ (CDCl₃) ;
 3.41 (2H, d, J=6.8Hz), 3.48 (3H, s), 3.94 (3H, s), 4.03 (3H, s), 4.12 (3H, s), 4.77 (2H, d, J=5.2Hz), 5.06 (2H, m), 5.21 (2H, s), 5.78 (1H, brs), 5.98 (1H, m), 6.71 (1H, s), 7.07 (1H, d, J=8.4Hz), 7.23 (1H, s), 7.24 (1H, d, J=8.4Hz), 8.65 (1H, s)

Example 27

4-(Benzimidazol-5-ylmethyl)amino-6,7,8-trimethoxyquinazoline


[0171]



- molecular formula; $C_{19}H_{19}N_5O_3$
- yield(%); 52
- m.p.(°C); 235 ~ 240 (dec.)
- Mass; 366 (M+H)⁺
- NMR δ (DMSO-d₆) ;
 3.93 (3H, s), 3.95 (3H, s), 3.98 (3H, s), 4.97 (2H, d, J=6.0Hz), 7.30 (1H, dd, J=8.4Hz, 1.6Hz), 7.57 (1H, d, J=8.4Hz), 7.63 (1H, d, J=1.6Hz), 7.83 (1H, s), 8.31 (1H, s), 8.36 (1H, brs), 8.52 (1H, s), 9.76 (1H, brs)

Example 29**4-(4-Chloro-3-nitrobenzyl)amino-6,7,8-trimethoxyquinazoline**


[0172]



- molecular formula; $C_{18}H_{17}N_4O_5Cl$
- yield(%); 88
- m.p.(°C); 218 ~ 219 (dec.)
- Mass; 405 (M+H)⁺
- NMR δ (CDCl₃) ;
 3.98 (3H, s), 4.04 (3H, s), 4.13 (3H, s), 4.93 (2H, d, J=6.0Hz), 5.98 (1H, brs), 6.75 (1H, s), 7.50 (1H, d, J=8.4Hz), 7.58 (1H, dd, J=8.4Hz, 2.0Hz), 7.87 (1H, d, J=2.0Hz), 8.61 (1H, s)

Example 30**4-(2-Propoxybenzyl)amino-6,7,8-trimethoxyquinazoline**


[0173]



- molecular formula; $C_{21}H_{25}N_3O_4$
- yield(%); 80
- m.p.(°C); 139 ~ 140
- Mass; 384 (M+H)⁺
- NMR δ (CDCl₃) ;
 1.07 (3H, t, J=7.4Hz), 1.85 (2H, m), 3.95 (3H, s), 4.02 (3H, s), 4.02 (2H, t, J=6.4Hz), 4.10 (3H, s), 4.89 (2H, d, J=5.6Hz), 6.72 (1H, s), 6.9 (2H, m), 7.28 (1H, m), 7.38 (1H, d, J=7.2Hz), 8.64 (1H, s)

Example 314-(2,4,6-Trimethoxybenzyl)amino-6,7,8-trimethoxyquinazoline


[0174]



- molecular formula; $C_{21}H_{25}N_3O_6$
 - yield(%); 64
 - m.p.(°C); 213 ~ 215
 - Mass; 416 (M+H)⁺
 - NMR δ (CDCl₃) ;
- 3.85 (9H, s), 3.92 (3H, s), 4.01 (3H, s), 4.11 (3H, s), 4.79 (2H, d, J=4.4Hz), 5.65 (1H, brs), 6.20 (2H, s), 6.60 (1H, s), 8.68 (1H, s)

Example 324-(3,4,5-Trimethoxybenzyl)amino-6,7,8-trimethoxyquinazoline


[0175]



- molecular formula; $C_{21}H_{25}N_3O_6$
 - yield(%); 60
 - m.p.(°C); 153 ~ 154
 - NMR δ (CDCl₃) ;
- 3.85 (9H, s), 3.97 (3H, s), 4.03 (3H, s), 4.13 (3H, s), 4.80 (2H, d, J=5.6Hz), 6.66 (2H, s), 6.80 (1H, s), 8.66 (1H, s)

Example 334-(2-Chloro-4,5-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0176]

• molecular formula; $C_{19}H_{18}N_3O_5Cl$

• yield(%); 76


• m.p.(°C); 220 ~ 221

• Mass; 404 (M+H)⁺• NMR δ (CDCl₃) ;

3.97 (3H, s), 4.02 (3H, s), 4.11 (3H, s), 4.86 (2H, d, J=6.0Hz), 5.95 (2H, s), 6.70 (1H, brt, J=6.0Hz), 6.86 (1H, s), 6.95 (1H, s), 6.98 (1H, s), 8.61 (1H, s)

Example 344-(4,5-Methylenedioxy-2-nitrobenzyl)amino-6,7,8-trimethoxyquinazoline

[0177]

• molecular formula; $C_{19}H_{18}N_4O_7$

• yield(%); 15

• m.p.(°C); 182 ~ 183

• Mass; 415 (M+H)⁺• NMR δ (CDCl₃) ;


3.99 (3H, s), 4.02 (3H, s), 4.10 (3H, s), 5.08 (2H, d, J=6.4Hz), 6.09 (2H, s), 6.82 (2H, s & brs), 7.27 (1H, s), 7.57 (1H, s), 8.61 (1H, s)

Example 354-[2-(4-Nitrophenyl)ethyl]amino-6,7,8-trimethoxyquinazoline

5 [0178]

10

15



- 20 • molecular formula; $C_{19}H_{20}N_4O_5$
 • yield(%); 58
 • m.p. ($^{\circ}C$); 152 ~ 153
 • Mass; 385 (M+H)⁺
 • NMR δ ($CDCl_3$);
 25 3.18 (2H, t, J=7.2Hz), 3.92 (3H, s), 3.96 (3H, m), 4.04 (3H, s), 4.13 (3H, s), 5.57 (1H, brs), 6.58 (1H, s), 7.41 (2H, d, J=8.8Hz), 8.17 (2H, d, J=8.8Hz), 8.66 (1H, s)


Example 364-[2-(3,4-Methylenedioxyphenyl)ethyl]amino-6,7,8-trimethoxyquinazoline

30 [0179]

35

40

45




- molecular formula; $C_{20}H_{21}N_3O_5$
 • yield(%); 68
 • m.p. ($^{\circ}C$); 193 ~ 194
 50 • Mass; 384 (M+H)⁺
 • NMR δ ($CDCl_3$);
 2.96 (2H, t, J=6.8Hz), 3.87 (2H, m), 3.93 (3H, s), 4.03 (3H, s), 4.12 (3H, s), 5.43 (1H, brs), 5.95 (2H, s), 6.52 (1H, s), 6.71 (1H, d, J=8.0Hz), 6.77 (1H, s), 6.78 (1H, d, J=8.0Hz), 8.65 (1H, s)

55

Example 40**4-[N-Ethyl-(3,4-methylenedioxybenzyl)amino]-6,7,8-trimethoxyquinazoline**

[0180]

• molecular formula; $C_{21}H_{23}N_3O_5$

• yield(%); 73


• m.p.(°C); 100 ~ 101

• Mass; 398 (M+H)⁺• NMR δ (CDCl₃) ;

1.37 (3H, t, J=7.0Hz), 3.56 (3H, s), 3.67 (2H, q, J=7.0Hz), 4.03 (3H, s), 4.11 (3H, s), 4.79 (2H, s), 5.98 (2H, s), 6.85 (1H, d, J=7.2Hz), 6.93 (1H, s), 6.93 (1H, d, J=7.2Hz), 6.97 (1H, s), 8.69 (1H, s)

Example 41**4-[N-(Ethoxycarbonylmethyl)-(3,4-methylenedioxybenzyl)amino]-6,7,8-trimethoxyquinazoline**

[0181]

• molecular formula; $C_{23}H_{25}N_3O_7$

• yield(%); 41

• m.p.(°C); oily substance


• Mass; 456 (M+H)⁺• NMR δ (CDCl₃) ;

1.29 (3H, t, J=7.2Hz), 3.44 (3H, s), 4.02 (3H, s), 4.10 (3H, s), 4.20 (2H, s), 4.25 (2H, q, J=7.2Hz), 4.98 (2H, s), 6.00 (2H, s), 6.88 (1H, d, J=8.0Hz), 6.97 (1H, s), 7.01 (1H, d, J=8.0Hz), 8.64 (1H, s)

Example 42

4-[N-(2-Methoxyethyl)-(3,4-methylenedioxybenzyl)amino]-6,7,8-trimethoxyquinazoline

[0182]

• molecular formula; $C_{22}H_{25}N_3O_6$

• yield(%); 21

• m.p.(°C), 87 ~ 88


• Mass; 428 (M+H)⁺• NMR δ (CDCl₃) ;

3.36 (3H, s), 3.58 (3H, s), 3.80 ~ 3.85 (4H, m), 4.02 (3H, s), 4.10 (3H, s), 4.92 (2H, s), 5.97 (2H, s), 6.83 (1H, d, J=7.6Hz), 6.92 (1H, d, J=7.6Hz), 6.94 (1H, s), 7.19 (1H, s), 8.67 (1H, s)

Example 44

4-[4-(1-Hydroxyethyl)benzyl]amino-6-methoxyquinazoline

[0183]

• molecular formula; $C_{18}H_{19}N_3O_2$

• yield(%); 46


• m.p.(°C); amorphous

• Mass; 310 (M+H)⁺• NMR δ (CDCl₃) ;

1.47 (2H, d, J=6.4Hz), 3.91 (3H, s), 4.87 (2H, d, J=5.2Hz), 4.84 ~ 4.94 (1H, m), 7.34 ~ 7.42 (6H, m), 7.59 (1H, brs), 7.79 (1H, d, J=8.8Hz), 8.52 (1H, s)

Example 454-(Benzimidazol-5-ylmethyl)amino-6-methoxyquinazoline


[0184]



- molecular formula; $C_{17}H_{15}N_5O$
- yield(%): 18
- m.p.(°C); 254 ~ 255
- Mass; 306 (M+1)⁺
- NMR δ (DMSO- d_6) ;
 3.88 (3H, s), 4.91 (2H, d, J=6.0Hz), 7.24 (1H, d, J=8.4Hz), 7.40 (1H, dd, J=9.2Hz, 2.8Hz), 7.54 (1H, d, J=8.4Hz), 7.56 (1H, s), 7.63 (1H, d, J=9.2Hz), 7.73 (1H, d, J=2.8Hz), 8.16 (1H, s), 8.37 (1H, s), 8.67 (1H, t, J=6.0Hz), 12.33 (1H, brs)

Example 464-(3,4-Methylenedioxybenzyl)amino-6-methoxyquinazoline

[0185]




- molecular formula; $C_{17}H_{15}N_3O_3$
- yield(%): 86
- m.p.(°C); 207 ~ 208
- Mass; 310 (M+H)⁺
- NMR δ (CDCl₃) ;
 3.89 (3H, s), 4.78 (2H, d, J=5.2Hz), 5.70 (1H, brs), 5.97 (2H, s), 6.80 (1H, d, J=7.6Hz), 6.9 (3H, m), 7.40 (1H, d, J=9.2Hz), 7.80 (1H, d, J=9.2Hz), 8.63 (1H, s)

Example 48

4-(4-Methoxy-3-nitrobenzyl)amino-6-methoxyquinazoline

5 [0186]




- molecular formula: $C_{17}H_{16}N_4O_4$
 - yield(%); 22
 - 20 • m.p.(°C); 205 ~ 206 (dec.)
 - Mass; 341 (M+1)⁺
 - NMR δ ($CDCl_3$) ;
- 25 3.93 (3H, s), 3.94 (3H, s), 4.91 (2H, d, J=6.0Hz), 7.07 (1H, dd, J=8.4Hz, 1.2Hz), 7.21 (1H, d, J=1.2Hz), 7.39 (1H, dd, J=9.2Hz, 2.4Hz), 7.53 (1H, d, J=2.4Hz), 7.75 (1H, d, J=9.2Hz), 7.82 (1H, d, J=8.4Hz), 8.03 (1H, brs), 8.51 (1H, s)

Example 49

4-(3,4-Methylenedioxybenzyl)amino-6-methylthioquinazoline

30 [0187]



45 [0188] 4.12 g (0.0196 mol) of 4-chloro-6-methylthioquinazoline, 3.70 g (0.0245 mol) of piperonylamine and 3.50 g (0.0330 mol) of sodium carbonate were mixed with 100 ml of isopropyl alcohol. The obtained mixture was heated under reflux for 24 hours and distilled under a reduced pressure to remove the solvent. The obtained residue was purified by silica gel column chromatography (ethyl acetate/n-hexane) and recrystallized from chloroform/n-hexane to give 5.32 g of the title compound as a pale-yellow crystal.

- 50 • molecular formula; $C_{17}H_{15}O_2N_3S$
 - yield(%); 83
 - m.p.(°C); 174 ~ 175
 - Mass; 326 (M+H)⁺
 - NMR δ ($CDCl_3$) ;
- 55 2.59 (3H, s), 4.79 (2H, d, J=5.6Hz), 5.93 (2H, s), 6.77 (1H, d, J=8.0Hz), 6.89 (1H, d, J=8.0Hz), 6.94 (1H, s), 7.62 (1H, dd, J=8.8Hz, 2.0Hz), 7.75 (1H, d, J=8.8Hz), 7.97 (1H, d, J=2.0Hz), 8.10 (1H, brs), 8.56 (1H, s)


Examples 50 to 54

[0189] The following compounds were prepared in a similar manner to that of Example 49.

5 Example 50

4-(3,4-Dichlorobenzyl)amino-6-methylthioquinazoline

10 [0190]




- 25
- molecular formula; $C_{16}H_{13}N_3SCl_2$
 - yield(%); 85
 - m.p.(°C); 184 ~ 185
 - Mass; 350 (M+H)⁺
 - NMR δ ($CDCl_3$);
 2.61 (3H, s), 4.83 (2H, d, J=5.6Hz), 7.28 (1H, dd, J=8.4Hz, 2.0Hz), 7.40 (1H, d, J=8.4Hz), 7.51 (1H, d, J=2.0Hz), 7.64 (1H, dd, J=8.8Hz, 2.0Hz), 7.76 (1H, d, J=8.8Hz), 7.97 (1H, d, J=2.0Hz), 8.19 (1H, brs), 8.55 (1H, s)

30 Example 51

4-(3-Fluoro-4-methoxybenzyl)amino-6-methylthioquinazoline

35 [0191]




- 50
- molecular formula; $C_{17}H_{16}N_3OSF$
 - yield(%); 89
 - m.p.(°C); 168 ~ 169
 - Mass; 330 (M+H)⁺
 - NMR δ ($CDCl_3$);
 2.58 (3H, s), 3.90 (3H, s), 4.82 (2H, d, J=5.6Hz), 6.29 (1H, brs), 6.95 (1H, m), 7.13 - 7.18 (2H, m), 7.54 (1H, s), 7.63 (1H, d, J=8.8Hz), 7.79 (1H, d, J=8.8Hz), 8.64 (1H, s)
- 55

Example 52

4-(Benzimidazol-5-ylmethyl)amino-6-methylthioquinazoline

[0192]




- molecular formula; $C_{17}H_{15}N_5S$
- yield(%); 48
- m.p.(°C); 271 ~ 275 (dec.)
- Mass; 322 (M+H)⁺
- NMR δ (DMSO- d_6);
2.67 (3H, s), 5.06 (2H, d, J=5.6Hz), 7.47 (1H, d, J=8.4Hz), 7.68 (1H, d, J=8.8Hz), 7.77 (2H, m), 7.87 (1H, d, J=8.8Hz), 8.40 (1H, s), 8.77 (1H, s), 8.84 (1H, s), 10.68 (1H, brs)


Example 53

4-[N-(2-Methoxyethyl)-(3,4-methylenedioxybenzyl)amino]-6-methylthioquinazoline


[0193]



- molecular formula; $C_{20}H_{21}N_3O_3S$
- yield(%); 27
- m.p.(°C); 92 ~ 93
- Mass; 384 (M+H)⁺
- NMR δ (CDCl₃);
2.16 (3H, s), 3.35 (3H, s), 3.82 (2H, t, J=5.0Hz), 3.89 (2H, t, J=5.0Hz), 5.01 (2H, s), 5.98 (2H, s), 6.84 (1H, d, J=8.4Hz), 6.89 (1H, d, J=8.4Hz), 6.90 (1H, s), 7.56 (1H, dd, J=8.8Hz, 2.0Hz), 7.66 (1H, d, J=2.0Hz), 7.82 (1H, d, J=8.8Hz)

Example 54**4-[N-(2-Hydroxyethyl)-(3,4-methylenedioxybenzyl)amino]-6-methylthioquinazoline****[0194]**

- molecular formula; $C_{19}H_{19}N_3O_3S$
- yield(%); 21
- m.p.(°C); 146 ~ 147 (dec.)
- Mass; 370 (M+H)⁺
- NMR δ (CDCl₃) ;
 2.00 (3H, s), 3.93 (2H, t, J=4.2Hz), 4.01 (2H, t, J=4.2Hz), 5.00 (2H, s), 6.01 (2H, s), 6.89 (3H, m), 7.57 (2H, m), 7.82 (1H, d, J=9.2Hz), 8.55 (1H, s)


Example 55**4-(4-Chloro-3-nitrobenzyl)amino-6-chloroquinazoline****[0195]**

[0196] 3.00 g (0.015 mol) of 4,6-dichloroquinazoline and 3.80 g (0.0170 mol) of 4-chloro-3-nitrobenzylamine hydrochloride were dissolved in a mixture comprising 100 ml of isopropyl alcohol and 15 ml of triethylamine. The obtained solution was heated under reflux for 24 hours and distilled under a reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (chloroform/ethyl acetate) and recrystallized from chloroform/n-hexane to give 4.85 g of the title compound as a pale-yellow crystal.

- molecular formula; $C_{15}H_{10}N_4O_2Cl_2$
- yield(%); 92
- m.p.(°C); 199 ~ 200
- Mass; 349 (M+H)⁺
- NMR δ (CDCl₃) ;
 4.85 (2H, d, J=6.0Hz), 7.49 (1H, d, J=8.4Hz), 7.61 (1H, dd J=8.4Hz, 2.0Hz), 7.66 (1H, dd, J=8.8Hz, 2.0Hz), 7.76 (1H, d, J=8.8Hz), 7.96 (1H, d, J=2.0Hz), 8.20 (1H, d, J=2.0Hz), 8.23 (1H, brt, J=6.0Hz), 8.58 (1H, s)

Preparative Example 564-(α -Ethoxycarbonyl-3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0197]



[0198] 30 ml of 2-propanol, 1.07 g of triethylamine and 1.01 g of α -ethoxycarbonyl-3,4-methylenedioxybenzylamine were added to 704 mg of 4,6-dichloroquinazoline. The obtained mixture was refluxed for 4 hours, followed by the addition of water. The obtained mixture was extracted with chloroform thrice. The chloroform layers were combined, dried over magnesium sulfate and distilled under a reduced pressure to remove the solvent. The residue was recrystallized (from ethanol/ethyl acetate/hexane) to give 1.167 g of the title compound.


- molecular formula; $C_{19}H_{16}O_4Cl$
 - yield(%); 86
 - m.p.($^{\circ}C$); 169 ~ 170
 - Mass m/e; 386 (M+1)
 - NMR δ ($CDCl_3$);
- 1.28 (3H, t, J=7.2Hz), 4.27 (2H, m), 5.85 (1H, d, J=6.4Hz), 5.98 (2H, s), 6.70 (1H, brs), 6.81 (1H, d, J=8.8Hz), 6.99 (2H, m), 7.10 (1H, dd, J=8.8Hz, 2.4Hz), 7.83 (1H, d, J=2.4Hz), 8.85 (1H, d, J=8.8Hz), 8.63 (1H, s)

Examples 57 to 64

[0199] The following compounds were prepared in a similar manner to that of Preparative Example 56 or Example 57.

Example 574-(3,4-Methylenedioxybenzyl)amino-6-chloroquinazoline

[0200]




- molecular formula; $C_{16}H_{12}N_2O_2Cl$
 - yield(%); 76
 - m.p.($^{\circ}C$); 199 ~ 200
 - Mass; 314 (M+H)⁺
 - NMR δ ($CDCl_3$);
- 4.76 (2H, d, J=5.6Hz), 5.82 (1H, brs), 5.98 (2H, s), 6.81 (1H, d, J=8.0Hz), 6.87 (1H, d, J=8.0Hz), 6.89 (1H,

s), 7.67 (1H, s), 7.69 (1H, d, J=8.0Hz), 7.81 (1H, d, J=8.0Hz), 8.70 (1H, s)

Example 58

5 4-(3,4-Dichlorobenzyl)amino-6-chloroquinazoline

[0201]




- 20
- molecular formula; $C_{15}H_{10}N_3Cl_3$
 - yield(%); 72
 - m.p.(°C); 215 ~ 216
 - Mass; 338 (M+H)⁺
 - NMR δ ($CDCl_3$);
- 25
- 4.85 (2H, d, J=5.6Hz), 5.94 (1H, brs), 7.24 (1H, d, J=8.4Hz), 7.43 (1H, d, J=8.4Hz), 7.70 (1H, d, J=9.2Hz), 7.72 (1H, s), 7.83 (1H, d, J=9.2Hz), 8.68 (1H, s)

Example 59

30 4-(3,4-Dimethoxybenzyl)amino-6-chloroquinazoline

[0202]




- 45
- molecular formula; $C_{17}H_{16}N_3O_2Cl$
 - yield(%); 73
 - m.p.(°C); 174 ~ 175
 - Mass; 330 (M+H)⁺
 - NMR δ ($CDCl_3$);
- 50
- 3.87 (6H, s), 4.78 (2H, d, J=5.2Hz), 6.85 (1H, d, J=8.0Hz), 6.96 (1H, d, J=8.0Hz), 6.98 (1H, s), 7.34 (1H, brs), 7.65 (1H, dd, J=9.2Hz, 2.0Hz), 7.78 (1H, d, J=9.2Hz), 8.08 (1H, d, J=2.0Hz), 8.65 (1H, s)

55

Example 60

4-(Benzimidazol-5-ylmethyl)amino-6-chloroquinazoline

[0203]




- molecular formula; $C_{16}H_{12}N_5Cl$
- yield(%); 76
- m.p.(°C); 243 ~ 244 (dec.)
- Mass; 310 (M+H)⁺
- NMR δ (DMSO- d_6) ;
4.89 (2H, d, J=5.6Hz), 7.27 (1H, d, J=8.4Hz), 7.55 (1H, d, J=8.4Hz), 7.59 (1H, s), 7.72 (1H, d, J=8.8Hz), 7.80 (1H, dd, J=8.8Hz, 2.4Hz), 8.25 (1H, s), 8.50 (1H, s), 8.53 (1H, d, J=2.4Hz), 9.07 (1H, brt, J=5.6Hz)

Example 61

4-(2-Methoxy-2,3-dihydrobenzofuran-5-yl)methylamino-6-chloroquinazoline


[0204]



- molecular formula; $C_{18}H_{16}N_3O_2Cl$ (341.798)
- yield(%); 53
- m.p. (°C) ; 178 ~ 179
- Mass; 342 (MH)⁺
- NMR δ (DMSO- d_6) ;
2.88 (1H, dd, J=2.0Hz, 17.0Hz), 3.28 ~ 3.34 (1H, m), 4.68 (1H, d, J=5.7Hz), 5.68 (1H, dd, J=2.0Hz, 6.6Hz), 6.79 (1H, d, J=8.2Hz), 7.14 (1H, d, J=8.2Hz), 7.24 (1H, s), 7.70 (1H, d, J=9.0Hz), 7.79 (1H, dd, J=2.2Hz, 9.0Hz), 8.46 (1H, d, J=2.2Hz), 8.48 (1H, s), 8.82 (1H, t, J=5.7Hz)

Example 624-(2-Methylbenzimidazol-5-ylmethyl)amino-6-chloroquinazoline


[0205]



- molecular formula; $C_{17}H_{14}N_5Cl$
- yield(%); 17
- m.p.(°C); 273 ~ 274 (dec.)
- Mass; 324 (M+H)⁺
- NMR δ (DMSO- d_6);
2.71 (3H, s), 4.94 (2H, d, J=5.6Hz), 7.48 (1H, d, J=8.4Hz), 7.63 (1H, d, J=8.4Hz), 7.70 (1H, s), 7.77 (1H, d, J=8.8Hz), 7.86 (1H, dd, J=8.8Hz, 2.0Hz), 8.58 (1H, s), 8.65 (1H, d, J=2.0Hz), 9.65 (1H, brs)

Example 644-(3,4-Methylenedioxybenzyl)amino-6-ethoxyquinazoline


[0206]



- molecular formula; $C_{18}H_{17}N_3O_3$
- yield(%); 44
- m.p.(°C); 190 ~ 191
- Mass; 324 (M+H)⁺
- NMR δ (CDCl₃);
1.46 (3H, t, J=6.8Hz), 4.10 (2H, q, J=6.8Hz), 4.77 (2H, d, J=5.2Hz), 5.68 (1H, brs), 5.97 (2H, s), 6.80 (1H, d, J=8.0Hz), 6.87 ~ 6.92 (3H, m), 7.39 (1H, dd, J=9.2Hz, 2.8Hz), 7.79 (1H, d, J=9.2Hz), 8.62 (1H, s)

Example 654-(3,4-Methylenedioxybenzyl)amino-6-cyanoquinazoline

[0207]



[0208] 15 ml of isopropyl alcohol, 75 mg of triethylamine and 125 mg of piperonylamine were added to 140 mg of 4-chloro-6-cyanoquinazoline. The obtained mixture was heated under reflux for 5 hours and filtered to recover a precipitate. This precipitate was introduced to a silica gel column, followed by eluting with ethyl acetate to give 200 mg of the title compound.


- molecular formula; $C_{17}H_{12}N_4O_2$
- yield(%); 89
- m.p.(°C); 243 ~ 244
- Mass; 305 (M+1)⁺
- NMR δ (DMSO- d_6) ;
4.67 (2H, d, J=5.6Hz), 5.96 (2H, s), 6.84 (2H, s), 6.95 (1H, s), 7.77 (1H, d, J=8.4Hz), 8.56 (1H, s), 8.89 (1H, s), 9.04 (1H, br)

Examples 66 to 87

[0209] The following compounds were prepared in a similar manner to that of Example 65.

Example 674-(Benzimidazol-5-yl)methylamino-6-cyanoquinazoline


[0210]



- molecular formula; $C_{17}H_{12}N_6$
- yield(%); 68
- m.p.(°C); 274 ~ 277
- Mass; 301 (M+1)⁺
- NMR δ (DMSO- d_6) ;
4.88 (2H, d, J=5.6Hz), 7.21 ~ 7.24 (1H, m), 7.35 ~ 7.76 (2H, m), 7.78 (1H, d, J=8.8Hz), 7.06 (1H, dd, J=8.8Hz, 1.6Hz), 8.15 (1H, s), 8.57 (1H, s), 8.92 (1H, s), 9.14 (1H, m), 12.32 (1H, m)

Example 684-(3,4-Methylenedioxybenzyl)amino-6-ethoxycarbonylquinazoline

[0211]



- molecular formula; $C_{19}H_{17}N_3O_4$

- yield(%); 48

- m.p.(°C); 156 ~ 157


- Mass; 352 (M+H)⁺

- NMR δ (CDCl₃);

1.43 (3H, t, J=7.2Hz), 4.44 (2H, q, J=7.2Hz), 4.79 (2H, d, J=5.2Hz), 5.98 (2H, s), 6.14 (1H, brs), 6.82 (1H, d, J=8.0Hz), 6.89 (1H, d, J=8.0Hz), 6.90 (1H, s), 7.87 (1H, d, J=8.8Hz), 8.33 (1H, d, J=8.8Hz), 8.46 (1H, s), 8.74 (1H, s)

Example 694-(3,4-Methylenedioxybenzyl)amino-6-methylquinazoline

[0212]



- molecular formula; $C_{17}H_{15}N_3O_2$

- yield(%); 68

- m.p.(°C); 203 ~ 204

- Mass; 294 (M+H)⁺

- NMR δ (CDCl₃);


2.49 (3H, s), 4.76 (2H, d, J=5.6Hz), 5.79 (1H, brs), 5.96 (2H, s), 6.81 (1H, d, J=8.0Hz), 6.88 (1H, d, J=8.0Hz), 6.91 (1H, s), 7.44 (1H, s), 7.57 (1H, d, J=8.4Hz), 7.76 (1H, d, J=8.4Hz), 8.66 (1H, s)

Example 704-(3,4-Methylenedioxybenzyl)amino-6,7-dimethoxyquinazoline

5 [0213]

10

15



20

- molecular formula: $C_{18}H_{17}N_3O_4$
- yield(%): 77
- m.p. ($^{\circ}C$): 221 ~ 222
- Mass; 340 ($M+H$)⁺
- NMR δ (DMSO- d_6) ;
 3.88 (3H, s), 3.89 (3H, s), 4.68 (2H, d, $J=6.0Hz$), 5.97 (2H, s), 6.85 (2H, s), 6.94 (1H, s), 7.09 (1H, s), 7.64 (1H, s), 8.33 (1H, s), 8.37 (1H, t, $J=6.0Hz$)


25

Example 714-(3,4-Methylenedioxybenzyl)amino-6,8-dimethoxyquinazoline

30 [0214]

35

40



45


- molecular formula: $C_{18}H_{17}N_3O_4$
- yield(%): 88
- m.p. ($^{\circ}C$): 217 ~ 218
- Mass; 340 ($M+H$)⁺
- NMR δ ($CDCl_3$) ;
 3.89 (3H, s), 4.01 (3H, s), 4.77 (2H, d, $J=5.2Hz$), 5.63 (1H, brs), 5.97 (2H, s), 6.42 (1H, d, $J=2.4Hz$), 6.77 (1H, d, $J=2.4Hz$), 6.80 (1H, d, $J=7.6Hz$), 6.88 (1H, dd, $J=7.6Hz$, 1.6Hz), 6.92 (1H, d, $J=1.6Hz$), 8.65 (1H, s)

50

55

Example 724-(3,4-Methylenedioxybenzyl)amino-5,6-dimethoxyquinazoline


[0215]



- molecular formula; $C_{18}H_{17}N_3O_4$
- yield(%); 74
- m.p.(°C); 122 ~ 123
- Mass; 340 (M+1)⁺
- NMR δ (CDCl₃) ;
 3.97 (6H, s), 4.77 (2H, d, J=5.2Hz), 5.97 (2H, s), 6.81 (1H, d, J=8.0Hz), 6.86 (1H, dd, J=8.0Hz, 1.6Hz), 6.88 (1H, d, J=1.6Hz), 7.49 (1H, d, J=8.8Hz), 7.82 (1H, d, J=8.8Hz), 8.51 (1H, s), 8.64 (1H, brs)

Example 734-(3,4-Methylenedioxybenzyl)amino-6-acetamido-7-methoxyquinazoline

[0216]




- molecular formula; $C_{19}H_{18}N_4O_4$
- yield(%); 66
- m.p.(°C); 164 ~ 165
- Mass; 367 (M+H)⁺
- NMR δ (CDCl₃) ;
 2.26 (3H, s), 4.04 (3H, s), 4.76 (2H, d, J=5.6Hz), 5.95 (2H, s), 6.22 (1H, brs), 6.77 (1H, d, J=8.0Hz), 6.85 (1H, d, J=8.0Hz), 6.89 (1H, s), 7.31 (1H, s), 8.02 (1H, brs), 8.59 (1H, s), 8.81 (1H, s)

Example 744-(3,4-Methylenedioxybenzyl)amino-6-methylthio-7-methoxyquinazoline

5 [0217]

10

15



20

- molecular formula; $C_{18}H_{17}N_3O_3S$
- yield(%); 39
- m.p.(°C) ; 200 ~ 205 (dec.)
- Mass; 356 (M+H)⁺
- NMR δ (CDCl₃) ;
 2.50 (3H, s), 4.01 (3H, s), 4.78 (2H, d, J=5.6Hz), 5.95 (2H, s), 6.13 (1H, brs), 6.79 (1H, d, J=8.0Hz), 6.88 (1H, d, J=8.0Hz), 6.91 (1H, s), 7.15 (1H, s), 7.33 (1H, s), 8.56 (1H, s)


25

Example 754-(3,4-Methylenedioxybenzyl)aminoquinazoline

30 [0218]

35

40



45

- molecular formula; $C_{16}H_{13}N_3O_2$
- yield(%); 69
- m.p. (°C) ; 197 ~ 198
- Mass; 280 (M+H)⁺
- NMR δ (CDCl₃) ;
 4.78 (2H, d, J=5.2Hz), 5.85 (1H, brs), 5.96 (2H, s), 6.80 (1H, d, J=8.0Hz), 6.88 (1H, d, J=8.0Hz), 6.91 (1H, s), 7.46 (1H, t, J=8.0Hz), 7.68 (1H, d, J=8.0Hz), 7.75 (1H, t, J=8.0Hz), 7.87 (1H, d, J=8.0Hz), 8.71 (1H, s)

50


55

Example 76**4-(3,4-Methylenedioxybenzyl)amino-8-methoxyquinazoline**

5 [0219]

10

15



- molecular formula; $C_{17}H_{15}N_3O_3$
 - yield(%); 76
 - 20 • m.p.(°C); 195 ~ 196
 - Mass; 310 (M+H)⁺
 - NMR δ (CDCl₃) ;
- 4.03 (3H, s), 4.78 (2H, d, J=5.6Hz), 5.94 (2H, s), 6.77 (1H, d, J=8.0Hz), 6.89 (1H, d, J=8.0Hz), 6.92 (1H, s), 6.95 (1H, brs), 7.12 (1H, d, J=8.0Hz), 7.39 (1H, t, J=8.0Hz), 7.48 (1H, d, J=8.0Hz), 8.70 (1H, s)


25

Example 77**4-(3,4-Methylenedioxybenzyl)amino-7-chloroquinazoline**

30 [0220]

35

40




- molecular formula; $C_{21}H_{22}N_3O_2Cl$
 - yield(%); 62
 - m.p.(°C) ; 209 ~ 210
 - 45 • Mass; 314 (M+H)⁺
 - NMR δ (CDCl₃) ;
- 4.77 (2H, d, J=5.6Hz), 5.95 (2H, s), 6.78 (1H, d, J=8.0Hz), 6.88 (1H, d, J=8.0Hz), 6.92 (1H, s), 7.39 (1H, dd, J=8.8Hz, 2.0Hz), 7.4 (1H, brs), 7.83 (1H, d, J=2.0Hz), 7.96 (1H, d, J=8.8Hz), 8.63 (1H, s)

50

55

Example 784-(3,4-Methylenedioxybenzyl)amino-6,7-methylenedioxyquinazoline


[0221]



- molecular formula; $C_{20}H_{15}N_3O_2$ (329)
- yield(%); 45
- m.p.(°C); 265 (dec.)
- Mass; 330 (M+1)⁺
- NMR δ (DMSO- d_6);
 4.92 (2H, d, J=6.0Hz), 5.97 (2H, s), 6.88 (1H, d, J=8.0Hz), 6.94 (1H, dd, J=8.0Hz, 1.6Hz), 7.06 (1H, d, J=1.6Hz), 7.68 ~ 7.81 (2H, m), 8.11 (1H, d, J=8.4Hz), 8.21 (1H, d, J=8.4Hz), 8.33 (1H, s), 8.90 (1H, s), 9.36 (1H, s), 11.09 (1H, br)

Example 794-(3,4-Methylenedioxybenzyl)amino-6,7-methylenedioxyquinazoline


[0222]



- molecular formula; $C_{17}H_{13}N_3O_4$ (323)
- yield(%); 55
- m.p.(°C); 229 ~ 231
- Mass; 324 (M+1)⁺
- NMR δ (DMSO- d_6);
 4.62 (2H, d, J=5.6Hz), 5.94 (2H, s), 6.16 (2H, s), 6.79 (1H, d, J=8.0Hz), 6.82 (1H, dd, J=8.0Hz, 2.0Hz), 6.89 (1H, d, J=2.0Hz), 7.06 (1H, s), 7.68 (1H, s), 8.26 (1H, brt, J=5.6Hz), 8.28 (1H, s)

Example 80**4-(3,4,5-Trimethoxybenzyl)amino-6,7-methylenedioxyquinazoline**


5 [0223]



- molecular formula; $C_{19}H_{19}N_3O_5$ (369)
 - yield(%); 59
 - 20 • m.p.(°C); 240 ~ 241
 - Mass; 370 (M+1)⁺
 - NMR δ (DMSO- d_6);
 3.61 (3H, s), 3.70 (6H, s), 4.65 (2H, d, J=6.0Hz), 6.16 (2H, s), 6.675 (2H, s), 7.06 (1H, s), 7.72 (1H, s), 8.23
 (1H, brt, J=6.0Hz), 8.30 (1H, s)
- 25


Example 81**2-Methyl-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline**

30 [0224]




- molecular formula; $C_{20}H_{21}N_3O_5$
 - 45 • yield(%); 58
 - m.p.(°C); 190 ~ 191
 - Mass; 384 (M+H)⁺
 - NMR δ (CDCl₃);
 2.67 (3H, s), 3.93 (3H, s), 4.01 (3H, s), 4.11 (3H, s), 4.77 (2H, d, J=5.2Hz), 5.96 (2H, s), 6.70 (1H, s) 6.79
 (1H, d, J=7.6Hz), 6.89 (1H, d, J=7.6Hz), 6.93 (1H, s)
- 50


55

Example 82**2-Isopropyl-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline****[0225]**

- molecular formula; $C_{20}H_{21}N_3O_3$
- yield(%); 84
- m.p.(°C); 157 ~ 158
- Mass; 352 ($M+1$)⁺
- NMR δ ($CDCl_3$);
 1.36 (6H, d, $J=6.8$ Hz), 3.15 (1H, septet, $J=6.8$ Hz), 3.88 (3H, s), 4.81 (2H, d, $J=5.6$ Hz), 5.94 (2H, s), 6.78 (1H, d, $J=8.0$ Hz), 6.91 (1H, dd, $J=8.0$ Hz, 2.0Hz), 6.96 (1H, d, $J=2.0$ Hz), 6.99 (1H, brd, $J=2.4$ Hz), 7.32 (1H, dd, $J=9.2$ Hz, 2.4Hz), 7.79 (1H, d, $J=9.2$ Hz)

Example 83**2-(2-Propoxyphenyl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline****[0226]**

- molecular formula; $C_{25}H_{22}N_3O_3Cl$
- yield(%); 20
- m.p.(°C); 208 ~ 209
- Mass; 446 ($M+1$)⁺
- NMR δ ($CDCl_3$);
 0.97 (3H, t, $J=7.6$ Hz), 1.71 ~ 1.81 (2H, m), 4.01 (2H, t, $J=6.4$ Hz), 4.81 (2H, brs), 5.80 (1H, br), 5.96 (2H, s), 6.79 ~ 7.86 (10H, m)

Example 84**2-(2-Propoxyphenyl)-4-(3,4-methylenedioxybenzyl)aminoquinazoline****[0227]**

- molecular formula: $C_{25}H_{23}N_3O_3$ (413)


- yield(%): 15

- m.p. ($^{\circ}C$) : 130 ~ 131

- Mass; 414 ($M+1$)⁺

- NMR δ ($CDCl_3$) ;

0.96 (3H, t, $J=7.2Hz$), 1.71 ~ 1.77 (2H, m), 4.00 (2H, t, $J=6.4Hz$), 4.83 (2H, s), 5.95 (2H, s), 6.77 ~ 7.93 (12H, m)

Example 86**4-(3,4-Methylenedioxybenzyl)oxy-6,7,8-trimethoxyquinazoline****[0228]**

- molecular formula: $C_{19}H_{18}N_2O_6$


- yield(%): 49

- m.p. ($^{\circ}C$) : 141 ~ 142


- Mass; 371 ($M+H$)⁺

- NMR δ ($CDCl_3$) ;

3.97 (3H, s), 4.05 (3H, s), 4.13 (3H, s), 5.53 (2H, s), 5.99 (2H, s), 6.84 (1H, d, $J=8.0Hz$), 7.00 (1H, dd, $J=8.0Hz$, 2.0Hz), 7.02 (1H, d, $J=2.0Hz$), 7.20 (1H, s), 8.74 (1H, s)

Example 87**4-(3,4-Methylenedioxybenzyl)oxy-6-methylthioquinazoline****[0229]**

- molecular formula; $C_{17}H_{14}N_2O_3S$
- yield(%); 69
- m.p.(°C); 104 ~ 105
- Mass; 327 (M+H)⁺
- NMR δ (CDCl₃) ;
 2.59 (3H, s), 5.56 (2H, s), 6.00 (2H, s), 6.85 (1H, d, J=8.0Hz), 7.01 (1H, dd, J=8.0Hz, 1.6Hz), 7.03 (1H, d, J=1.6Hz), 7.72 (1H, dd, J=8.8Hz, 1.6Hz), 7.88 (1H, d, J=8.8Hz), 7.89 (1H, d, J=1.6Hz), 8.78 (1H, s)


Example 89**2,6-Dimethoxy-4-(3,4-methylenedioxybenzyl)aminoquinazoline****[0230]**

[0231] 3.75 g (24.8 mmol) of piperonylamine was added to a solution of 2.00 g (8.26 mmol) of the 2,4,6-trimethoxyquinazoline prepared in Example 88 in dimethyl sulfoxide (15 ml). The obtained mixture was stirred under heating at 150 to 160°C. After one hour, the reaction mixture was purified by silica gel column chromatography (ethyl acetate/n-hexane) and recrystallized from ethyl acetate/n-hexane to give 0.50 g of the title compound as a pale-yellow crystal.

- molecular formula; $C_{18}H_{17}N_3O_4$
- yield(%); 18
- m.p. (°C) ; 166 ~ 167
- Mass; 340 (M+1)⁺
- NMR δ (CDCl₃) ;
 3.89 (3H, s), 4.03 (3H, s), 4.77 (2H, d, J=5.2Hz), 5.94 (2H, s), 6.76 (1H, d, J=8.0Hz), 6.89 (1H, dd, J=8.0Hz, 1.2Hz), 6.93 (1H, d, J=1.2Hz), 7.29 (1H, dd, J=8.8Hz, 2.8Hz), 7.32 (1H, brs), 7.59 (1H, d, J=8.8Hz)

Example 912-Benzyloxy-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline

[0232]




[0233] 1.25 g (8.27 mmol) of piperonylamine was added to a solution of 1.00 g (2.69 mmol) of the 2,4-bisbenzyloxy-6-methoxyquinazoline prepared in Example 90 in dimethyl sulfoxide (10 ml). The obtained mixture was stirred at 160 to 180°C. After one hour, the reaction mixture was purified by silica gel column chromatography (ethyl acetate/n-hexane) and recrystallized from ethyl acetate/n-hexane to give 0.20 g of the title compound as a colorless needle.

- molecular formula; $C_{24}H_{21}N_3O_4$
- yield(%); 18
- m.p.(°C); 163 ~ 164
- Mass; 416 (M+H)⁺
- NMR δ (CDCl₃) ;
 3.86 (3H, s), 4.75 (2H, d, J=5.2Hz), 5.49 (2H, s), 5.68 (1H, brs), 5.96 (2H, s), 6.79 (1H, d, J=8.0Hz), 6.84 ~ 6.87 (3H, m), 7.28 ~ 7.36 (4H, m), 7.51 ~ 7.53 (2H, m), 7.63 (1H, d, J=9.2Hz)

Example 922,6-Dichloro-4-(3,4-methylenedioxybenzyl)aminoquinazoline

[0234]



[0235] A mixture comprising 3.6 g of 2,4,6-trichloroquinazoline, 2.4 g of piperonylamine, 1.6 g of triethylamine and 50 ml of isopropyl alcohol was heated under reflux for 1.5 hours and hot-filtered to give 5.2 g of the title compound as a filter cake.


- molecular formula; $C_{16}H_{11}N_3O_2Cl_2$
- yield(%); 98
- m.p.(°C); 215
- Mass; 349 (M+1)⁺
- NMR δ (DMSO- D_6);
 4.61 (2H, s), 5.97 (2H, s), 6.85 (2H, s), 6.95 (1H, s), 7.63 (1H, d, J=8.8Hz), 7.80 (1H, dd, J=8.8Hz, 2.4Hz), 8.45 (1H, d, J=2.4Hz), 9.24 (1H, br)

Example 932-Chloro-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

5 [0236]

10

15



20 [0237] 35 ml of isopropyl alcohol, 900 mg of triethylamine and 1.35 g of piperonylamine were added to 2 g of 2,4-dichloro-6-cyanoquinazoline. The obtained mixture was heated under reflux for 1.5 hours and hot-filtered to recover a precipitate. Thus, 2.4 g of the title compound was obtained.


- molecular formula; $C_{17}H_{11}N_4O_2Cl$
- yield(%); 79
- m.p.(°C); 234 ~ 236 (dec.)
- 25 • Mass; 339 (M+1)⁺
- NMR δ (DMSO- d_6);
 4.63 (2H, d, J=5.6Hz), 5.97 (2H, s), 6.86 (2H, s), 6.97 (1H, s), 7.72 (1H, d, J=8.4Hz), 8.10 (1H, dd, J=8.4Hz, 1.8Hz), 8.90 (1H, d, J=1.8Hz), 9.50 (1H, br)

30 Example 942-Chloro-4-(3-chloro-4-methoxybenzyl)amino-6-cyanoquinazoline

35 [0238]

35

40



45

50 [0239] 3.9 g of 3-chloro-4-methoxybenzylamine, 3.97 g of triethylamine and 200 ml of 2-propanol were added to 4 g of 2,4-dichloro-6-cyanoquinazoline. The obtained mixture was refluxed for 30 minutes, cooled to room temperature and filtered to recover a crystalline precipitate. The precipitate was washed with water and chloroform successively to give 5.563 g of the title compound.

50


- molecular formula; $C_{17}H_{12}N_4OCl_2$
- yield(%); 87
- m.p.(°C); 264 ~ 266
- Mass m/e; 359 (M+1)
- 55 • NMR δ (CDCl₃);
 3.90 (3H, s), 4.73 (2H, d, J=5.2Hz), 6.92 (1H, d, J=8.4), 7.33 (1H, dd, J=8.4Hz, 2.0Hz), 7.45 (1H, d, J=2.0Hz), 7.74 (1H, d, J=8.4Hz), 7.83 (1H, dd, J=8.4Hz, 1.6Hz), 8.78 (1H, d, J=1.6Hz), 8.85 (1H, brs)

Examples 95 to 105

[0240] The following compounds were prepared in a similar manner to those of Examples 88 to 94.

Example 952-Chloro-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline


[0241]



- molecular formula; $C_{19}H_{18}N_3O_5Cl$
- yield(%); 50
- m.p.(°C); 193 ~ 194
- Mass; 404 (M+H)⁺
- NMR δ (CDCl₃) ;
 3.94 (3H, s), 4.03 (3H, s), 4.10 (3H, s), 4.75 (2H, d, J=5.2Hz), 5.65 (1H, brs), 5.98 (2H, s), 6.59 (1H, s), 6.81 (1H, d, J=8.0Hz), 6.89 (1H, d, J=8.0Hz), 6.91 (1H, s)

Example 962-Chloro-4-(3-chloro-4-methoxybenzyl)amino-6,7,8-trimethoxyquinazoline


[0242]



- molecular formula; $C_{19}H_{19}Cl_2N_3O_4$
- yield(%); 45
- m.p.(°C); 199 ~ 200
- Mass; 424 (M+1)⁺
- NMR δ (CDCl₃) ;
 3.89 (3H, s), 3.95 (3H, s), 4.02 (3H, s), 4.08 (3H, s), 4.76 (2H, d, J=5.6Hz), 6.39 (1H, brs), 6.83 (1H, s), 6.89 (1H, d, J=8.3Hz), 7.31 (1H, dd, J=8.4Hz, 2.0Hz), 7.40 (1H, d, J=2.0Hz)

Example 972-Chloro-4-(3,4-methylenedioxybenzyl)amino-6,7-dimethoxyquinazoline


[0243]



- molecular formula; $C_{18}H_{16}N_3O_4Cl$
- yield(%); 97
- m.p.(°C); 177 ~ 178
- Mass; 374 (M+H)⁺
- NMR δ (CDCl₃);
 3.95 (3H, s), 3.97 (3H, s), 4.75 (2H, d, J=5.2Hz), 5.74 (1H, brt, J=5.2Hz), 5.97 (2H, s), 6.80 (1H, d, J=8.0Hz),
 6.81 (1H, s), 6.88 (1H, dd, J=8.0Hz, 2.0Hz), 6.91 (1H, d, J=2.0Hz), 7.14 (1H, s)

Example 982-Chloro-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline


[0244]



- molecular formula; $C_{17}H_{14}N_3O_3Cl$
- yield(%); 80
- m.p.(°C); 202 ~ 203
- Mass; 344 (M+1)⁺
- NMR δ (CDCl₃);
 3.91 (3H, s), 4.77 (2H, d, J=5.6Hz), 5.94 (2H, s), 6.76 (1H, d, J=8.0Hz), 6.91 (1H, dd, J=8.0Hz, 1.6Hz), 6.95
 (1H, d, J=1.6Hz), 7.35 (1H, dd, J=9.2Hz, 2.8Hz), 7.46 (1H, brd, J=2.8Hz), 7.69 (1H, d, J=9.2Hz), 7.90 (1H, brs)

Example 992-Chloro-4-(3-chloro-4-methoxybenzyl)amino-6-methoxyquinazoline


[0245]



- molecular formula; $C_{17}H_{15}N_3O_2Cl_2$
- yield(%); 88
- m.p.(°C); 171 ~ 172
- Mass; 364 (M+1)⁺
- NMR δ (DMSO);
3.83 (3H, s), 3.88 (3H, s), 4.68 (2H, d, J=5.6Hz), 7.13 (1H, d, J=8.8Hz), 7.33 (1H, dd, J=2.4Hz, 8.8Hz), 7.44 (1H, dd, J=2.8Hz, 9.2Hz), 7.46 (1H, d, J=2.4Hz), 7.58 (1H, d, J=9.2Hz), 7.72 (1H, d, J=2.8Hz), 9.05 (1H, t, J=5.6Hz)

Example 1002,6-Dichloro-4-benzylaminoquinazoline


[0246]



- molecular formula; $C_{15}H_{11}N_3Cl_2$
- yield(%); 77
- m.p.(°C); 227 ~ 228
- NMR δ (CDCl₃);
4.85 (2H, d, J=5.2Hz), 5.97 (1H, brs), 7.33 ~ 7.43 (5H, m), 7.62 (1H, d, J=2.0Hz), 7.68 (1H, dd, J=8.8Hz, 2.0Hz), 7.74 (1H, d, J=8.8Hz)

Example 1012,6-Dichloro-4-[2-(3,4-methylenedioxyphenyl)ethyl]aminoquinazoline


[0247]



- molecular formula; $C_{17}H_{13}N_3O_2Cl_2$
- yield(%); 71
- m.p.(°C); 228 ~ 229
- NMR δ (DMSO- d_6);
2.88 (2H, t, $J=7.4$ Hz), 3.68 (2H, m), 5.96 (2H, s), 6.70 (1H, dd, $J=8.0$ Hz, 1.6Hz), 6.81 (1H, d, $J=8.0$ Hz), 6.87 (1H, d, $J=1.6$ Hz), 7.63 (1H, d, $J=8.8$ Hz), 7.80 (1H, dd, $J=8.8$ Hz, 2.0Hz), 8.40 (1H, d, $J=2.0$ Hz), 8.86 (1H, d, $J=5.2$ Hz)

Example 1022,6-Dichloro-4-(3-chloro-4-methoxybenzyl)aminoquinazoline

[0248]




- molecular formula; $C_{16}H_{12}N_3OCl_3$
- yield(%); 93
- m.p.(°C); 207 ~ 208
- Mass m/e; 368 (M+1)
- NMR δ ($CDCl_3$);
3.90 (3H, s), 4.73 (2H, d, $J=5.6$ Hz), 6.91 (1H, d, $J=8.4$ Hz), 7.32 (1H, d, $J=8.4$ Hz, 2.0Hz), 7.45 (1H, d, $J=2.0$ Hz), 7.62 (1H, dd, $J=8.8$ Hz, 2.0Hz), 7.66 (1H, d, $J=8.8$ Hz), 8.07 (1H, brs), 8.16 (1H, d, $J=2.0$ Hz)

Example 1032,6-Dichloro-4-(benzimidazol-5-yl)methylaminoquinazoline

5 [0249]

10

15



- molecular formula; $C_{16}H_{11}N_5Cl_2$ (344.205)

- yield(%); 81

20

- m.p.(°C); >290

- Mass; 344 (M+1)⁺

- NMR δ (DMSO);

4.85 (2H, d, J=6.0Hz), 7.25 (1H, dd, J=1.6Hz, 6.4Hz), 7.57 (1H, d, J=6.4Hz), 7.60 (1H, s), 7.66 (1H, d, J=8.8Hz), 7.83 (1H, dd, J=2.0Hz, 8.8Hz), 8.21 (1H, s), 8.44 (1H, brs), 8.52 (1H, d, J=2.0Hz), 9.37 (1H, t, J=6.0Hz)


25

Example 1042-Chloro-4-(benzimidazol-5-yl)methylamino-6-cyanoquinazoline

30 [0250]

35

40



- molecular formula; $C_{17}H_{11}N_6Cl$ (334.5)

- yield(%); 58

- m.p.(°C); >290

45

- Mass; 335 (M+1)⁺

- NMR δ (DMSO- d_6);


4.81 (2H, s), 7.21 ~ 7.68 (3H, m), 7.73 (1H, d, J=8.8Hz), 8.10 (1H, d, J=8.8Hz), 8.17 (1H, s), 8.91 (1H, s), 9.55 (1H, br)

50

55

Example 1052-Chloro-4-[N-(2-hydroxyethyl)-(3,4-methylenedioxybenzyl)amino]-6,7,8-trimethoxyquinazoline


[0251]



- molecular formula; $C_{21}H_{22}N_3O_6Cl$
- yield(%); 55
- Mass; 448 (M+H)⁺
- NMR δ ($CDCl_3$) ;
3.38 (3H, s), 3.88 (2H, t, J=4.4Hz), 4.01 (2H, t, J=4.4Hz), 4.03 (3H, s), 4.07 (3H, s), 4.92 (2H, s), 6.01 (2H, s), 6.88 ~ 6.91 (3H, m), 7.00 (1H, s)

Example 1062-Formyl-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0252]



[0253] 0.50 g (0.0013 mol) of 2-ethoxycarbonyl-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline was dissolved in a solvent mixture comprising 20 ml of methylene chloride and 20 ml of tetrahydrofuran. 2.6 ml of a 1.0 M solution of diisobutylaluminum hydride in toluene was dropped into the solution prepared above at -78°C under stirring. The obtained mixture was stirred at -78°C for several hours, followed by the addition of 20 ml of methanol. The obtained mixture was distilled under a reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography and recrystallized from ethyl acetate/n-hexane to give 0.23 g of the title compound as a pale-yellow crystal.


- yield(%); 52
- m.p.(°C); 200 ~ 202 (dec.)
- Mass; 342 (M+1)⁺
- NMR δ ($CDCl_3$) ;
4.86 (2H, d, J=5.2Hz), 5.98 (2H, s), 6.81 (1H, d, J=7.6Hz), 6.90 (1H, d, J=7.6Hz), 6.92 (1H, s), 7.72 (1H, d, J=2.0Hz), 7.77 (1H, dd, J=8.8Hz, 2.0Hz), 8.01 (1H, d, J=8.8Hz), 10.05 (1H, s)

Example 1072-Ethoxycarbonyl-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

5 [0254]

10

15



20

[0255] 2.72 g (0.0100 mol) of 2-ethoxycarbonyl-4,6-dichloroquinazoline, 1.75 g (0.0116 mol) of piperonylamine and 1.60 g (0.0151 mol) of sodium carbonate were mixed with 100 ml of isopropyl alcohol. The obtained mixture was heated under reflux for 24 hours and distilled under a reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography and recrystallized from chloroform/n-hexane to give 3.56 g of the title compound as a colorless needle.

25

- molecular formula; $C_{19}H_{16}N_3O_4Cl$
- yield(%); 92
- m.p.(°C); 212 ~ 213
- Mass; 386 (M+H)⁺
- NMR δ (CDCl₃);

30

1.49 (3H, t, J=7.2Hz), 1.54 (2H, q, J=7.2Hz), 4.83 (2H, d, J=5.6Hz), 5.96 (1H, brs), 5.97 (2H, s), 6.80 (1H, d, J=8.0Hz), 6.91 (1H, dd, J=8.0Hz, 1.6Hz), 6.97 (1H, d, J=1.6Hz), 7.70 (1H, d, J=2.0Hz), 7.72 (1H, dd, J=8.8Hz, 2.0Hz), 8.00 (1H, d, J=8.8Hz)

Examples 108 to 111

35

[0256] The following compounds were prepared in a similar manner to that of Examples 106 or 107.


Example 1082-Ethoxycarbonyl-4-(3-chloro-4-methoxybenzyl)amino-6-chloroquinazoline

40

[0257]

45

50



55


- molecular formula; $C_{19}H_{17}N_3O_3Cl_2$
 - yield(%); 88
 - m.p.(°C); 185 ~ 186
 - Mass; 406 (M+1)⁺
 - NMR δ (CDCl₃);
- 1.49 (3H, t, J=7.2Hz), 3.90 (3H, s), 4.54 (2H, q, J=7.2Hz), 4.84 (2H, d, J=5.2Hz), 6.09 (1H, brs), 6.90 (1H,

d, J=8.4Hz), 7.33 (1H, dd, J=8.4Hz, 2.4Hz), 7.48 (1H, d, J=2.4Hz), 7.72 (1H, dd, J=8.8Hz, 2.4Hz), 7.74 (1H, d, J=2.4Hz), 7.99 (1H, d, J=8.8Hz)

Example 109

2-Ethoxycarbonyl-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0258]




- molecular formula; $C_{22}H_{23}N_3O_7$
- yield(%); quantitative
- m.p.(°C); 163 ~ 165 (dec.)
- Mass; 442 (M+1)⁺
- NMR δ (CDCl₃) ;
 1.45 (3H, t, J=7.2Hz), 3.94 (3H, s), 4.02 (3H, s), 4.18 (3H, s), 4.46 (2H, q, J=7.2Hz), 4.80 (2H, d, J=5.2Hz),
 5.89 (1H, brt, J=5.2Hz), 5.94 (2H, s), 6.74 (1H, d, J=7.6Hz), 6.76 (1H, s), 6.86 (1H, dd, J=7.6Hz, 1.6Hz), 6.94 (1H,
 d, J=1.6Hz)

Example 110

2-Ethoxycarbonyl-4-(3-chloro-4-methoxybenzyl)amino-6-methoxyquinazoline


[0259]



- molecular formula; $C_{20}H_{20}N_3O_4Cl$
- yield(%); 73
- m.p.(°C); 192 ~ 193
- Mass; 402 (M+1)⁺
- NMR δ (CDCl₃) ;
 1.49 (3H, t, J=7.2Hz), 3.90 (3H, s), 3.91 (3H, s), 4.53 (2H, q, J=7.2Hz), 4.86 (2H, d, J=5.6Hz), 5.90 (1H, brt,
 J=5.6Hz), 6.90 (1H, d, J=8.4Hz), 6.96 (1H, d, J=2.4Hz), 7.36 (1H, dd, J=8.4Hz, 2.4Hz), 7.44 (1H, dd, J=9.2Hz,
 2.4Hz), 7.49 (1H, d, J=2.4Hz), 8.00 (1H, d, J=9.2Hz)

Example 1112-Ethoxycarbonyl-4-(benzimidazol-5-ylmethyl)amino-6-methoxyquinazoline


[0260]



- molecular formula; $C_{20}H_{19}N_5O_3$
- yield(%); 48
- m.p.(°C); 244 ~ 245 (dec.)
- Mass; 378 (M+1)⁺
- NMR δ (DMSO- d_6) ;
 1.35 (3H, t, J=7.2Hz), 3.90 (3H, s), 4.33 (2H, q, J=7.2Hz), 4.94 (2H, d, J=6.0Hz), 7.31 (1H, d, J=8.0Hz), 7.47 (1H, dd, J=8.8Hz, 2.8Hz), 7.53 (1H, d, J=8.0Hz), 7.65 (1H, brs), 7.77 (1H, d, J=8.8Hz), 7.78 (1H, s), 8.17 (1H, s), 8.89 (1H, brt, J=6.0Hz)

Example 112(E)-2-(2-Ethoxycarbonyl-1-propenyl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0261]



[0262] 0.52 g (0.013 mol) of sodium hydride was added to a solution of 4.00 g (0.0117 mol) of 2-formyl-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline in 250 ml of tetrahydrofuran. 2.8 ml (0.013 mol) of triethyl 2-phosphonopropionate was dropped into the mixture prepared above under stirring and cooling with ice. The mixture thus prepared was stirred under cooling with ice for a while, heated to room temperature and stirred for additional one hour, followed by the addition of 1.5 ml of 8M hydrochloric acid/ethanol. The obtained mixture was passed through a small amount of silica gel and distilled under a reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (ethyl acetate/ n-hexane) and recrystallized from chloroform/n-hexane to give 2.00 g of the title compound.

- molecular formula; $C_{22}H_{20}N_3O_4Cl$
- yield(%); 40
- m.p.(°C); 179 ~ 180 (dec.)
- Mass; 426 (M+1)⁺
- NMR δ (CDCl₃) ;
 1.35 (3H, t, J=7.2Hz), 2.50 (3H, d, J=1.6Hz), 4.29 (2H, q, J=7.2Hz), 4.78 (2H, d, J=5.2Hz), 5.77 (1H, brt,

J=5.2Hz), 5.97 (2H, s), 6.81 (1H, d, J=8.0Hz), 6.87 (1H, dd, J=8.0Hz, 1.6Hz), 6.89 (1H, d, J=1.6Hz), 7.62 (1H, q, J=1.6Hz), 7.64 (1H, d, J=2.0Hz), 7.68 (1H, dd, J=8.8Hz, 2.0Hz), 7.81 (1H, d, J=8.8Hz)


Examples 113 to 119

[0263] The following compounds were prepared in a similar manner to that of Example 112.

Example 113

(Z)-2-(2-Ethoxycarbonyl-1-propenyl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0264]




- molecular formula; $C_{22}H_{20}N_3O_4Cl$
- yield(%); 13
- amt. of product(g); 0.64
- m.p.(°C); 162 ~ 164 (dec.)
- Mass; 426 (M+1)⁺
- NMR δ ($CDCl_3$);
1.20 (3H, t, J=7.2Hz), 2.17 (3H, d, J=1.6Hz), 4.21 (2H, q, J=7.2Hz), 4.70 (2H, d, J=4.8Hz), 5.64 (1H, brs), 5.97 (2H, s), 6.53 (1H, q, J=1.6Hz), 6.81 (1H, d, J=7.6Hz), 6.85 (1H, dd, J=7.6Hz, 1.6Hz), 6.87 (1H, d, J=1.6Hz), 7.58 (1H, d, J=2.4Hz), 7.62 (1H, dd, J=8.8Hz, 2.4Hz), 7.71 (1H, d, J=8.8Hz)

Example 113

(E)-2-(2-Ethoxycarbonylvinyl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline


[0265]



- molecular formula; $C_{21}H_{18}N_3O_4Cl$
- yield(%); 67
- m.p.(°C); 195 ~ 196
- Mass; 412 (M+1)⁺
- NMR δ ($CDCl_3$);
1.35 (3H, t, J=7.2Hz), 4.29 (2H, q, J=7.2Hz), 4.80 (2H, d, J=5.2Hz), 5.77 (1H, brs), 5.97 (2H, s), 6.81 (1H, d, J=7.6Hz), 6.89 (1H, d, J=7.6Hz), 6.90 (1H, s), 7.21 (1H, d, J=15.6Hz), 7.64 (1H, d, J=2.0Hz), 7.66 (1H, d, J=15.6Hz), 7.68 (1H, dd, J=9.2Hz, 2.0Hz), 7.82 (1H, d, J=9.2Hz)

Example 115(E)-2-(2-Ethoxycarbonylvinyl)-4-(3-chloro-4-methoxybenzyl)amino-6-chloroquinazoline


[0266]



- molecular formula; $C_{21}H_{19}N_3O_4Cl_2$
- yield(%); 74
- m.p.(°C); 211 ~ 212
- Mass; 432 (M+1)⁺
- NMR δ (CDCl₃) ;
 1.35 (3H, t, J=7.2Hz), 3.89 (3H, s), 4.28 (2H, q, J=7.2Hz), 4.79 (2H, d, J=5.6Hz), 6.91 (1H, d, J=8.4Hz), 7.16 (1H, d, J=15.6Hz), 7.33 (1H, dd, J=8.4Hz, 2.0Hz), 7.46 (1H, d, J=2.0Hz), 7.62 (1H, d, J=15.6Hz), 7.64 (1H, dd, J=8.8Hz, 2.4Hz), 7.75 (1H, d, J=8.8Hz), 7.77 (1H, brs), 8.16 (1H, d, J=2.4Hz)

Example 116(E)-2-(2-Ethoxycarbonyl-1-propenyl)-4-(3-chloro-4-methoxybenzyl)amino-6-chloroquinazoline


[0267]



- molecular formula; $C_{22}H_{21}N_3O_3Cl_2$
- yield(%); 54
- m.p.(°C); 154 ~ 155
- Mass; 446 (M+1)⁺
- NMR δ (CDCl₃) ;
 1.35 (3H, t, J=7.2Hz), 2.48 (3H, d, J=1.6Hz), 3.91 (3H, s), 4.29 (2H, q, J=7.2Hz), 4.80 (2H, d, J=5.2Hz), 5.82 (1H, brt, J=5.2Hz), 6.92 (1H, d, J=8.8Hz), 7.27 (1H, dd, J=8.8Hz, 2.0Hz), 7.42 (1H, d, J=2.0Hz), 7.62 (1H, q, J=1.6Hz), 7.67 (1H, d, J=2.4Hz), 7.69 (1H, dd, J=8.8Hz, 2.4Hz), 7.82 (1H, d, J=8.8Hz)

Example 117(Z)-2-(2-Ethoxycarbonyl-1-propenyl)-4-(3-chloro-4-methoxybenzyl)amino-6-chloroquinazoline

[0268]

• molecular formula; $C_{22}H_{21}N_3O_4Cl_2$

• yield(%); 11


• m.p. (°C); 141 ~ 142

• Mass; 446 (M+1)⁺• NMR δ (CDCl₃);

1.19 (3H, t, J=7.2Hz), 2.17 (3H, d, J=1.6Hz), 3.91 (3H, s), 4.19 (2H, q, J=7.2Hz), 4.73 (2H, d, J=5.2Hz), 5.69 (1H, brt, J=5.2Hz), 6.53 (1H, q, J=1.6Hz), 6.92 (1H, d, J=8.4Hz), 7.26 (1H, dd, J=8.4Hz, 2.0Hz), 7.40 (1H, d, J=2.0Hz), 7.60 (1H, d, J=2.0Hz), 7.63 (1H, dd, J=8.8Hz, 2.0Hz), 7.71 (1H, d, J=8.8Hz)

Example 118(E)-2-(2-Ethoxycarbonyl-1-propenyl)-4-(3,4-methylenedioxybenzyl)amino-6,7,8-tribethoxyquinazoline

[0269]

• molecular formula; $C_{25}H_{27}N_3O_7$

• yield(%); 51

• m.p. (°C); 175 ~ 176


• Mass; 482 (M+1)⁺• NMR δ (CDCl₃);

1.35 (3H, t, J=7.2Hz), 2.52 (3H, d, J=1.6Hz), 3.95 (3H, s), 4.04 (3H, s), 4.14 (3H, s), 4.28 (2H, q, J=7.2Hz), 4.80 (2H, d, J=5.2Hz), 5.60 (1H, brt, J=5.2Hz), 5.96 (2H, s), 6.67 (1H, s), 6.80 (1H, d, J=8.0Hz), 6.87 (1H, dd, J=8.0Hz, 1.6Hz), 6.90 (1H, d, J=1.6Hz), 7.69 (1H, q, J=1.6Hz)

Example 119

(Z)-2-(2-Ethoxycarbonyl-1-propenyl)-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0270]



- molecular formula; $C_{25}H_{27}N_3O_7$

- yield(%); 11

- m.p.(°C); 157 ~ 158 (dec.)

- Mass; 482 (M+1)⁺


- NMR δ ($CDCl_3$);

1.19 (3H, t, J=7.2Hz), 2.16 (3H, s), 3.92 (3H, s), 4.02 (3H, s), 4.09 (3H, s), 4.21 (2H, q, J=7.2Hz), 4.72 (2H, d, J=5.2Hz), 5.43 (1H, brs), 5.96 (2H, s), 6.59 ~ 6.61 (2H, m), 6.80 (1H, d, J=8.0Hz), 6.86 ~ 6.89 (2H, m)

Example 120

(E)-2-(2-Carboxy-1-propenyl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0271]



[0272] 1.00 g (0.0023 mol) of (E)-2-(2-ethoxycarbonylpropenyl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline was dissolved in a mixture comprising 5 ml of tetrahydrofuran and 20 ml of ethanol, followed by the addition of 20 ml of a 1N aqueous solution of sodium hydroxide. The obtained mixture was stirred at room temperature for several hours, neutralized with 20 ml of 1N hydrochloric acid and concentrated under a reduced pressure. The crystal thus formed was recovered by filtration, washed with water and air-dried to give 0.85 g of the title compound.

- molecular formula; $C_{20}H_{16}N_3O_4Cl$

- yield(%); 91

- m.p.(°C); 145 ~ 146

- Mass; 398 (M+1)⁺

- NMR δ ($DMSO-d_6$);

2.36 (3H, d, J=1.6Hz), 4.70 (2H, d, J=5.6Hz), 5.97 (2H, s), 6.85 (2H, s), 6.95 (1H, s), 7.34 (1H, q, J=1.6Hz), 7.72 (1H, d, J=8.8Hz), 7.79 (1H, dd, J=8.8Hz, 2.0Hz), 8.46 (1H, d, J=2.0Hz), 8.86 (1H, brt, J=5.6Hz)


Examples 121 to 128

[0273] The following compounds were prepared in a similar manner to that of Example 120.

5 Example 121

2-Carboxy-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

10 [0274]




- 15
- molecular formula; $C_{17}H_{12}N_3O_4Cl$
 - yield(%); quantitative
 - m.p. ($^{\circ}C$); 240 (dec.)
 - 25 • Mass; 402 (M-1+2Na)⁺
 - NMR δ (DMSO- d_6);
 4.71 (2H, d, J=5.6Hz), 5.96 (2H, s), 6.83 (1H, d, J=8.0Hz), 6.89 (1H, dd, J=8.0Hz, 1.2Hz), 7.06 (1H, d, J=1.2Hz), 7.75 (1H, dd, J=8.8Hz, 2.4Hz), 7.90 (1H, d, J=8.8Hz), 8.48 (1H, d, J=2.4Hz), 8.82 (1H, brt, J=5.6Hz)

30 Example 122

(E)-2-(2-Carboxyvinyl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

35 [0275]



- 40
- molecular formula; $C_{19}H_{14}N_3O_4Cl$
 - yield(%); 43
 - m.p. ($^{\circ}C$); 114 ~ 115
 - 50 • Mass; 428 (M-1+2Na)⁺
 - NMR δ (DMSO- d_6);
 4.71 (2H, d, J=5.6Hz), 5.96 (2H, s), 6.84 (1H, d, J=8.0Hz), 6.90 (1H, dd, J=8.0Hz, 1.6Hz), 6.99 (1H, d, J=1.6Hz), 7.02 (1H, d, J=15.6Hz), 7.23 (1H, d, J=15.6Hz), 7.73 (1H, d, J=9.2Hz), 7.78 (1H, dd, J=9.2Hz, 2.0Hz), 8.44 (1H, d, J=2.0Hz), 8.89 (1H, brt, J=5.6Hz)
- 55


Example 123

(Z)-2-(2-carboxy-1-propenyl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

5 [0276]

10

15



- molecular formula; $C_{20}H_{16}N_3O_4Cl$
- yield(%); quantitative
- 20 • m.p.(°C); 195 ~ 196
- Mass; 398 (M+1)⁺
- NMR 6 (DMSO- d_6) ;
- 25 2.10 (3H, d, J=1.6Hz), 4.70 (2H, d, J=5.6Hz), 5.97 (2H, s), 6.56 (1H, d, J=1.6Hz), 6.86 (1H, d, J=8.0Hz), 6.91 (1H, dd, J=8.0Hz, 1.6Hz), 7.00 (1H, d, J=1.6Hz), 7.65 (1H, d, J=9.2Hz), 7.81 (1H, dd, J=9.2Hz, 2.4Hz), 8.46 (1H, d, J=2.4Hz), 8.96 (1H, brt, J=5.6Hz)

Example 124


(E)-2-(2-Carboxyvinyl)-4-(3-chloro-4-methoxybenzyl)amino-6-chloroquinazoline

30

[0277]

35

40




- molecular formula; $C_{19}H_{15}N_3Cl_2O$
- 45 • yield(%); quantitative
- m.p.(°C); 109 ~ 110
- Mass; 448 (M-1+2Na)⁺
- NMR δ (DMSO- d_6);
- 50 3.81 (3H, s), 4.73 (2H, d, J=5.6Hz), 6.95 (1H, d, J=15.6Hz), 7.05 (1H, d, J=15.6Hz), 7.08 (1H, d, J=8.4Hz), 7.37 (1H, dd, J=8.4Hz, 2.0Hz), 7.48 (1H, d, J=2.0Hz), 7.68 (1H, d, J=8.8Hz), 7.73 (1H, dd, J=8.8Hz, 2.0Hz), 8.42 (1H, d, J=2.0Hz), 8.91 (1H, brt, J=5.6Hz)

55

Example 125(E)-2-(2-Carboxy-1-propenyl)-4-(3-chloro-4-methoxybenzyl)amino-6-chloroquinazoline


[0278]



- molecular formula; $C_{20}H_{17}N_3O_3Cl_2$
- yield(%); quantitative
- m.p.(°C); 151 ~ 152
- Mass; 462 ($M+2Na$)
- NMR δ (DMSO- d_6):
 2.33 (3H, d, $J=1.2$ Hz), 3.82 (3H, s), 4.72 (2H, d, $J=5.6$ Hz), 7.09 (1H, d, $J=8.4$ Hz), 7.20 (1H, d, $J=1.2$ Hz), 7.32 (1H, dd, $J=8.4$ Hz, 2.0Hz), 7.44 (1H, d, $J=2.0$ Hz), 7.67 (1H, d, $J=8.8$ Hz), 7.74 (1H, dd, $J=8.8$ Hz, 2.4Hz), 8.43 (1H, d, $J=2.4$ Hz), 8.87 (1H, brt, $J=5.6$ Hz)

Example 126(Z)-2-(2-Carboxy-1-propenyl)-4-(3-chloro-4-methoxybenzyl)amino-6-chloroquinazoline

[0279]




- molecular formula; $C_{20}H_{17}N_3O_3Cl_2$
- yield(%); quantitative
- m.p.(°C); 207 ~ 208 (dec.)
- Mass; 418 ($M+1$)⁺
- NMR δ (DMSO- d_6):
 2.10 (3H, d, $J=1.4$ Hz), 3.83 (3H, s), 4.72 (2H, d, $J=5.2$ Hz), 6.54 (1H, d, $J=1.4$ Hz), 7.10 (1H, d, $J=8.4$ Hz), 7.38 (1H, dd, $J=8.4$ Hz, 2.4Hz), 7.49 (1H, d, $J=2.4$ Hz), 7.65 (1H, d, $J=8.8$ Hz), 7.81 (1H, dd, $J=8.8$ Hz, 2.4Hz), 8.44 (1H, d, $J=2.4$ Hz), 8.95 (1H, brt, $J=5.2$ Hz)

Example 127

(E)-2-(2-Carboxy-1-propenyl)-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0280]

• molecular formula; $C_{23}H_{23}N_3O_7$

• yield(%); 91

• m.p.(°C); 200 ~ 201 (dec.)


• Mass; 454 (M+1)⁺• NMR δ (DMSO- d_6);

2.38 (3H, s), 3.89 (3H, s), 3.92 (3H, s), 4.01 (3H, s), 4.71 (2H, d, J=5.6Hz), 5.97 (2H, s), 6.85 (2H, s), 6.93 (1H, s), 7.37 (1H, s), 7.53 (1H, s), 8.53 (2H, brt, J=5.6Hz), 12.55 (1H, brs)

Example 128

(Z)-2-(2-Carboxy-1-propenyl)-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0281]

• molecular formula; $C_{23}H_{23}N_3O_7$

• yield(%); 90

• m.p.(°C); 237 ~ 238 (dec.)

• Mass; 454 (M+1)⁺• NMR δ (DMSO- d_6);


2.11 (3H, d, J=1.2Hz), 3.92 ((3H, s), 3.93 (3H, s), 3.94 (3H, s), 4.76 (2H, d, J=5.6Hz), 5.98 (2H, s), 6.8 ~ 6.9 (3H, m), 6.97 (1H, s), 7.61 (1H, s), 9.08 (1H, brt, J=5.6Hz)

Preparative Example 1294-(α -Carboxy-3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

5 [0282]

10

15



[0283] 10 ml of ethanol, 5 ml of water and 20 mg of sodium hydroxide were added to 100 mg of 4-(α -ethoxycarbonyl-3,4-methylenedioxybenzyl)amino-6-chloroquinazoline. The obtained mixture was refluxed for 10 minutes and concentrated under a reduced pressure, followed by the addition of 20 ml of water. The obtained mixture was neutralized with 1N hydrochloric acid. The crystal thus precipitated was recovered by filtration. Thus, 45 mg of the title compound was obtained.

- molecular formula; $C_{17}H_{12}N_3O_4Cl$
- yield(%); 49
- m.p. ($^{\circ}C$); 235 ~ 236
- Mass m/e; 358 (M+1)
- NMR δ (DMSO- d_6);
 5.75 (1H, d, J=6.4Hz), 6.01 (2H, s), 6.89 (1H, d, J=8.0Hz), 7.00 (1H, d, J=8.0Hz), 7.08 (1H, s), 7.70 (1H, d, J=8.8Hz), 7.75 (1H, dd, J=1.6Hz, 8.8Hz), 8.49 (1H, s), 8.59 (1H, d, J=6.4Hz), 8.70 (1H, d, J=1.6Hz)

Examples 130 to 131


[0284] The following compounds were prepared in a similar manner to that of Preparative Example 129.

Example 1304-[N-(Carboxymethyl)-(3,4-methylenedioxybenzyl)]amino-6,7,8-trimethoxyquinazoline

40 [0285]

45

50




- molecular formula; $C_{21}H_{21}N_3O_7$
- yield(%); 90
- m.p. ($^{\circ}C$); 134 ~ 136
- Mass; 428 (M+H) $^{+}$

- NMR δ (CDCl_3) ;
3.43 (3H, s), 4.06 (3H, s), 4.17 (3H, s), 4.62 (2H, s), 5.16 (2H, s), 6.03 (2H, s), 6.87 (1H, s), 6.91 (2H, s),
7.06 (1H, s), 8.87 (1H, s)

5 Example 131

4-(3,4-Methylenedioxybenzyl)amino-6-carboxyquinazoline

[0286]




- molecular formula; $\text{C}_{17}\text{H}_{13}\text{N}_3\text{O}_4$
- yield(%); 98
- m.p.($^{\circ}\text{C}$); 247 ~ 248 (dec.)
- Mass; 324 ($\text{M}+\text{H}$)⁺
- NMR δ ($\text{DMSO}-d_6$) ;
4.86 (2H, d, $J=5.6\text{Hz}$), 5.99 (2H, s), 6.89 (1H, d, $J=8.0\text{Hz}$), 6.92 (1H, d, $J=8.0\text{Hz}$), 7.02 (1H, s), 7.92 (1H, d,
 $J=8.8\text{Hz}$), 8.46 (1H, d, $J=8.8\text{Hz}$), 8.96 (1H, s), 9.20 (1H, s), 10.88 (1H, brs)

30 Preparative Example 132

4-(α -Carbamoyl-3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0287]



[0288] 20 ml of a 10 % solution of ammonia in ethanol was added to 200 mg of 4-(α -ethoxycarbonyl-3,4-methylenedioxybenzyl)amino-6-chloroquinazoline. The obtained mixture was stirred at room temperature for 3 days. The crystal thus precipitated was recovered by filtration. Thus, 60 mg of the title compound was obtained.

- molecular formula; $\text{C}_{17}\text{H}_{13}\text{N}_4\text{O}_3\text{Cl}$
- yield(%); 32
- m.p.($^{\circ}\text{C}$) ; 230 ~ 231
- Mass m/e; 357 ($\text{M}+1$)
- NMR δ ($\text{CDCl}_3+\text{DMSO}-d_6$) ;
5.96 (3H, m), 6.42 (1H, brs), 6.79 (1H, d, $J=8.0\text{Hz}$), 7.09 (1H, dd, $J=8.0\text{Hz}$, 1.6Hz), 7.14 (1H, d, $J=1.6\text{Hz}$),
7.15 (1H, brs), 7.67 (1H, dd, $J=8.8\text{Hz}$, 2.0Hz), 7.75 (1H, d, $J=8.8\text{Hz}$), 8.28 (1H, d, $J=2.0\text{Hz}$), 8.57 (1H, s)


Examples 133 and 134

[0289] The following compounds were prepared in a similar manner to that of Preparative Example 132.

5 Example 133

4-(3,4-Methylenedioxybenzyl)amino-6-carbamoylquinazoline

10 [0290]



20 • molecular formula; $C_{17}H_{14}N_4O_3$

• Mass; 323 (M+H)⁺


• NMR δ (DMSO- d_6);

4.68 (2H, d, J=6.0Hz), 5.97 (2H, s), 6.85 (1H, d, J=8.0Hz), 6.88 (1H, d, J=8.0Hz), 6.97 (1H, s), 7.55 (1H, brs), 7.70 (1H, d, J=8.4Hz), 7.97 (1H, brs), 8.18 (1H, dd, J=8.4Hz, 1.6Hz), 8.50 (1H, s), 8.84 (1H, d, J=1.6Hz), 8.92 (1H, brt, J=6.0Hz)

Example 134

30 2-Carbamoyl-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0291]



45 • molecular formula; $C_{17}H_{13}ClN_4O_3$

• yield(%); 71

• m.p.(°C); 245 ~ 247 (dec.)


• Mass; 357 (M+1)

• NMR δ (DMSO- d_6);

50 4.77 (2H, d, J=5.2Hz), 5.97 (2H, s), 6.85 (1H, d, J=8.0Hz), 6.92 (1H, d, J=8.0Hz), 7.04 (1H, s), 7.66 (1H, brs), 7.83 (2H, m), 8.07 (1H, brs), 8.49 (1H, s), 8.99 (1H, brs)

Example 1364-[(3,4-Methylenedioxybenzyl)amino]-6-hydroxymethylquinazoline

[0292]




[0293] The title compound was prepared in a similar manner to that of Example 135.

- molecular formula; $C_{17}H_{15}N_3O_3$
 - yield(%); 34
 - m.p.(°C); 176 ~ 177
 - Mass m/e; 310 (M+1)
 - NMR δ (DMSO- d_6);
- 4.62 (2H, d, J=5.6Hz), 4.65 (2H, d, J=5.6Hz), 5.36 (1H, t, J=5.6Hz), 5.94 (2H, s), 6.82 (1H, s), 6.82 (1H, s), 6.92 (1H, s), 7.63 (1H, d, J=8.4Hz), 7.70 (1H, d, J=8.4Hz), 8.20 (1H, s), 8.41 (1H, s), 8.74 (1H, t, J=5.6Hz)

Example 1374-[(3,4-Methylenedioxybenzyl)amino]-6-methylsulfinylquinazoline

[0294]




[0295] A solution of 1.20 g (6.95 mmol) of m-chloroperbenzoic acid in 30 ml of chloroform was dropped into a solution of 1.80 g (5.53 mmol) of 4-[(3,4-methylenedioxybenzyl)amino]-6-methylthioquinazoline in 100 ml of chloroform under cooling with ice and stirring. The obtained mixture was stirred under cooling with ice for several hours, washed with a saturated aqueous solution of sodium hydrogencarbonate, dried over anhydrous magnesium sulfate and filtered. The filtrate was purified by silica gel column chromatography (ethyl acetate/acetone) and recrystallized from chloroform/n-hexane to give 1.51 g of the title compound as a pale-yellow crystal.

- molecular formula; $C_{17}H_{15}N_3O_3S$
 - yield(%); 80
 - m.p.(°C); 154 ~ 155
 - Mass; 342 (M+H)⁺
 - NMR δ (CDCl₃);
- 2.75 (3H, s), 4.80 (2H, d, J=5.2Hz), 5.96 (2H, s), 6.80 (1H, d, J=8.0Hz), 6.89 (1H, d, J=8.0Hz), 6.91 (1H, s), 7.06 (1H, brs), 7.64 (1H, d, J=8.8Hz), 7.98 (1H, d, J=8.8Hz), 8.43 (1H, s), 8.74 (1H, s)

Example 1384-(3,4-Methylenedioxybenzyl)amino-6-methylsulfonylquinazoline

[0296]




[0297] A solution of 0.65 g (3.8 mmol) of m-chloroperbenzoic acid in 20 ml of chloroform was dropped into a solution of 1.00 g (2.93 mmol) of the 4-(3,4-methylenedioxybenzyl)amino-6-methylsulfonylquinazoline prepared in Example 137 under stirring at room temperature. The obtained mixture was stirred at room temperature for several hours, washed with a saturated aqueous solution of sodium hydrogencarbonate, dried over anhydrous magnesium sulfate and filtered. The filtrate was purified by silica gel column chromatography (ethyl acetate) and recrystallized from chloroform/n-hexane to give 0.85 g of the title compound as a yellow crystal.

- molecular formula; $C_{17}H_{15}N_3O_4S$
- yield(%); 81
- m.p.(°C); 192 ~ 193
- Mass; 358 (M+H)⁺
- NMR δ (CDCl₃);
3.13 (3H, s), 4.80 (2H, d, J=5.2Hz), 5.95 (2H, s), 6.79 (1H, d, J=8.0Hz), 6.91 (1H, d, J=8.0Hz), 6.95 (1H, s), 8.05 (1H, d, J=8.8Hz), 8.17 (1H, d, J=8.8Hz), 8.72 (1H, s), 8.81 (1H, brs), 8.98 (1H, s)

Example 1392-Hydroxymethyl-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline

[0298]



[0299] 1.5 g of 10% palladium/carbon powder was added to a solution of 1.26 g (2.93 mmol) of 2-benzyloxymethyl-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline in an ethyl acetate/ethanol (20 ml - 20 ml) mixture. The obtained mixture was stirred at room temperature in a stream of hydrogen for 24 hours and filtered through Celite. The filter cake was washed with hot ethyl acetate/ethanol. The filtrate and the washings were distilled under a reduced pressure to remove the solvent. Thus 0.89 g of the title compound was obtained as a pale-yellow crystal.

- molecular formula; $C_{18}H_{17}N_3O_4$
- yield(%); 89
- m.p.(°C); 216 ~ 218
- Mass; 340 (M+H)⁺


NMR δ (CDCl_3);

3.91 (3H, s), 4.15 (1H, brs), 4.68 (2H, brs), 4.77 (2H, d, $J=5.6\text{Hz}$), 5.95 (2H, s), 6.79 (1H, d, 7.6Hz), 6.85 (1H, brs), 6.88 (1H, dd, $J=7.6\text{Hz}$, 1.6Hz), 6.92 (1H, d, $J=1.6\text{Hz}$), 7.21 (1H, d, $J=2.8\text{Hz}$), 7.37 (1H, dd, $J=9.2\text{Hz}$, 2.8Hz), 7.72 (1H, d, $J=9.2\text{Hz}$)

Example 140

2-Hydroxy-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline

[0300]



[0301] The title compound was prepared in a similar manner to that of Example 139.

- molecular formula; $\text{C}_{17}\text{H}_{15}\text{N}_3\text{O}_4$

- yield(%); 16

- m.p. ($^{\circ}\text{C}$); 215 ~ 217 (dec.)

- Mass; 326 ($\text{M}+\text{H}$) $^{+}$


- NMR δ ($\text{DMSO}-d_6$);

3.79 (3H, s), 4.62 (2H, d, $J=5.6\text{Hz}$), 5.98 (2H, s), 6.84 ~ 6.87 (2H, m), 6.94 (1H, s), 7.09 (1H, d, $J=8.8\text{Hz}$), 7.22 (1H, dd, $J=8.8\text{Hz}$, 2.8Hz), 7.60 (1H, d, $J=2.8\text{Hz}$), 8.65 (1H, brt, $J=5.6\text{Hz}$), 10.55 (1H, s)

Example 141

2-Formyl-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline

[0302]




[0303] A solution of 1.5 ml of dimethyl sulfoxide in 5 ml of methylene chloride was dropped into a solution of 1.0 ml (11 mmol) of oxalyl chloride in 10 ml of methylene chloride under stirring at -78°C . The obtained mixture was stirred at -78°C for 15 minutes, followed by the dropwise addition of a solution of 0.74 g (2.2 mmol) of 2-hydroxymethyl-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline in 7 ml of dimethyl sulfoxide. After the mixture thus obtained had been stirred at -78°C for 20 minutes, 5 ml of triethylamine was dropped into the resulting mixture. The mixture thus prepared was stirred for 30 minutes, while raising the temperature to room temperature. Water was added to the reaction mixture and the resulting mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was distilled under a reduced pressure to remove the solvent. Thus, 0.74 g of the title compound was obtained as a crude brown oil.

- molecular formula; $C_{18}H_{15}N_3O_4$
- yield(%); quantitative
- NMR δ ($CDCl_3$) :
 3.93 (3H, s), 4.86 (2H, d, $J=5.6$ Hz), 5.95 (2H, s), 6.28 (1H, brs), 6.78 (1H, d, $J=8.0$ Hz), 6.89 (1H, dd, $J=8.0$ Hz, 1.6Hz), 6.92 (1H, d, $J=1.6$ Hz), 7.09 (1H, d, $J=2.8$ Hz), 7.47 (1H, dd, $J=9.2$ Hz, 2.8Hz), 7.97 (1H, d, $J=9.2$ Hz), 10.02 (1H, s)

Example 1422-Carboxy-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline

[0304]



[0305] 1.00 g of silver (I) oxide and 15 ml of a 1N aqueous solution of sodium hydroxide were added to a solution of 0.59 g (1.8 mmol) of the 2-formyl-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline prepared in Example 141 in 20 ml of 1,4-dioxane. The obtained mixture was stirred at 60°C. After 30 minutes, the reaction mixture was filtered through Celite and the filter cake was washed with a small amount of dioxane and water. The filtrate and washings were neutralized with 1N hydrochloric acid and extracted with chloroform/ethanol. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was distilled under a reduced pressure to remove the solvent. The crystal thus formed was recovered by filtration and washed with chloroform to give 0.34 g of the title compound as a pale-yellow crystal.

- molecular formula; $C_{18}H_{15}N_3O_5$
- yield(%); 55
- m.p.(°C); 190 ~ 191 (dec.)
- Mass; 354 ($M+H$)⁺
- NMR δ ($DMSO-d_6$);
 3.90 (3H, s), 4.77 (2H, d, $J=5.6$ Hz), 5.97 (2H, s), 6.86 (1H, d, $J=8.0$ Hz), 6.92 (1H, d, $J=8.0$ Hz), 7.05 (1H, s), 7.49 (1H, dd, $J=9.2$ Hz, 2.8Hz), 7.76 (1H, d, $J=2.8$ Hz), 7.79 (1H, d, $J=9.2$ Hz), 8.91 (1H, brt, $J=5.6$ Hz)

Examples 143 to 145


[0306] The following compounds were prepared in a similar manner to that of Example 141 or 142.

Example 1434-(3-Formylbenzyl)amino-6,7,8-trimethoxyquinazoline

5 [0307]

10

15



- molecular formula; $C_{19}H_{19}N_3O_4$
- yield(%); quantitative
- m.p.(°C); oily substance
- NMR δ ($CDCl_3$) ;
 3.96 (3H, s), 4.04 (3H, s), 4.13 (3H, s), 4.97 (2H, d, $J=5.6$ Hz), 5.97 (1H, brt, $J=5.6$ Hz), 6.76 (1H, s), 7.53 (1H, t, $J=7.6$ Hz), 7.70 (1H, d, $J=7.6$ Hz), 7.81 (1H, d, $J=7.6$ Hz), 7.91 (1H, s), 8.64 (1H, s), 10.00 (1H, s)


25

Example 1444-(3-Carboxybenzyl)amino-6,7,8-trimethoxyquinazoline

30 [0308]

35


40




- molecular formula; $C_{19}H_{19}N_3O_5$
- yield(%); 45
- m.p.(°C); 245 ~ 246 (dec.)
- Mass; 370 (M+H)⁺
- NMR δ (DMSO- d_6);
 3.89 (3H, s), 3.93 (3H, s), 3.98 (3H, s), 4.86 (2H, d, $J=5.6$ Hz), 7.46 (1H, d, $J=7.6$ Hz), 7.56 (1H, s), 7.62 (1H, d, $J=7.6$ Hz), 7.83 (1H, d, $J=7.6$ Hz), 7.95 (1H, s), 8.39 (1H, s), 8.83 (1H, brs)

50

55

Example 145**4-(4-Acetylbenzyl)amino-6-methoxyquinazoline****[0309]**

- molecular formula; $C_{18}H_{17}N_3O_2$
- yield(%); 41
- m.p.(°C); 204 ~ 206
- Mass; 308 (M+H)⁺
- NMR δ ($CDCl_3$):
2.60 (3H, s), 3.91 (3H, s), 4.97 (2H, d, J=5.6Hz), 5.96 (1H, brs), 6.98 (1H, s), 7.42 (1H, d, J=9.2Hz), 7.50 (2H, d, J=8.0Hz), 7.82 (1H, d, J=9.2Hz), 7.94 (2H, d, J=8.0Hz), 8.61 (1H, s)

Example 146**2-Hydroxyiminomethyl-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline****[0310]**

[0311] 0.60 g of hydroxylamine hydrochloride and 3.0 ml of a 1N aqueous solution of sodium hydroxide were added to a solution of 1.00 g (2.93 mmol) of 2-formyl-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline in 30 ml of ethanol. The obtained mixture was stirred at 60°C for 30 minutes and cooled by allowing to stand. The crystal thus precipitated was recovered by filtration, washed with ethanol and n-hexane and air-dried to give 1.00 g of the title compound as a white crystal.


- molecular formula; $C_{17}H_{13}N_4O_3Cl$
- yield(%); 96
- m.p. (°C); 245 ~ 246 (dec.)
- Mass; 357 (M+1)
- NMR δ ($DMSO-d_6$):
4.69 (2H, d, J=6.0Hz), 5.96 (2H, s), 6.84 (1H, d, J=7.6Hz), 6.91 (1H, d, J=7.6Hz, 1.6Hz), 7.05 (1H, d, J=1.6Hz), 7.72 (1H, d, J=8.8Hz), 7.78 (1H, dd, J=8.8Hz, 2.0Hz), 7.96 (1H, s), 8.45 (1H, d, J=2.0Hz), 8.91 (1H, brt, J=6.0Hz), 11.83 (1H, s)

Examples 147 to 149

[0312] The following compounds were prepared in a similar manner to that of Example 146.

Example 1472-Hydroxyiminomethyl-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline


[0313]



- molecular formula; $C_{18}H_{16}N_4O_4$
- yield(%); 46
- m.p.(°C); 229 ~ 230 (dec.)
- Mass; 353 (M+H)⁺
- NMR δ (DMSO- d_6) ;
 3.88 (3H, s), 4.72 (2H, d, J=5.6Hz), 5.96 (2H, s), 6.85 (1H, d, J=8.0Hz), 6.91 (1H, d, J=8.0Hz), 7.05 (1H, s),
 7.40 (1H, dd, J=9.2Hz, 2.8Hz), 7.66 (1H, d, J=9.2Hz), 7.69 (1H, d, J=2.8Hz), 7.94 (1H, s), 8.62 (1H, brt, J=5.6Hz),
 11.63 (1H, s)

Example 1484-(3-Hydroxyiminomethylbenzyl)amino-6,7,8-trimethoxyquinazoline


[0314]



- molecular formula; $C_{19}H_{20}N_4O_4$
- yield(%); 56
- m.p.(°C); 231 ~ 232 (dec.)
- Mass; 369 (M+H)⁺
- NMR δ (DMSO- d_6) ;
 3.88 (3H, s), 3.91 (3H, s), 3.98 (3H, s), 4.80 (2H, d, J=6.0Hz), 7.3 ~ 7.5 (3H, m), 7.52 (1H, s), 7.60 (1H, s),
 8.11 (1H, s), 8.35 (1H, s), 8.60 (1H, brs), 11.17 (1H, s)

Example 1494-[4-(1-Hydroxyiminoethyl)benzyl]amino-6-methoxyquinazoline


[0315]



- molecular formula; $C_{18}H_{18}N_4O_2$
- yield(%); quantitative
- m.p.(°C); 245 ~ 246 (dec.)
- Mass; 323 (M+H)⁺
- NMR δ (DMSO- d_6);
2.13 (3H, s), 3.95 (3H, s), 4.97 (2H, d, J=5.6Hz), 7.44 (2H, d, J=8.4Hz), 7.63 (2H, d, J=8.4Hz), 7.68 (1H, dd, J=9.2Hz, 2.8Hz), 7.83 (1H, d, J=9.2Hz), 8.14 (1H, d, J=2.8Hz), 8.84 (1H, s), 10.75 (1H, brs), 11.18 (1H, s)

Example 1502-Ethoxycarbonylmethoxyiminomethyl-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0316]




[0317] 0.10 g (2.5 mmol) of sodium hydride was added to a suspension of 0.50 g (1.4 mmol) of 2-hydroxyiminomethyl-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline in 25 ml of dimethylformamide. The obtained mixture was stirred. After 30 minutes, 25 ml (2.3 mmol) of ethyl bromoacetate was dropped into the mixture. The mixture thus obtained was stirred at room temperature for several hours, followed by the addition of water. The obtained mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was distilled under a reducer pressure to remove the solvent. The residue was purified by silica gel column chromatography (ethyl acetate/ n-hexane) to give 0.52 g of the title compound as a pale-yellow crystal.

- molecular formula; $C_{21}H_{19}N_4O_5Cl$
- yield(%); 84
- m.p.(°C); 154 ~ 155
- Mass; 443 (M+1)
- NMR δ (CDCl₃);
1.29 (3H, t, J=7.2Hz), 4.23 (2H, q, J=7.2Hz), 4.74 (2H, d, J=5.2Hz), 4.88 (2H, s), 5.96 (2H, s), 6.03 (1H, brt, J=5.2Hz), 6.78 (1H, d, J=7.6Hz), 6.87 (1H, d, J=7.6Hz, 1.6Hz), 6.93 (1H, d, J=1.6Hz), 7.65 (1H, dd, J=8.8Hz, 2.0Hz), 7.70 (1H, d, J=2.0Hz), 7.84 (1H, d, J=8.8Hz), 8.25 (1H, s)

Example 1514-(3-Amino-4-chlorobenzyl)amino-6-chloroquinazoline

[0318]




[0319] A mixture comprising 1.00 g (2.86 mmol) of 4-(4-chloro-3-nitrobenzyl)amino-6-chloroquinazoline, 0.85 g of powdered iron, 10 ml of acetic acid and 50 ml of ethanol was heated under reflux for several hours and distilled under a reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (ethyl acetate/n-hexane) to give 0.91 g of the title compound as a pale-yellow crystal. · molecular formula; $C_{15}H_{12}N_4Cl_2$

- yield(%); quantitative
- m.p.(°C); 226 ~ 229 (dec.)
- Mass; 319 (M+H)⁺
- NMR δ (CDCl₃) ;
 4.19 (2H, brs), 4.73 (2H, d, J=6.0Hz), 6.71 (1H, dd, J=8.0Hz, 2.0Hz), 6.83 (1H, d, J=2.0Hz), 7.18 (1H, d, J=8.0Hz), 7.64 (1H, dd, J=8.8Hz, 2.0Hz), 7.72 (1H, brs), 7.74 (1H, d, J=8.8Hz), 8.19 (1H, d, J=2.0Hz), 8.60 (1H, s)

Example 1524-(4-Chloro-3-formamidobenzyl)amino-6-chloroquinazoline

[0320]



[0321] 0.90 g (2.82 mmol) of the 4-(3-amino-4-chlorobenzyl)amino-6-chloroquinazoline prepared in Example 151 was dissolved in 15 ml of formic acid, followed by the addition of 1 ml of acetic anhydride. The obtained mixture was stirred at room temperature for several hours and distilled under a reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (ethyl acetate) and recrystallized from ethyl acetate to give 0.64 g of the title compound as a pale yellow crystal.


- molecular formula; $C_{16}H_{12}N_4OCl_2$
- yield(%); 65
- m.p.(°C); 229 ~ 230
- Mass; 347 (M+H)⁺
- NMR δ (DMSO-d₆);
 4.74 (2H, d, J=5.6Hz), 7.15 (1H, dd, J=8.4Hz, 2.0Hz), 7.43 (1H, d, J=8.4Hz), 7.72 (1H, d, J=8.8Hz), 7.80

(1H, dd, J=8.8Hz, 2.0Hz), 8.16 (1H, d, J=2.0Hz), 8.32 (1H, d, J=2.0Hz), 8.45 (1H, s), 8.46 (1H, s), 8.95 (1H, brs), 9.83 (1H, brs)

Example 153

4-(3-Formamido-4-methoxybenzyl)amino-6-chloroquinazoline


[0322]



[0323] 1 g of powdered iron was added in portions to a mixture comprising 1 g of 4-(3-nitro-4-methoxybenzyl)amino-6-chloroquinazoline, 4 ml of acetic acid, 4 ml of water and 40 ml of ethanol, while heating the mixture under mild reflux. The obtained mixture was heated under reflux for 2 hours and filtered to remove insolubles. Concentrated hydrochloric acid was added in portions to the brown filtrate obtained above to give a yellow transparent solution. This solution was cooled with ice to precipitate crystals. The crystals were recovered by filtration and dried to give 1.1 g of 4-(3-amino-4-methoxybenzyl)amino-6-chloroquinazoline hydrochloride. This hydrochloride was dissolved in ethanol/water and the obtained solution was made alkaline by adding a 15% aqueous solution of sodium hydroxide in portions. Water was added to the resulting alkaline solution in portions to precipitate crystals. The crystals were recovered by filtration, washed with water and dried to give 770 mg of 4-(3-amino-4-methoxybenzyl)amine-6-chloroquinazoline (an aniline derivative). Separately, 1 ml of formic acid was dropped into 2 ml of acetic anhydride under cooling with ice and the obtained mixture was heated at 50°C for 15 minutes and immediately cooled with ice, followed by the addition of the above aniline derivative as such (in a crystalline state). The obtained mixture was reacted at that temperature for one hour and at room temperature for one hour, followed by the addition of water. The crystals thus formed were recovered by filtration, washed with water and dried to give 130 mg of the title compound.

- molecular formula; $C_{17}H_{15}N_4O_2Cl$ (342.786)
- yield(%); 60
- m.p.(°C); 208 ~ 209
- Mass; 343 (MH)⁺
- NMR δ (DMSO- d_6) ;

3.82 (3H, s), 4.68 (2H, d, J=5.7Hz), 6.98 (1H, d, J=8.2Hz), 7.09 (1H, dd, J=2.0Hz, 8.2Hz), 7.71 (1H, d, J=9.0Hz), 7.79 (1H, dd, J=2.4Hz, 9.0Hz), 8.23 (1H, d, J=2.0Hz), 8.27 (1H, d, J=2.4Hz), 8.47 (2H, s), 8.88 (1H, t, J=5.7Hz), 9.62 (1H, brs)


Example 154**4-(3-Methanesulfonylamino-4-chlorobenzyl)amino-6-chloroquinazoline****[0324]**

[0325] 75 μ l of methanesulfonyl chloride was added to a mixture comprising 100 mg of 4-(3-amino-4-chlorobenzyl)amino-6-chloroquinazoline and 3 ml of pyridine. The obtained mixture was stirred at room temperature for 1.5 hours. 20 ml of water was added in portions to the reaction mixture to precipitate crystals. The crystals were recovered by filtration, washed with water and dried to give 109 mg of the title compound.

- molecular formula; $C_{16}H_{14}N_4O_2SCl_2$ (397.284)
- yield(%); 88
- m.p.(°C) ; 209 ~ 210
- Mass; 397 (MH)⁺
- NMR δ (DMSO- d_6) ;
 3.01 (3H, s), 4.75 (2H, d, J=5.7Hz), 7.23 (1H, dd, J=2.2Hz, 8.2Hz), 7.45 (1H, d, J=8.2Hz), 7.46 (1H, d, J=2.2Hz), 7.73 (1H, d, J=9.0Hz), 7.81 (1H, dd, J=2.4Hz, 9.0Hz), 8.45 (1H, d, J=2.4Hz), 8.47 (1H, s), 8.97 (1H, brt, J=5.7Hz), 9.4 (1H, brs)

Examples 155 to 161

[0326] The following compounds were prepared in a similar manner to those of Examples 151 to 154.

Example 155**4-(3-Amino-4-hydroxybenzyl)amino-6,7,8-trimethoxyquinazoline****[0327]**

- molecular formula; $C_{18}H_{20}N_4O_4$
- yield(%); quantitative
- m.p.(°C); amorphous
- Mass; 357 (M+H)⁺
- NMR δ (CDCl₃) ;


EP 0 607 439 B1

3.68 (1H, brs), 3.82 (1H, brs), 3.95 (3H, s), 4.02 (3H, s), 4.11 (3H, s), 4.68 (2H, d, J=4.4Hz), 6.61 (1H, brs), 6.64 (1H, d, J=7.6Hz), 6.77 (1H, d, J=7.6Hz), 7.01 (1H, s), 8.50 (1H, brs), 8.60 (1H, s)

Example 156

4-(3-Ethoxycarbonylamino-4-ethoxycarbonyloxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0328]




- molecular formula; $C_{24}H_{28}N_4O_8$
- yield(%); 54
- m.p. ($^{\circ}C$); 229 ~ 230 (dec.)
- Mass; 501 (M+H)⁺
- NMR δ ($CDCl_3$);
 1.31 (3H, t, J=7.2Hz), 1.40 (3H, t, J=7.2Hz), 3.95 (3H, s), 4.03 (3H, s), 4.11 (3H, s), 4.21 (2H, q, J=7.2Hz), 4.35 (2H, q, J=7.2Hz), 4.81 (1H, d, J=5.2Hz), 5.80 (1H, brt, J=5.2Hz), 6.74 (1H, s), 6.87 (1H, s), 7.13 (1H, d, J=8.0Hz), 7.20 (1H, d, J=8.0Hz), 8.18 (1H, brs), 8.64 (1H, s)

Example 157

4-[Benzoxazol-2(3H)-on-5-ylmethyl]amino-6,7,8-trimethoxyquinazoline


[0329]



- molecular formula; $C_{19}H_{18}N_4O_5$
- yield(%); 62
- m.p. ($^{\circ}C$); 232 ~ 233 (dec.)
- Mass; 383 (M+H)⁺
- NMR δ (DMSO- d_6);
 3.87 (3H, s), 3.90 (3H, s), 3.96 (3H, s), 4.78 (2H, d, J=5.6Hz), 7.06 (1H, s), 7.07 (1H, d, J=8.0Hz), 7.20 (1H, d, J=8.0Hz), 7.50 (1H, s), 8.35 (1H, s), 8.58 (1H, brt, J=5.6Hz), 11.48 (1H, brs)

Example 1584-(4-Hydroxy-3-methanesulfonylamino-phenyl)amino-6,7,8-trimethoxyquinazoline


[0330]



- molecular formula; $C_{19}H_{22}N_4O_6S$
 - yield(%); 56
 - m.p.(°C); 215 ~ 216 (dec.)
 - Mass; 435 (M+H)⁺
 - NMR δ (DMSO- d_6);
- 2.91 (3H, s), 3.86 (3H, s), 3.89 (3H, s), 3.96 (3H, s), 4.65 (2H, d, J=5.6Hz), 6.83 (1H, d, J=8.0Hz), 7.04 (1H, dd, J=8.0Hz, 2.0Hz), 7.22 (1H, d, J=2.0Hz), 7.50 (1H, s), 8.34 (1H, s), 8.52 (1H, brt, J=5.6Hz), 8.66 (1H, brs), 9.75 (1H, brs)

Example 1594-(3-Amino-4-chlorophenyl)amino-6,7,8-trimethoxyquinazoline


[0331]



- molecular formula; $C_{18}H_{19}N_4O_3Cl$
 - yield(%); 86
 - m.p.(°C); 181 ~ 182 (dec.)
 - Mass; 375 (M+H)⁺
 - NMR δ (CDCl₃);
- 3.95 (3H, s), 4.03 (3H, s), 4.08 (2H, brs), 4.13 (3H, s), 4.75 (2H, d, J=5.6Hz), 5.65 (1H, brs), 6.67 (1H, s), 6.72 (1H, dd, J=8.0Hz, 2.0Hz), 6.81 (1H, d, J=2.0Hz), 7.23 (1H, d, J=8.0Hz), 8.65 (1H, s)

Example 160**4-(4-Chloro-3-formamidobenzyl)amino-6,7,8-trimethoxyquinazoline**

[0332]

• molecular formula; $C_{19}H_{19}N_4O_4Cl$

• yield(%); 68


• m.p.(°C); 202 ~ 204 (dec.)

• Mass; 403 (M+H)⁺• NMR δ (DMSO- d_6);

3.88 (3H, s), 3.91 (3H, s), 3.98 (3H, s), 4.75 (2H, d, J=5.6Hz), 7.14 (1H, dd, J=8.4Hz, 2.0Hz), 7.42 (2H, d, J=8.4Hz), 7.52 (1H, s), 8.15 (1H, d, J=2.0Hz), 8.32 (1H, s), 8.35 (1H, s), 8.67 (1H, brs), 9.83 (1H, brs)

Example 161**4-(3-Acetamido-4-chlorobenzyl)amino-6-chloroquinazoline**

[0333]

• molecular formula; $C_{17}H_{14}N_4OCl_2$ (361.232)

• yield(%); 77


• m.p.(°C); 267 ~ 268

• Mass; 361 (MH)⁺• NMR δ (DMSO- d_6);

2.06 (3H, s), 4.74 (2H, d, J=5.7Hz), 7.17 (1H, dd, J=2.0Hz, 8.2Hz), 7.42 (1H, d, J=8.2Hz), 7.69 (1H, brs), 7.72 (1H, d, J=9.0Hz), 7.81 (1H, dd, J=2.4Hz, 9.0Hz), 8.45 (1H, d, J=2.4Hz), 8.46 (1H, s), 8.96 (1H, brt, J=5.7Hz), 9.48 (1H, brs)

Example 1624-(3,4-Dihydroxybenzyl)amino-6,7,8-trimethoxyquinazoline hydrochloride

[0334]




[0335] 30 ml of a 1.0 M solution of boron trichloride in methylene chloride was dropped into a solution of 2.00 g (5.41 mmol) of 4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline in 150 ml of chloroform under stirring at room temperature. The obtained mixture was stirred at room temperature for 2 days, followed by the addition of methanol and the obtained mixture was distilled under a reduced pressure to remove the solvent. This procedure was repeated thrice and the obtained residue was purified by silica gel column chromatography (chloroform/n-hexane). Hydrochloric acid/ethanol was added to the eluate and the obtained mixture was distilled under a reduced pressure to remove the solvent, followed by the addition of ethanol. The crystals thus formed were recovered by filtration. Thus, 0.59 g of the title compound was obtained as a colorless needle.

- molecular formula; $C_{18}H_{19}N_3O_5 \cdot HCl$
- yield(%); 28
- m.p.(°C); 204 ~ 205 (dec.)
- Mass; 358 (M+H)⁺
- NMR δ (DMSO- d_6);
 3.98 (3H, s), 3.99 (3H, s), 3.99 (3H, s), 4.78 (2H, d, J=5.6Hz), 6.65 ~ 7.71 (2H, m), 6.79 (1H, s), 7.94 (1H, s), 8.71 (1H, s), 8.90 (2H, brs), 10.54 (1H, brs), 14.06 (1H, brs)

Example 1634-(3,4-Dihydroxybenzyl)amino-6-chloroquinazoline hydrochloride

[0336]



[0337] 40 ml of a 1.0 M solution of boron trichloride in methylene chloride was dropped into a solution of 2.00 g (6.37 mmol) of 4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline in 150 ml of chloroform under stirring at room temperature. The obtained mixture was stirred at room temperature for 2 days, followed by the addition of methanol, and the obtained mixture was distilled under a reduced pressure to remove the solvent. This procedure was repeated twice. The crystals thus precipitated were washed with methanol and recrystallized from ethanol to give 1.53 g of the title


compound as a yellow crystal.

- molecular formula; $C_{15}H_{12}N_3O_2Cl \cdot HCl$
- yield(%); 71
- m.p.(°C); 154 ~ 155 (dec.)
- Mass; 302 (M+H)⁺
- NMR δ (DMSO- d_6) ;
 4.74 (2H, d, J=5.6Hz), 7.67 (1H, dd, J=8.0Hz, 2.0Hz), 6.70 (1H, d, J=8.0Hz), 6.81 (1H, d, J=2.0Hz), 7.87 (1H, d, J=8.8Hz), 8.02 (1H, dd, J=8.8Hz, 2.0Hz), 8.76 (1H, d, J=2.0Hz), 8.85 (1H, s), 8.90 (2H, brs), 10.42 (1H, brs)

Example 164

2-(2-Methoxyethoxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0338]



[0339] A mixture comprising 20 ml of ethylene glycol monomethyl ether and 70 mg of 55% sodium hydride was heated to 100°C, followed by the addition of a mixture comprising 500 mg of 2,6-dichloro-4-(3,4-methylenedioxybenzyl)aminoquinazoline and 5 ml of ethylene glycol monomethyl ether. The obtained mixture was heated under reflux for 2 hours and poured into 50 ml of water. The obtained mixture was extracted with 50 ml of ethyl acetate twice. The organic layers were together washed with 70 ml of an aqueous solution of sodium chloride twice, dried over magnesium sulfate and concentrated under a reduced pressure to give a crystalline residue. This residue was reprecipitated from ethyl acetate/n-hexane to give 420 mg of the title compound.


- molecular formula; $C_{19}H_{18}N_3O_4Cl$
- yield(%); 75
- m.p.(°C); 138 ~ 139
- Mass; 388 (M+1)⁺
- NMR δ (CDCl₃) ;
 3.43 (3H, s), 3.78 ~ 3.81 (2H, m), 4.57 ~ 4.61 (2H, m), 4.73 (2H, d, J=5.2Hz), 5.72 (1H, br), 5.96 (2H, s), 6.79 ~ 6.87 (3H, m), 7.52 ~ 7.58 (3H, m)

Examples 165 to 177

[0340] The following compounds were prepared in a similar manner to those of Examples 162 to 164.

Example 1652-Methoxy-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline


[0341]



- molecular formula; $C_{17}H_{14}N_3O_3Cl$
- yield(%); 15
- m.p. ($^{\circ}C$); 187 ~ 189
- Mass; 344 ($M+1$)⁺
- NMR δ ($CDCl_3$);
4.03 (3H, s), 4.50 (2H, d, $J=5.6Hz$), 5.91 (1H, br), 5.96 (2H, s), 6.78 (1H, d, $J=7.6Hz$), 6.81 (1H, dd, $J=7.6Hz$, 1.6Hz), 6.82 (1H, d, $J=1.6Hz$), 7.58 ~ 7.60 (3H, m)

Example 1662-Methoxy-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline


[0342]



- molecular formula; $C_{18}H_{14}N_4O_3$ (334)
- yield(%); 23
- m.p. ($^{\circ}C$); 224 (dec.)
- Mass; 335 ($M+1$)⁺
- NMR δ ($DMSO-d_6$);
3.87 (3H, s), 4.60 (2H, brs), 5.95 (2H, s), 6.84 (2H, s), 6.95 (1H, s), 7.55 (1H, d, $J=8.8Hz$), 7.94 (1H, dd, $J=8.8Hz$, 1.6Hz), 8.83 (1H, d, $J=1.6Hz$), 9.18 (1H, br)

Example 1672,6,7,8-Tetramethoxy-4-(3,4-methylenedioxybenzyl)aminoquinazoline

[0343]



- molecular formula; $C_{20}H_{21}N_3O_6$

- yield(%); 28

- m.p. (°C); 128 ~ 129


- Mass; 400 (M+H)⁺

- NMR δ (CDCl₃);

3.91 (3H, s), 4.04 (3H, s), 4.07 (3H, s), 4.14 (3H, s), 4.75 (2H, d, J=5.2Hz), 5.51 (1H, brs), 5.97 (2H, s), 6.60 (1H, s), 6.80 (1H, d, J=8.0Hz), 6.87 (1H, dd, J=8.0Hz, 2.0Hz), 6.90 (1H, d, J=2.0Hz)

Example 1682-(2-Hydroxyethoxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0344]



- molecular formula; $C_{18}H_{16}N_3O_4Cl$ (373.5)

- yield(%); 97

- m.p. (°C); 191 ~ 193


- Mass; 374 (M+1)⁺

- NMR δ (DMSO-d₆);

3.65 ~ 3.69 (2H, m), 4.27 (2H, dd, J=8.8Hz, 5.6Hz), 4.60 (2H, d, J=5.2Hz), 4.82 (1H, t, J=5.6Hz), 5.95 (2H, s), 6.81 ~ 6.84 (2H, m), 6.92 (1H, s), 7.47 (1H, d, J=8.8Hz), 7.65 (1H, dd, J=8.8Hz, 2.2Hz), 8.34 (1H, d, J=2.2Hz), 8.82 (1H, br)

Example 1692-(2-Hydroxyethoxy)-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

[0345]



- molecular formula; $C_{19}H_{16}N_4O_4$ (364)
- yield(%); 94
- m.p.(°C); 227 ~ 229
- Mass; 365 ($M+1$)⁺
- NMR δ (DMSO- d_6) ;
 3.68 (2H, t, J=5.2Hz), 4.30 (2H, t, J=5.2Hz), 4.44 (1H, brs), 5.97 (2H, s), 6.82 (2H, s), 6.95 (1H, s), 7.54 (1H, d, J=8.4Hz), 7.95 (1H, dd, J=8.4Hz, 1.6Hz), 8.78 (1H, d, J=1.6Hz), 9.04 (1H, br)

Example 1702-(2-Methoxyethoxy)-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline


[0346]



- molecular formula; $C_{20}H_{21}N_3O_5$ (383)
- yield(%); 68
- m.p.(°C); 118 ~ 119
- Mass; 384 ($M+1$)⁺
- NMR δ (DMSO- d_6);
 3.26 (3H, s), 3.60 (2H, t, J=4.8Hz), 3.61 (3H, s), 4.33 (2H, t, J=4.8Hz), 4.63 (2H, d, J=6.0Hz), 5.95 (2H, s), 6.81 (1H, d, J=7.6Hz), 6.84 (1H, dd, J=7.6Hz, 0.4Hz), 6.91 (1H, d, J=0.4Hz), 7.29 (1H, dd, J=8.8Hz, 2.8Hz), 7.40 (1H, d, J=8.8Hz), 7.63 (1H, d, J=2.8Hz), 8.62 (1H, br)

Example 1712-(2-Methoxyethoxy)-4-(benzimidazol-5-yl)methylamino-6-cyanoquinazoline


[0347]



- molecular formula; $C_{20}H_{18}N_6O_2$ (374)
- yield(%); 68
- m.p.(°C); 267 (dec.)
- Mass; 375 (M+1)⁺
- NMR δ (DMSO- d_6) ;
3.21 (3H, s), 3.60 (2H, s), 4.40 (2H, s), 4.82 (2H, s), 7.17 ~ 7.66 (4H, m), 7.94 (1H, d, J=9.6Hz), 8.16 (1H, s), 8.81 (1H, s), 9.15 (1H, br)

Example 1722-Propoxy-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0348]




- molecular formula; $C_{22}H_{25}N_3O_6$
- yield(%); 6
- m.p.(°C); 122 ~ 123
- Mass; 428 (M+H)⁺
- NMR δ (CDCl₃) ;
1.05 (3H, t, J=7.4Hz), 1.89 (2H, m), 3.90 (3H, s), 4.03 (3H, s), 4.13 (3H, s), 4.41 (2H, t, J=7.0Hz), 4.76 (2H, d, J=5.2Hz), 5.49 (1H, brs), 5.97 (2H, s), 6.60 (1H, s), 6.80 (1H, d, J=8.0Hz), 6.87 (1H, d, J=8.0Hz), 6.90 (1H, s)

Example 1732-(3-Hydroxypropoxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

5 [0349]

10

15



- molecular formula; $C_{19}H_{18}N_3O_4Cl$ (387.5)
- yield(%); 60
- 20 • m.p.(°C); 118 ~ 120
- Mass; 388 (M+1)⁺
- NMR δ ($CDCl_3$) ;
 2.02 (2H, tt, J=5.6Hz, 5.6Hz), 3.70 (2H, t, J=5.6Hz), 3.95 (1H, br), 4.66 (2H, t, J=5.6Hz), 4.71 (2H, d, J=5.2Hz),
 5.95 (2H, s), 6.08 (1H, br), 6.77 (1H, d, J=8.0Hz), 6.83 (1H, d, J=8.0Hz), 6.85 (1H, s), 7.51 (1H, d, J=8.8Hz), 7.56
 25 (1H, dd, J=8.8Hz, 2.0Hz), 7.61 (1H, d, J=2.0Hz)


Example 1742-(4-Hydroxybutoxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

30

[0350]

35

40



- molecular formula; $C_{20}H_{20}N_3O_4Cl$ (401.5)
- 45 • yield(%); 23
- m.p.(°C); 121 ~ 124
- Mass; 402 (M+1)⁺
- NMR δ ($CDCl_3$) ;
 1.47 ~ 1.73 (4H, m), 3.40 ~ 3.47 (2H, m), 4.20 (2H, t, J=6.7Hz), 4.55 (2H, d, J=5.2Hz), 5.72 (2H, s), 6.56
 50 (1H, d, J=8.0Hz), 6.66 (1H, dd, J=8.0Hz, 1.6Hz), 6.71 (1H, d, J=1.6Hz), 7.30 (2H, s), 7.88 (1H, br, J=5.2Hz), 7.99
 (1H, s)

55


Example 175

2-(4-Methoxybutoxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

5 [0351]

10

15



20

25

- molecular formula; $C_{21}H_{22}N_3O_4Cl$ (415.5)
- yield(%); 26
- m.p.(°C); 120 ~ 123
- Mass; 416 (M+1)⁺
- NMR δ ($CDCl_3$);
 1.77 (2H, tt, J=8.8Hz, 6.8Hz), 1.90 (2H, tt, J=8.8Hz, 6.8Hz), 3.34 (3H, s), 3.44 (2H, t, J=6.8Hz), 4.44 (2H, t, J=6.8Hz), 4.72 (2H, d, J=5.2Hz), 5.71 (1H, br), 5.96 (2H, s), 6.79 (1H, d, J=8.0Hz), 6.84 (1H, dd, J=8.0Hz, 1.8Hz), 6.87 (1H, d, J=1.8Hz), 7.53 ~ 7.59 (3H, m)


Example 176

2-(6-Hydroxybutoxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

30 [0352]

35

40



45


50

55

- molecular formula; $C_{22}H_{24}N_3O_4Cl$ (429.5)
- yield(%); 66
- m.p.(°C); 144 ~ 146
- Mass; 430 (M+1)⁺
- NMR δ ($CDCl_3$);
 1.14 ~ 1.40 (6H, m), 1.58 ~ 1.64 (2H, m), 3.06 (1H, br), 3.38 (2H, br), 4.17 (2H, t, J=6.8Hz), 4.52 (2H, d, J=5.6Hz), 5.73 (2H, s), 6.56 (1H, d, J=8.0Hz), 6.66 (1H, dd, J=8.0Hz, 1.6Hz), 6.71 (1H, d, J=1.6Hz), 7.30 (2H, s), 7.85 (1H, br), 7.96 (1H, s)

Example 1772-Hydroxy-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0353]



- molecular formula; $C_{16}H_{12}N_3O_3Cl$ (329.5)


- m.p.(°C); 257 (dec.)

- NMR δ (DMSO- d_6) ;

4.668 (2H, d, J=5.6Hz), 5.967 (2H, s), 6.846 ~ 6.905 (2H, m), 6.995 (1H, s), 7.821 ~ 7.859 (2H, m), 8.508 (1H, s), 10.103 (1H, br), 11.916 (1H, s)

Example 1782-(2,3-Dihydroxypropyl)oxy-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0354]



[0355] 100 mg of sodium hydride was added to a mixture comprising 300 mg of 5-hydroxy-2-phenyl-1,3-dioxane and 5 ml of dimethylformamide. The obtained mixture was heated to 80°C. After the bubbling had been discontinued, 300 mg of 2,6-dichloro-4-(3,4-methylenedioxybenzyl)aminoquinazoline was added in a crystalline state. The obtained mixture was heated at 140°C for 2 hours and cooled, followed by the addition of water. The obtained mixture was extracted with ethyl acetate. The extract was purified by silica gel column chromatography using an ethyl acetate/benzene mixture to give 118 mg of 2-(2-phenyl-1,3-dioxan-5-yl)oxy-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline. 100 mg of this compound was hydrolyzed with concentrated hydrochloric acid/ethanol by a conventional process to give 60 mg of the title compound through rearrangement.

- molecular formula; $C_{19}H_{18}ClN_3O_5$

- yield(%); 73

- m.p.(°C); 106 ~ 107

- Mass; 404 (MH⁺)


- NMR δ (DMSO- d_6);

3.42 (2H, t, J=5.7Hz), 3.79 (1H, sextet, J=5Hz), 4.17 (1H, dd, J=6.6Hz, 11.0Hz), 4.31 (1H, dd, J=4.2Hz, 11.0Hz), 4.63 (2H, d, J=5.7Hz), 4.66 (1H, t, J=6.0Hz), 4.94 (1H, d, J=5.3Hz), 5.98 (2H, s), 6.85 (2H, s), 6.95 (1H, s), 7.49 (1H, d, J=9.0Hz), 7.68 (1H, dd, J=2.4Hz, 9.0Hz), 8.37 (1H, d, J=2.4Hz), 8.83 (1H, t, J=5.7Hz)

Example 179

2-(3-Carboxypropyl)oxy-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

[0356]



[0357] 250 μ l of dimethyl sulfoxide was slowly dropped into a mixture comprising 150 μ l of oxalyl chloride and 15 ml of methylene chloride which had been preliminarily cooled in a dry ice/acetone bath. After 10 minutes, a solution of 500 mg of 2-(2-hydroxyethyl)oxy-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline in 1 ml of dimethyl sulfoxide was dropped into the mixture prepared above at the same temperature and after 10 minutes, 1.4 ml of N,N-diisopropylethylamine was dropped thereinto at the same temperature. The obtained mixture was stirred at the same temperature for 10 minutes and brought to room temperature. After 20 minutes, 600 mg of ethoxycarbonylmethylenetriphenylphosphorane was added in a crystalline state to the resulting mixture to conduct a reaction for 30 minutes, followed by the addition of water. The obtained mixture was extracted with ethyl acetate and the extract was purified by silica gel column chromatography using an ethyl acetate/benzene mixture to give 400 mg of 2-(3-ethoxycarbonyl-2-propenyl)oxy-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline (cis/trans mixture).

[0358] The whole of the above compound was dissolved in 30 ml of ethyl acetate and catalytically reduced with a 10% palladium/carbon catalyst under normal pressure. The reaction mixture was purified by silica gel column chromatography using an ethyl acetate/benzene mixture to give 250 mg of 2-(3-ethoxycarbonylpropyl)oxy-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline (a saturated ester).

[0359] 250 mg of the above saturated ester was dissolved in 50 ml of ethanol, followed by the addition of 1.7 ml of a 1N aqueous solution of sodium hydroxide. The obtained mixture was reacted at room temperature for 10 hours and then at 40°C for 2 hours, cooled and neutralized by the addition of 1.7 ml of 1N aqueous hydrochloric acid, followed by the addition of water. The crystals thus formed were recovered by filtration and recrystallized from ethanol/water to give 200 mg of the title compound.

- molecular formula; $C_{21}H_{18}N_4O_5$ (406.398)

- yield(%); 86

- m.p.(°C); >290


- Mass; 407 (MH⁺)

- NMR δ (DMSO);

1.93 (2H, quintet, J=7Hz), 2.35 (2H, t, J=7.3Hz), 4.32 (2H, t, J=6.6Hz), 4.64 (2H, d, J=5.7Hz), 5.98 (2H, s), 6.87 (2H, s), 6.97 (1H, s), 7.56 (1H, d, J=8.8Hz), 7.96 (1H, dd, J=1.8Hz, 8.8Hz), 8.80 (1H, d, J=1.8Hz), 9.05 (1H, t, J=5.7Hz)

Example 1802-Methylthio-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0360]




[0361] 20 ml of N,N-dimethylformamide and 221 mg of sodium thiomethoxide were added to 1 g of 2,6-dichloro-4-(3,4-methylenedioxybenzyl)aminoquinazoline. The obtained mixture was stirred at 110°C for one hour, neutralized with 1N hydrochloric acid and stirred at room temperature for one hour, followed by the addition of water. The crystals thus precipitated were recovered by filtration to give 780 mg of the title compound.

- molecular formula; $C_{17}H_{14}ClN_3O_2S$
- yield(%); 76
- m.p. (°C); 214 ~ 216
- Mass m/e; 360 (M+1)
- NMR δ ($CDCl_3$);
 2.66 (3H, s), 4.85 (2H, d, J=5.6Hz), 5.93 (2H, s), 6.73 (1H, d, J=8.0Hz), 6.89 (1H, d, J=8.0Hz), 6.93 (1H, s),
 7.64 (1H, dd, J=8.8Hz, 2.0Hz), 8.16 (1H, d, J=8.8Hz), 8.77 (1H, d, J=2.0Hz)

Example 1812-Morpholino-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

[0362]



[0363] A mixture comprising 338 mg of 2-chloro-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline, 435 mg of morpholine and 20 ml of isopropyl alcohol was heated under rellux for 3 hours, followed by the addition of 30 ml of water under heating. The precipitate thus formed was recovered by filtration and washed with 30 ml of water and 30 ml of ethyl acetate. Thus, 310 mg of the title compound was obtained.

- molecular formula; $C_{21}H_{19}N_5O_3$ (389)
- yield(%); 80
- m.p.(°C); 270 ~ 272 (dec.)
- Mass; 390 (M+1)⁺
- NMR δ ($DMSO-d_6$);
 3.57 ~ 3.61 (4H, m), 3.73 ~ 3.79 (4H, m), 4.57 (2H, d, J=5.6Hz), 5.95 (2H, s), 6.82 (1H, d, J=8.0Hz), 6.85

(1H, d, J=8.0Hz), 6.93 (1H, s), 7.27 (1H, d, J=8.8Hz), 7.74 (1H, dd, J=8.8Hz, 1.6Hz), 8.56 (1H, d, J=1.6Hz), 8.75 (1H, brt, J=5.6Hz)


Examples 182 to 183

[0364] The following compounds were prepared in a similar manner to that of Example 181.

Example 182

2-Morpholino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0365]




- molecular formula; $C_{20}H_{19}N_4O_3Cl$ (398.850)
- yield(%); 96
- m.p.(°C); 208 ~ 209
- Mass; 399 (MH)⁺
- NMR δ (DMSO- d_6); 3.61 (4H, t, J=5Hz), 3.72 (4H, t, J=5Hz), 4.58 (2H, d, J=5.7Hz), 5.97 (2H, s), 6.85 (2H, s), 6.95 (1H, s), 7.28 (1H, d, J=9.0Hz), 7.51 (1H, dd, J=2.4Hz, 9.0Hz), 8.18 (1H, d, J=2.4Hz), 8.60 (1H, t, J=5.7Hz)

Example 183

2-Morpholino-4-(3-chloro-4-methoxybenzyl)amino-6-cyanoquinazoline


[0366]



- molecular formula; $C_{21}H_{20}N_5O_2Cl$ (407.5)
- yield(%); 51
- m.p.(°C); 222 ~ 223
- Mass; 410 (M+1)⁺
- NMR δ (DMSO- d_6);
3.56 ~ 3.61 (4H, m), 3.74 ~ 3.80 (4H, m), 3.80 (3H, s), 4.58 (2H, d, J=5.2Hz), 7.27 ~ 7.32 (2H, m), 7.44 (1H, d, J=1.6Hz), 7.75 (1H, dd, J=8.8Hz, 1.6Hz), 8.55 (1H, d, J=1.6Hz), 8.80 (1H, brt, J=5.2Hz)

Example 1842-(4-Hydroxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

[0367]



[0368] A mixture comprising 339 mg of 2-chloro-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline, 500 mg of 4-hydroxypiperidine and 20 ml of N,N-dimethylformamide was heated under reflux for 5 hours and poured into 50 ml of water, followed by the addition of 50 ml of ethyl acetate. The obtained mixture was filtered to remove insolubles. The organic layer of the filtrate was dried over magnesium sulfate and concentrated under a reduced pressure to give a crystalline residue. This residue was washed with chloroform to give 145 mg of the title compound.


- molecular formula; $C_{22}H_{21}N_5O_3$ (403)
- yield(%); 36
- m.p.(°C); 229
- Mass; 404 (M+1)⁺
- NMR δ (DMSO- d_6);
 1.19 ~ 1.30 (2H, m), 1.64 ~ 1.77 (2H, m), 3.21 ~ 3.30 (2H, m), 3.63 ~ 3.75 (1H, m), 4.34 ~ 4.38 (2H, m),
 4.55 (2H, d, J=5.6Hz), 4.66 (1H, d, J=4.0Hz), 5.94 (2H, s), 6.80 ~ 6.86 (2H, m), 6.93 (1H, d, J=0.8Hz), 7.24 (1H,
 d, J=8.4Hz), 7.70 (1H, dd, J=8.4Hz, 1.6Hz), 8.52 (1H, d, J=1.6Hz), 8.70 (1H, br)

Examples 185 to 191

[0369] The following compounds were prepared in a similar manner to that of Example 184.

Example 1852-(4-Hydroxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0370]




- molecular formula; $C_{21}H_{21}N_4O_3Cl$ (412.877)
- yield(%); 56

- m.p.(°C); 157 ~ 158
- Mass; 413 (MH⁺)
- NMR δ (DMSO-d₆);
 1.2 ~ 1.3 (2H, m), 1.6 ~ 1.8 (2H, m), 3.1 ~ 3.2 (2H, m), 3.6 ~ 3.7 (1H, m), 4.3 ~ 4.4 (2H, m), 4.55 (2H, d, J=5.7Hz), 4.65 (1H, d, J=4.4Hz), 5.96 (2H, s), 6.84 (2H, s), 6.95 (1H, s), 7.24 (1H, d, J=9.0Hz), 7.47 (1H, dd, J=2.4Hz, 9.0Hz), 8.13 (1H, d, J=2.4Hz), 8.53 (1H, t, J=5.7Hz)

Example 186

10 2-(4-Hydroxypiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-cyanoquinazoline

[0371]




- molecular formula; C₂₂H₂₂N₅O₂Cl (423.5)
- yield(%); 80
- m.p.(°C); 207 ~ 208
- Mass; 424 (M+1)⁺
- NMR δ (DMSO-d₆);
 1.18 ~ 1.30 (2H, m), 1.65 ~ 1.76 (2H, m), 3.21 ~ 3.33 (2H, m), 3.30 (3H, s), 3.64 ~ 3.72 (1H, m), 4.29 ~ 4.37 (2H, m), 4.57 (2H, d, J=5.6Hz), 4.66 (1H, d, J=1.8Hz), 7.07 (1H, d, J=8.4Hz), 7.24 (1H, d, J=8.8Hz), 7.29 (1H, dd, J=8.4Hz, 2.0Hz), 7.43 (1H, d, J=2.0Hz), 7.71 (1H, dd, J=8.8Hz, 2.0Hz), 8.51 (1H, d, J=2.0Hz), 8.74 (1H, brt, J=1.8Hz)

Example 187

40 2-(2-Hydroxyethyl)amino-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0372]




- molecular formula; C₂₁H₂₄N₄O₆
- yield(%); 38
- m.p.(°C); amorphous
- Mass; 429 (M+H)⁺

- NMR δ (CDCl_3) ;
3.60 (2H, m), 3.88 (3H, s & 1H, m), 3.99 (3H, s), 4.01 (3H, s), 4.67 (2H, d, $J=5.6\text{Hz}$), 5.32 (1H, brs), 5.53 (1H, brs), 5.97 (2H, s), 6.55 (1H, s), 6.80 (1H, d, $J=8.0\text{Hz}$), 6.85 (1H, d, $J=8.0\text{Hz}$), 6.89 (1H, s)

5 Example 188

2-(2-Hydroxyethyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0373]




- molecular formula; $\text{C}_{18}\text{H}_{17}\text{N}_4\text{O}_3\text{Cl}$
- yield(%); 47
- m.p.($^{\circ}\text{C}$); 138 ~ 139
- Mass m/e; 373 ($\text{M}+1$)
- NMR δ (CDCl_3 (+DMSO- d_6)) ;
3.60 (2H, m), 3.79 (2H, t, $J=4.8\text{Hz}$), 4.65 (2H, d, $J=5.2\text{Hz}$), 5.94 (2H, s), 6.76 (1H, d, $J=8.0\text{Hz}$), 6.85 (1H, dd, $J=8.0\text{Hz}$, 2.0Hz), 6.90 (1H, d, $J=2.0\text{Hz}$), 7.34 (1H, d, $J=8.8\text{Hz}$), 7.44 (1H, dd, $J=8.8\text{Hz}$, 2.4Hz), 8.02 (2H, brs)

30 Example 189

2-[N-(2-Hydroxyethyl)-N-methylamino]-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0374]




- molecular formula; $\text{C}_{19}\text{H}_{19}\text{N}_4\text{O}_3\text{Cl}$
- yield(%); 48
- m.p.($^{\circ}\text{C}$); 146 ~ 148
- Mass m/e; 387 ($\text{M}+1$)
- NMR δ (CDCl_3 (+DMSO- d_6)) ;
3.27 (3H, s), 3.82 (2H, t, $J=4.8\text{Hz}$), 3.89 (2H, t, $J=4.8\text{Hz}$), 4.67 (2H, d, $J=5.6\text{Hz}$), 5.95 (2H, s), 6.77 (1H, d, $J=8.0\text{Hz}$), 6.86 (1H, dd, $J=8.0\text{Hz}$, 1.6Hz), 6.90 (1H, d, $J=1.6\text{Hz}$), 7.43 (2H, m), 7.76 (1H, brs)

Example 1902-(2-Hydroxymethylpyrrolidin-1-yl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

5 [0375]

10

15



20

25

- molecular formula; $C_{21}H_{21}N_4O_3Cl$ (412.877)
- yield(%); 70
- m.p.(°C); 182 ~ 183
- Mass; 413 (MH^+)
- NMR δ (DMSO- d_6);
 1.8 ~ 2.0 (4H, br 2 peaks), 3.4 ~ 3.7 (3H, br 2 peaks), 4.1 ~ 4.2 (1H, brs), 4.58 (2H, d, $J=5.8$ Hz), 5.96 (2H, s), 6.84 (1H, d, $J=8.0$ Hz), 6.88 (1H, dd, $J=1.3$ Hz, 8.0Hz), 6.96 (1H, d, $J=1.3$ Hz), 7.23 (1H, d, $J=8.8$ Hz), 7.47 (1H, dd, $J=2.4$ Hz, 8.8Hz), 8.15 (1H, d, $J=2.4$ Hz), 8.4 ~ 8.6 (1H, brs)

30


Example 1912-Bis(2-hydroxyethyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

35

[0376]

40

45




50

- molecular formula; $C_{20}H_{21}N_4O_4Cl$ (416.865)
- yield(%); 56
- m.p.(°C); 167 ~ 168
- Mass; 417 (MH^+)
- NMR δ (DMSO- d_6);
 3.5 ~ 3.7 (8H, br 2 peaks), 4.56 (2H, d, $J=5.7$ Hz), 5.96 (2H, s), 6.85 (2H, s), 6.93 (1H, s), 7.22 (1H, d, $J=9.0$ Hz), 7.47 (1H, dd, $J=2.4$ Hz, 9.0Hz), 8.15 (1H, d, $J=2.4$ Hz), 8.55 (1H, brt, $J=5.7$ Hz)

55

Example 1922-(1-imidazolyl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0377]



[0378] 103 mg of imidazole was added to a suspension of 66 mg of sodium hydride in 6 ml of dimethylformamide at 0°C. The obtained mixture was stirred for 10 minutes. 500 mg of 2,6-dichloro-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline was added to the resulting mixture at room temperature. The mixture thus prepared was stirred at 100°C for 20 minutes, followed by the addition of water. The crystals precipitated were recovered by filtration and washed with water and ethano/acetone successively to give 325 mg of the title compound.

- molecular formula; $C_{19}H_{14}N_5O_2Cl$

- yield(%); 59

- m.p.(°C); 275 ~ 276 (dec.)

- Mass m/e; 380 (M+1)

- NMR δ (DMSO- d_6);


4.74 (2H, d, J=5.6Hz), 5.96 (2H, s), 6.85 (1H, d, J=8.0Hz), 6.95 (1H, dd, J=8.0Hz, 1.6Hz), 7.03 (1H, d, J=1.6Hz), 7.08 (1H, d, J=1.2Hz), 7.68 (1H, d, J=8.8Hz), 7.78 (1H, dd, J=8.8Hz, 2.4Hz), 7.94 (1H, d, J=1.2Hz), 8.47 (1H, d, J=2.4Hz), 8.58 (1H, t, J=2.4Hz), 9.28 (1H, t, J=5.6Hz)

Examples 193 to 197

[0379] The following compounds were prepared in a similar manner to that of Example 192.

Example 1932-(1-imidazol-1-yl)-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

[0380]



- molecular formula; $C_{20}H_{14}N_6O_2$ (370)

- yield(%); 81

- m.p.(°C); >290

- Mass; 371 (M+1)⁺


NMR δ (DMSO- d_6):

4.74 (2H, d, $J=6.0$ Hz), 5.95 (2H, s), 6.86 (1H, d, $J=8.0$ Hz), 6.95 (1H, dd, $J=8.0$ Hz, 1.6Hz), 7.04 (1H, d, $J=1.6$ Hz), 7.09 (1H, d, $J=1.6$ Hz), 7.73 (1H, d, $J=8.4$ Hz), 7.95 (1H, d, $J=1.6$ Hz), 8.06 (1H, dd, $J=8.4$ Hz, 1.6Hz), 8.61 (1H, d, $J=1.6$ Hz), 8.87 (1H, d, $J=1.6$ Hz), 9.47 (1H, brt, $J=6.0$ Hz)

Example 194

2-Pentylamino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0381]



molecular formula; $C_{21}H_{23}N_4O_2Cl$

yield(%); 97

m.p.(°C); 194 ~ 195

Mass m/e; 399 (M+1)


NMR δ ($CDCl_3$);

0.86 (3H, t, $J=7.2$ Hz), 1.29 (4H, m), 1.58 (2H, quintet, $J=6.8$ Hz), 3.47 (2H, q, $J=6.8$ Hz), 4.78 (2H, d, $J=5.6$ Hz), 5.87 (2H, s), 6.66 (1H, d, $J=8.0$ Hz), 6.89 (1H, d, $J=8.0$ Hz), 6.94 (1H, s), 7.26 (1H, d, $J=8.8$ Hz), 7.41 (1H, d, $J=8.8$ Hz), 7.90 (1H, t, $J=5.6$ Hz), 8.55 (1H, s), 9.53 (1H, brs)

Example 195

2-(2-Aminoethyl)amino-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0382]



molecular formula; $C_{21}H_{25}N_5O_5$

yield(%); 87

m.p.(°C); amorphous


Mass; 428 (M+H)⁺

NMR δ ($CDCl_3$);

1.44 (2H, s), 2.93 (2H, t, $J=6.0$ Hz), 3.57 (2H, brs), 3.88 (3H, s), 4.00 (3H, s), 4.07 (3H, s), 4.70 (2H, d, $J=4.8$ Hz), 5.16 (1H, brs), 5.51 (1H, brs), 5.96 (2H, s), 6.56 (1H, s), 6.80 (1H, d, $J=8.0$ Hz), 6.86 (1H, d, $J=8.0$ Hz), 6.90 (1H, s)

Example 1962-Hydrazino-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline


[0383]



- molecular formula; $C_{19}H_{21}N_5O_5$
- yield(%); 12
- m.p.(°C); oily substance
- Mass; 400 (M+H)⁺
- NMR δ ($CDCl_3$) ;
 3.88 (3H, s), 3.99 (3H, s), 4.05 (3H, s), 4.66 (2H, d, J=3.6Hz), 5.92 (2H, s), 6.75 (1H, d, J=8.0Hz), 6.83 (1H, d, J=8.0Hz), 6.87 (1H, s), 7.04 (2H, brs)

Example 1972-(Carbamoylmethyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline


[0384]



- molecular formula; $C_{18}H_{16}N_5O_3Cl$
- yield(%); 63
- m.p.(°C); 259 ~ 260 (dec.)
- Mass m/e; 386 (M+1)
- NMR δ (DMSO- d_6) ;
 4.02 (2H, d, J=4.8Hz), 4.66 (2H, d, J=5.6Hz), 5.97 (2H, s), 6.86 (1H, d, J=8.0Hz), 6.91 (1H, d, J=8.0Hz), 6.99 (1H, s), 7.19 (1H, s), 7.50 (1H, d, J=8.8Hz), 7.61 (1H, s), 7.83 (1H, d, J=8.8Hz), 8.09 (1H, brs), 8.49 (1H, brs), 10.03 (1H, brs)

Example 2002-Amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0385]




[0386] 2.0 g of 2,6-dichloro-4-(3,4-methylenedioxybenzyl)aminoquinazoline was heated to 120°C in 50 ml of ethanolic ammonia put in a pressure vessel for 18 hours, cooled and concentrated under a reduced pressure. The obtained residue was introduced to a silica gel column and eluted with a chloroform/ methanol (9 : 1) mixture to give 830 mg of the title compound.

- molecular formula; $C_{16}H_{13}N_4O_2Cl$
- yield(%); 44
- m.p.(°C); 285 (dec.)
- Mass; 329 (M+1)⁺
- NMR δ ($CDCl_3$) ;
4.67 (2H, d, J=5.6Hz), 4.98 (2H, br), 5.74 (1H, br), 5.96 (2H, s), 6.78 (1H, d, J=7.6Hz), 6.83 (1H, dd, J=7.6Hz, 1.6Hz), 6.86 (1H, d, J=1.6Hz), 7.38 (1H, d, J=9.6Hz), 7.46 ~ 7.49 (2H, m)

Example 2012-Amino-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

[0387]




[0388] The title compound was prepared in a similar manner to those of Examples 199 and 200.

- molecular formula; $C_{17}H_{13}N_5O_2$ (319)
- yield(%); 60
- m.p.(°C); 284 (dec.)
- Mass; 320 (M+1)⁺
- NMR δ ($CDCl_3$) ;
4.31 (2H, d, J=5.6Hz), 5.25 (2H, brs), 5.58 (2H, s), 6.40 (1H, d, J=7.6Hz), 6.51 (1H, dd, J=7.6Hz, 1.2Hz), 6.57 (1H, d, J=1.2Hz), 6.95 (1H, d, J=8.4Hz), 7.25 (1H, dd, J=8.4Hz, 1.6Hz), 8.00 (1H, br), 8.20 (1H, d, J=1.6Hz)

Example 2022-(Methylcarbamoyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0389]



[0390] 4 ml of dimethyl sulfoxide and 260 mg of methyl isocyanate were added to 500 mg of 2-amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline. The obtained mixture was stirred at 50°C for 3 hours and distilled under a reduced pressure to remove excess methyl isocyanate, followed by the addition of chloroform and water. The mixture thus obtained was filtered and the filtrate was extracted with chloroform twice. The organic layers were combined, washed with water twice, dried over magnesium sulfate and distilled under a reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (benzene/acetone) and recrystallized (from benzene/chloroform/ethanol) to give 72 mg of the title compound.


- molecular formula; $C_{18}H_{16}N_5O_3Cl$
- yield(%); 12
- m.p.(°C); 245 ~ 247
- Mass m/e; 386 (M+1)
- NMR δ (DMSO- d_6) :
 2.75 (3H, d, J=4.4Hz), 4.56 (2H, d, J=6.0Hz), 5.95 (2H, s), 6.82 (1H, d, J=8.4Hz), 6.92 (1H, d, J=8.4Hz), 7.11 (1H, s), 7.56 (1H, d, J=8.8Hz), 7.67 (1H, dd, J=8.8Hz, 1.6Hz), 8.27 (1H, d, J=1.6Hz), 8.90 (1H, t, J=6.0Hz), 9.20 (1H, s), 9.38 (1H, d, J=4.4Hz)

Examples 203 and 204

[0391] The following compounds were prepared in a similar manner to that of Example 202.

Example 2032-Bis(methylcarbamoyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0392]




- molecular formula; $C_{20}H_{19}N_6O_4Cl$
- yield(%); 8
- amt. of product (mg); 45
- m.p.(°C); 243 ~ 245
- Mass m/e; 443 (M+1)
- NMR δ (DMSO- d_6);
 2.71 (6H, d, J=4.8Hz), 4.53 (2H, d, J=6.0Hz), 5.94 (2H, s), 6.80 (1H, d, J=8.0Hz), 6.85 (1H, d, J=8.0Hz), 6.95 (1H, s), 7.66 (1H, d, J=8.8Hz), 7.72 (1H, dd, J=8.8Hz, 2.0Hz), 8.32 (1H, dd, J=2.0Hz), 8.85 (1H, dd, J=4.8Hz), 9.01 (1H, t, J=6.0Hz)

Example 204

2-(n-Butylcarbamoyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0393]




- molecular formula; $C_{21}H_{22}N_5O_3Cl$
- yield(%); 40
- m.p.(°C); 209 ~ 210
- Mass m/e; 428 (M+1)
- NMR δ (DMSO- d_6);
 0.89 (3H, t, J=7.2Hz), 1.33 (2H, sextet, J=7.2Hz), 1.45 (2H, quintet, J=7.2Hz), 3.18 (2H, t, J=7.2Hz), 4.56 (2H, d, J=6.0Hz), 5.95 (2H, s), 6.83 (1H, d, J=8.0Hz), 6.91 (1H, d, J=8.0Hz), 7.09 (1H, s), 7.46 (1H, d, J=8.8Hz), 7.66 (1H, dd, J=8.8Hz, 2.0Hz), 8.27 (1H, d, J=2.0Hz), 8.90 (1H, t, J=6.0Hz), 9.17 (1H, s), 9.58 (1H, t, J=7.2Hz)

Example 205

2-(4-Ethoxycarbonylpiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0394]



[0395] 3.61 g of methyl isonipecotate, 2.32 g of triethylamine and 5 ml of 2-propanol were added to 1 g of 2,6-dichloro-4-(3,4-methylenedioxybenzyl)aminoquinazoline prepared in Example 92. The obtained mixture was refluxed for 100 minutes. The mixture thus obtained was extracted with chloroform twice. The organic layers were combined, washed


with water, dried over magnesium sulfate and freed from the solvent by distillation. The residue was recrystallized (from ethanol/water) to give 1.31 g of the title compound.

- molecular formula; $C_{24}H_{25}ClN_4O_4$
- yield(%); 97
- m.p.(°C); 118 ~ 119
- Mass; 469 (M+1)
- NMR δ (DMSO- d_6):
 1.18 (3H, t, J=7.2Hz), 1.42 (2H, m), 2.58 (1H, m), 2.98 (2H, m), 4.06 (2H, q, J=7.2Hz), 4.56 (2H, m, J=5.6Hz),
 4.62 (2H, m), 5.96 (2H, s), 6.82 (1H, d, J=8.0Hz), 6.86 (1H, dd, J=8.0Hz, 1.6Hz), 6.94 (1H, d, J=1.6Hz), 7.26 (1H,
 d, J=9.2Hz), 7.48 (1H, dd, J=9.2Hz, 2.4Hz), 8.15 (1H, d, J=2.4Hz), 8.56 (1H, brt, J=5.6Hz)

Example 206

2-(4-Ethoxycarbonylpiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline hydrochloride

[0396]




[0397] The title compound was prepared from the 2-(4-Ethoxycarbonylpiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline prepared in Example 205 by the use of ethanol-hydrochloric acid-ethanol.

- molecular formula; $C_{24}H_{25}ClN_4O_4 \cdot HCl$
- yield(%); 97
- m.p.(°C); 174 ~ 175
- NMR δ (DMSO- d_6):
 1.20(3H, t, J=7.2Hz), 1.59(2H, m), 1.97(2H, m), 2.75(1H, m), 3.31(2H, m), 4.09(2H, q, J=7.2Hz), 4.53(2H, m),
 4.67(2H, d, J=5.6Hz), 5.98(2H, s), 6.86(1H, d, J=8.0Hz), 6.90(1H, dd, J=8.0Hz, 1.6Hz), 7.01(1H, d, J=1.6Hz),
 7.83(1H, dd, J=8.8Hz, 2.0Hz), 7.91(1H, d, J=8.8Hz), 8.52(1H, d, J=2.0Hz), 10.15(1H, brs), 12.28(1H, brs)

Example 2072-(4-Ethoxycarbonylpiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

[0398]




[0399] 3.71 g of ethyl isonipecotate, 2.38 g of triethylamine and 10 ml of 2-propanol were added to 1 g of 2-chloro-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline. The obtained mixture was refluxed for 1 hour and cooled to room temperature. The crystals thus precipitated were recovered by filtration and washed with water and ether successively to give 1.126 g of the title compound.

- molecular formula; $C_{25}H_{25}N_5O_4$
- yield(%); 83
- m.p.(°C); 192 ~ 193
- Mass; 460 (M+1)
- NMR δ ($CDCl_3$) ;
 1.26 (3H, t, J=7.2Hz), 1.71 (2H, m), 1.99 (2H, m), 2.59 (1H, m), 3.12 (2H, brt, J=12.0Hz), 4.15 (2H, q, J=7.2Hz), 4.67 (2H, d, J=5.2Hz), 4.82 (2H, dt, J=13.2Hz, 3.6Hz), 5.96 (2H, s), 6.79 (1H, d, J=8.0Hz), 6.85 (1H, dd, J=8.0Hz, 1.6Hz), 6.88 (1H, d, J=1.6Hz), 7.42 (1H, brs), 7.61 (1H, dd, J=8.8Hz, 1.6Hz), 7.84 (1H, brs)

Example 2082-(4-Ethoxycarbonylpiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-cyanoquinazoline

[0400]



[0401] 3.5 g of ethyl isonipecotate, 2.25 g of triethylamine and 30 ml of 2-propanol were added to 1 g of 2-chloro-4-(3-chloro-4-methoxybenzyl)amino-6-cyanoquinazoline. The obtained mixture was refluxed for 30 minutes and cooled to room temperature. The crystals thus precipitated were recovered by filtration and washed with water and ethanol successively to give 1.13 g of the title compound.


- molecular formula; $C_{25}H_{26}N_5O_3Cl$

- yield(%); 85
- m.p. (°C) : 202 ~ 203
- Mass; 480 (M+1)
- NMR δ (CDCl₃):
 1.26 (3H, t, J=7.2Hz), 1.72 (2H, m), 1.99 (2H, m), 2.59 (1H, m), 3.13 (2H, brt, J=11.2Hz), 3.90 (3H, s), 4.15 (2H, q, J=7.2Hz), 4.69 (2H, d, J=5.6Hz), 4.80 (2H, m), 6.91 (1H, d, J=8.4Hz), 7.25 (1H, dd, J=8.4Hz, 2.4Hz), 7.42 (1H, d, J=2.4Hz), 7.43 (1H, brs), 7.61 (1H, dd, J=8.8Hz, 1.6Hz), 7.87 (1H, brs)

Example 209

2-[N-(3-Ethoxycarbonylpropyl)-N-methylamino]-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

[0402]



[0403] 858 mg of ethyl N-methyl-4-aminobutyrate hydrochloride, 238 mg of triethylamine, 4 ml of 2-propanol and 2 ml of N,N-dimethylformamide were added to 400 mg of 2-chloro-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline. The obtained mixture was refluxed for 1 hour, cooled to room temperature and filtered. The filtrate was distilled under a reduced pressure to remove the solvent and the residue was recrystallized (from ethanol/water) to give 410 mg of the title compound.


- molecular formula; C₂₄H₂₅N₅O₄
- yield(%); 78
- m.p.(°C); 152 ~ 153
- Mass; 448 (M+1)
- NMR δ (CDCl₃):
 1.22 (3H, t, J=6.8Hz), 1.97 (2H, brs), 2.30 (2H, brs), 3.24 (3H, s), 3.75 (2H, brs), 4.10 (2H, q, J=6.8Hz), 4.68 (2H, d, J=5.2Hz), 5.96 (2H, s), 6.79 (1H, d, J=8.0Hz), 6.84 (1H, d, J=8.0Hz), 6.87 (1H, s), 7.42 (1H, brs), 7.60 (1H, d, J=8.8Hz), 7.81 (1H, brs)

Examples 210 to 221

[0404] The following compounds were prepared in a similar manner to that of Examples 205 to 209.

Example 2102-(4-Ethoxycarbonylpiperidino)-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline hydrochloride

[0405]



- molecular formula; $C_{27}H_{32}N_4O_7 \cdot HCl$

- yield(%); 65

- m.p.(°C); 148 ~ 150


- Mass; 525 (M+1)

- NMR δ ($CDCl_3$);

1.275 (3H, t, J=7.2Hz), 1.76 (2H, m), 2.03 (2H, m), 2.63 (1H, m), 3.38 (2H, m), 3.99 (3H, s), 4.08 (3H, s), 4.12 (3H, s), 4.17 (2H, q, J=7.2Hz), 4.28 (2H, m), 4.63 (2H, d, J=6.0Hz), 5.88 (2H, s), 6.68 (1H, d, J=8.0Hz), 6.92 (1H, dd, J=8.0Hz, 1.6Hz), 6.97 (1H, d, J=1.6Hz), 8.23 (1H, s), 9.38 (1H, brs), 11.1 (1H, s)

Example 2112-(4-Ethoxycarbonylpiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6,7,8-trimethoxyquinazoline hydrochloride

[0406]



- molecular formula; $C_{27}H_{33}N_4O_6Cl \cdot HCl$

- yield(%); 93

- m.p. (°C); 177 ~ 178


- Mass; 545 (M+1)

- NMR δ ($CDCl_3$);

1.27 (3H, t, J=7.2Hz), 1.80 (2H, m), 2.06 (2H, m), 2.67 (1H, m), 3.40 (2H, m), 3.82 (3H, s), 3.98 (3H, s), 4.07 (3H, s), 4.11 (3H, s), 4.17 (2H, q, J=7.2Hz), 4.27 (2H, m), 4.65 (2H, d, J=6.0Hz), 6.84 (1H, d, J=8.8Hz), 7.40 (1H, d, J=2.0Hz), 7.48 (1H, dd, J=8.8Hz, 2.0Hz), 8.23 (1H, s), 9.26 (1H, s), 11.27 (1H, brs)

Example 2122-(4-Ethoxycarbonylpiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-chloroquinazoline hydrochloride


[0407]



- molecular formula; $C_{24}H_{26}N_4O_3Cl_2 \cdot HCl$
 - yield(%): 97
 - m.p.(°C); 201 ~ 204
 - Mass; 489 (M+1)
 - NMR δ (DMSO- d_6):
- 1.17 (3H, t, J=7.2Hz), 1.56 (2H, m), 1.93 (2H, m), 2.71 (1H, m), 3.30 (2H, m), 3.80 (3H, s), 4.06 (2H, q, J=7.2Hz), 4.48 (2H, m), 4.66 (2H, d, J=5.2Hz), 7.09 (1H, d, J=8.4Hz), 7.34 (1H, dd, J=8.4Hz, 2.0Hz), 7.49 (1H, d, J=2.0Hz), 7.83 (2H, brs), 8.48 (1H, brs), 10.8 (1H, brs)

Example 2132-(Ethoxycarbonylmethyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline


[0408]



- molecular formula; $C_{20}H_{19}N_4O_4Cl$
 - yield(%): 55
 - m.p.(°C); 218 ~ 219 (dec.)
 - Mass m/e; 415 (M+1)
 - NMR δ (DMSO- d_6):
- 1.13 (3H, t, J=7.2Hz), 4.07 (2H, q, J=7.2Hz), 4.18 (2H, brs), 4.63 (2H, brd, J=4.0Hz), 5.97 (2H, s), 6.85 ~ 6.92 (3H, m), 7.53 (1H, brs), 7.84 (1H, brd, J=8.0Hz), 8.35 (1H, brs), 8.50 (2H, m)

Example 2142-(3-Ethoxycarbonylpropyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline


[0409]



- molecular formula; $C_{22}H_{23}N_4O_4Cl$
- yield(%); 44
- m.p.(°C); 96 ~ 98
- Mass m/e; 443 (M+1)
- NMR δ ($CDCl_3$);
 1.24 (3H, t, J=6.8Hz), 1.96 (2H, quintet, J=7.2Hz), 2.41 (2H, t, J=7.2Hz), 3.54 (2H, q, J=7.2Hz), 4.12 (2H, q, J=6.8Hz), 4.66 (2H, q, J=5.2Hz), 5.97 (2H, s), 6.79 (1H, d, J=8.0Hz), 6.84 (1H, d, J=8.0Hz), 6.87 (1H, s), 7.30 (1H, d, J=8.0Hz), 7.44 (1H, s), 7.47 (1H, d, J=8.0Hz)

Example 2152-[N-(3-Ethoxycarbonylpropyl)-N-methylamino]-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline hydrochloride


[0410]



- molecular formula; $C_{23}H_{25}N_4O_4Cl \cdot HCl$
- yield(%); 67
- m.p.(°C); 182 ~ 183
- Mass; 457 (M+1)
- NMR δ ($CDCl_3 + DMSO-d_6$);
 1.23 (3H, t, J=7.2Hz), 1.90 (2H, brs), 2.25 (2H, brs), 2.84 (3H, brs), 3.56 (2H, brs), 4.10 (2H, q, J=7.2Hz), 4.70 (2H, d, J=5.6Hz), 5.94 (2H, s), 6.76 (1H, d, J=7.6Hz), 6.87 (2H, m), 7.54 (1H, dd, J=9.2Hz, 2.0Hz), 8.40 (1H, d, J=2.0Hz), 8.66 (1H, d, J=9.2Hz), 9.69 (1H, brs)

Example 216**2-(5-Ethoxycarbonylpentyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline**


[0411]



- molecular formula; $C_{24}H_{27}N_4O_4Cl$
- yield(%); 46
- m.p.(°C); 109 ~ 110
- Mass m/e; 471 (M+1)
- NMR δ ($CDCl_3$);
 1.25 (3H, t, J=7.2Hz), 1.43 (2H, quintet, J=7.6Hz), 1.66 (4H, m), 2.31 (2H, t, J=7.6Hz), 3.49 (2H, q, J=7.6Hz),
 4.12 (2H, q, J=7.2Hz), 4.68 (2H, d, J=5.2Hz), 5.97 (2H, s), 6.79 (1H, d, J=8.0Hz), 6.84 (1H, d, J=8.0Hz), 6.87 (1H,
 s), 7.43 (3H, m)

Example 217**(S)-2-(N-2-Ethoxycarbonylpyrrolidin-1-yl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline hydrochloride**

[0412]




- molecular formula; $C_{23}H_{23}N_4O_4Cl \cdot HCl$
- yield(%); 52
- m.p.(°C); 206 ~ 208
- Mass; 455 (M+1)
- NMR δ ($CDCl_3$);
 1.19 (3H, t, J=7.2Hz), 2.17 (3H, m), 2.32 (1H, m), 4.12 (2H, m), 4.24 (2H, m), 4.62 (2H, m), 4.67 (1H, m),
 5.93 (2H, s), 6.77 (1H, d, J=8.0Hz), 6.86 (1H, dd, J=8.0Hz, 1.6Hz), 6.89 (1H, d, J=1.6Hz), 7.54 (1H, d, J=8.8Hz),
 8.38 (1H, s), 8.64 (1H, d, J=8.8Hz), 9.67 (1H, brs), 13.38 (1H, brs)

Example 218

2-(N-Ethoxycarbonylmethyl-N-methylamino)-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

[0413]




- molecular formula; $C_{22}H_{21}N_5O_4$
 - yield(%); 75
 - m.p. ($^{\circ}C$); 171 ~ 172
 - Mass; 420 (M+1)
 - NMR δ (DMSO- d_6);
- 1.12 (3H, m), 3.18 (3H, s), 4.03 (2H, m), 4.38 (2H, m), 4.51 (2H, m), 5.95 (2H, s), 6.84 (3H, m), 7.30 (1H, m), 7.76 (1H, m), 8.58 (1H, s), 8.79 (1H, m)

Example 219

2-[N-Ethyl-N-(3-ethoxycarbonyl)amino]-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline


[0414]



- molecular formula; $C_{25}H_{27}N_5O_4$ (461.522)
 - yield(%); 61
 - m.p. ($^{\circ}C$); 142 ~ 143
 - Mass; 462 (M+1)
 - NMR δ (DMSO- d_6);
- 1.0 ~ 1.15 (3H, br 2 peaks), 1.13 (3H, t, J=7.1Hz), 1.65 ~ 1.9 (2H, br 2 peaks), 2.15 ~ 2.35 (2H, br 2 peaks), 3.58 (4H, brs), 4.01 (2H, q, J=7.1Hz), 4.58 (2H, d, J=5.7Hz), 5.96 (2H, s), 6.84 (2H, s), 6.93 (1H, s), 7.25 (1H, brs), 7.72 (1H, dd, J=1.8Hz, 8.8Hz), 8.56 (1H, d, J=1.8Hz), 8.72 (1H, t, J=5.7Hz)

Example 2202-(N-(3-Ethoxycarbonylpropyl)-N-methylamino)-4-(3-chloro-4-methoxybenzyl)amino-6-cyanoquinazoline

5 [0415]



- 20
- molecular formula; $C_{24}H_{26}N_5O_3Cl$
 - yield(%); 72
 - m.p.(°C); 127 ~ 128
 - Mass; 468 (M+1)
 - NMR δ (DMSO- d_6);
- 25
- 1.11 (3H, t, J=7.2Hz), 1.74 (2H, brs), 2.14 (2H, brs), 3.09 (3H, s), 3.62 (2H, brs), 3.81 (3H, s), 3.98 (2H, q, J=7.2Hz), 4.61 (2H, d, J=6.0Hz), 7.07 (1H, d, J=8.8Hz), 7.20 ~ 7.36 (2H, m), 7.42 (1H, s), 7.72 (1H, d, J=8.8Hz), 8.55 (1H, s), 8.75 (1H, t, J=6.0Hz)


Example 221

30

(S)-2-(N-2-Ethoxycarbonylpyrrolidin-1-yl)-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline hydrochloride

[0416]


35



- 50
- molecular formula; $C_{24}H_{23}N_5O_4 \cdot HCl$
 - yield(%); 44
 - m.p.(°C); 231 ~ 232
 - Mass; 446 (M+1)
 - NMR δ (CDCl₃);
- 55
- 1.21 (3H, t, J=7.2Hz), 2.19 (3H, m), 2.36 (1H, m), 4.15 (2H, m), 4.28 (2H, m), 4.62 (2H, m), 4.76 (1H, m), 5.95 (2H, s), 6.79 (1H, d, J=8.0Hz), 6.86 (1H, d, J=8.0Hz), 6.88 (1H, s), 7.80 (1H, dd, J=8.8Hz, 1.6Hz), 8.82 (1H, d, J=1.6Hz), 8.87 (1H, d, J=8.8Hz), 9.85 (1H, brs), 13.81 (1H, s)

Example 2222-(4-Carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

5 [0417]



20 [0418] 10 ml of ethanol, 5 ml of water and 820 mg of sodium hydroxide were added to 1 g of 2-(4-ethoxycarbonyl-piperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline. The obtained mixture was refluxed for 20 minutes, concentrated under a reduced pressure and neutralized with 1N hydrochloric acid. The crystals thus precipitated were recovered by filtration to give 920 mg of the title compound.

25 • molecular formula; $C_{22}H_{21}N_4O_4Cl$

• yield(%): 98

• m.p.(°C): 221 ~ 222

• Mass m/e: 441 (M+1)

• NMR δ (DMSO- d_6):

30 1.38 (2H, m), 1.80 (2H, dd, J=13.2Hz, 2.4Hz), 2.48 (1H, m), 2.96 (2H, t, J=12.0Hz), 4.54 (2H, d, J=5.6Hz), 4.56 (2H, dt, J=12.0Hz, 3.2Hz), 5.94 (2H, s), 6.81 (1H, d, J=8.0Hz), 6.84 (1H, d, J=8.0Hz), 6.93 (1H, s), 7.24 (1H, d, J=9.2Hz), 7.46 (1H, dd, J=9.2Hz, 2.0Hz), 8.13 (1H, d, J=2.0Hz), 8.55 (1H, t, J=5.6Hz)


Example 223

35

Sodium 2-(4-Carboxypiperidinol-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0419]

40




55 [0420] 12 ml of a 1N aqueous solution of sodium hydroxide and 40 ml of water were added to 5.00 g (11.3 mmol) of the 2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline prepared in Example 222. The obtained mixture was dissolved by heating and cooled by allowing to stand. The crystals thus precipitated were recovered by filtration under suction, washed with a small amount of water, and vacuum-dried in the presence of phosphorus pentaoxide to give 4.34 g of the title compound.

- molecular formula; $C_{22}H_{20}ClN_4O_4Na$
- yield(%): 98
- NMR δ (DMSO- d_6) ;
 1.42(2H, m), 1.73(2H, m), 2.06(1H, m), 2.95(2H, m), 4.52(2H, m), 4.56(2H, d, $J=5.6$ Hz), 5.95(2H, s), 6.81
 (1H, d, $J=8.0$ Hz), 6.86(1H, dd, $J=8.0$ Hz, 1.6Hz), 6.95(1H, d, $J=1.6$ Hz), 7.22(1H, d, $J=9.2$ Hz), 7.44(1H, dd, $J=9.2$ Hz,
 2.4Hz), 8.13(1H, d, $J=2.4$ Hz), 8.58(1H, brt, $J=5.6$ Hz)

Example 224

Potassium 2-(4-Carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0421]




[0422] 12.5 ml of a 1N aqueous solution of potassium hydroxide and 40 ml of water were added to 5.50 g (12.5 mmol) of the 2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzylamino)-6-chloroquinazoline prepared in Example 222. The obtained mixture was dissolved by heating and filtered. The filtrate was concentrated in a vacuum. Ethanol and ether were added to the obtained residue to precipitate crystals. The crystals were recovered by filtration, washed with ether, and vacuum-dried in the presence of phosphorus pentoxide to give 4.69 g of the title compound.

- molecular formula; $C_{22}H_{20}ClN_4O_4K$
- yield(%): 78
- m.p.(°C): 230 ~ 234 (dec.)
- NMR δ (DMSO- d_6) ;
 1.39(2H, m), 1.69(2H, m), 1.96(1H, m), 2.94(2H, m), 4.48(2H, m), 4.55(2H, d, $J=5.6$ Hz), 5.96(2H, s), 6.81(1H,
 d, $J=8.0$ Hz), 6.86(1H, dd, $J=8.0$ Hz, 1.6Hz), 6.94(1H, d, $J=1.6$ Hz), 7.22(1H, d, $J=8.8$ Hz), 7.43(1H, dd, $J=8.8$ Hz, 2,
 4Hz), 8.11 (1H, d, $J=2.4$ Hz), 8.50(1H, brt, $J=5.6$ Hz)

Example 225

2-(4-Carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline hydrochloride

[0423]




[0424] 2.00 g (4.54 mmol) of the 2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzylamino)-6-chloroquinazoline prepared in Example 222 was dissolved in a mixture comprising 25 ml of tetrahydrofuran and 25 ml of ethanol under heating, followed by the dropwise addition of 1.0 ml of an 8M ethanolic solution of hydrochloric acid. The obtained mixture was cooled by allowing to stand to precipitate crystals. The crystals were recovered by filtration, washed with tetrahydrofuran, and air-dried to give 1.87 g of the title compound.

- molecular formula; $C_{22}H_{21}N_4O_4Cl \cdot HCl$
- yield(%); 86
- m.p.(°C); 284 ~ 286
- NMR δ (DMSO- d_6) ;
1.58(2H, m), 1.96(2H, m), 2.65(1H, m), 3.3(2H, m), 4.47(2H, m), 4.67(2H, d, J=5.6Hz), 5.98(2H, s), 6.87(1H, d, J=8.0Hz), 6.90(1H, dd, J=8.0Hz, 1.6Hz), 7.00(1H, d, J=1.6Hz), 7.83(2H, brs), 8.49(1H, brs), 10.09(1H, brs), 12.11(1H, brs), 12.40(1H, brs)

Example 226

2-(4-Carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline methanesulfonate

[0425]




[0426] 2.00 g (4.54 mmol) of the 2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzylamino)-6-chloroquinazoline prepared in Example 222 was dissolved in a mixture comprising 25 ml of tetrahydrofuran and 25 ml of ethanol under heating, followed by the dropwise addition of 0.31 ml (4.78 mmol) of methanesulfonic acid. The obtained mixture was cooled by allowing to stand to precipitate crystals. The crystals were recovered by filtration, washed with tetrahydrofuran, and air-dried to give 2.21 g of the title compound.

- molecular formula; $C_{22}H_{21}N_4O_4Cl \cdot CH_3O_3S$
- yield(%); 91
- m.p. (°C) ; 265 ~ 266
- NMR δ (DMSO- d_6) ;
1.59(2H, m), 1.97(2H, m), 2.32(3H, s), 2.65(1H, m), 3.3(2H, m), 4.40(2H, m), 4.68(2H, d, J=5.6Hz), 5.98(2H, s), 6.87(1H, d, J=8.0Hz), 6.90(1H, dd, J=8.0Hz, 1.6Hz), 6.98(1H, d, J=1.6Hz), 7.67(1H, d, J=8.8Hz), 7.84(1H, dd, J=8.0Hz, 2.0Hz), 8.42(1H, d, J=2.0Hz), 9.95(1H, brs), 11.76(1H, brs), 12.37(1H, brs)

Example 2272-(4-Carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

[0427]




[0428] 20 ml of ethanol and 2.0 ml of a 1N aqueous solution of sodium hydroxide were added to 318 mg of 2-(4-ethoxycarbonylpiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline. The obtained mixture was stirred at 50°C for 30 minutes and neutralized with 1N hydrochloric acid. The crystal thus precipitated was recovered by filtration and purified by silica gel column chromatography (chloroform/ methanol) to give 116 mg of the title compound.

- molecular formula; $C_{23}H_{21}N_5O_4$
- yield(%); 39
- m.p.(°C); 269 ~ 271
- Mass m/e; 432 (M+1)
- NMR δ (DMSO- d_6);
 1.40 (2H, m), 1.79 (2H, m), 2.41 (1H, m), 3.04 (1H, dt, J=11.2Hz, 1.2Hz), 4.55 (2H, d, J=5.6Hz), 4.57 (2H, m), 5.95 (2H, s), 6.82 (1H, d, J=8.0Hz), 6.84 (1H, d, J=8.0Hz), 6.94 (1H, s), 7.25 (1H, d, J=8.8Hz), 7.71 (1H, d, J=8.8Hz), 8.53 (1H, s), 8.72 (1H, t, J=5.6Hz)

Example 2282-(4-Carboxypiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-cyanoquinazoline


[0429]



[0430] 30 ml of tetrahydrofuran, 30 ml of ethanol and 14 ml of a 1N aqueous solution of sodium hydroxide were added to 1.0 g of 2-(4-ethoxycarbonylpiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-cyanoquinazoline. The obtained mixture was stirred at room temperature for 16 hours and neutralized with 1N hydrochloric acid, followed by the addition of 100 ml of water. The crystals thus precipitated were recovered by filtration and recrystallized from tetrahydrofuran/ ethanol/water to give 860 mg of the title compound.


- molecular formula; $C_{23}H_{22}N_5O_3Cl$

- yield(%); 91
 - m.p.(°C); 277 ~ 278 (dec.)
 - Mass m/e; 452 (M+1)
 - NMR δ (DMSO- d_6);
- 1.40 (2H, m), 1.84 (2H, m), 2.51 (1H, m), 3.05 (2H, dt, J=12Hz, 2.4Hz), 3.82 (3H, s), 4.59 (2H, d, J=5.6Hz), 4.63 (2H, m), 7.08 (1H, d, J=8.4Hz), 7.28 (1H, d, J=8.8Hz), 7.32 (1H, dd, J=8.4Hz, 2.0Hz), 7.45 (1H, d, J=2.0Hz), 7.74 (1H, dd, J=8.8Hz, 2.0Hz), 8.54 (1H, d, J=2.0Hz), 8.79 (1H, t, J=5.6Hz)

Example 229**Sodium 2-(4-Carboxypiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-cyanoquinazoline****[0431]**

[0432] 1.00 g (2.21 mmol) of the 2-(4-carboxypiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-cyanoquinazoline prepared in Example 228 was dissolved in a mixture comprising 30 ml of tetrahydrofuran and 40 ml of ethanol under heating, followed by the addition of 2.3 ml of a 1N aqueous solution of sodium hydroxide and 100 ml of water. The obtained mixture was concentrated in a vacuum to precipitate crystals. The crystals were recovered by filtration, washed with water, and air-dried to give 0.45 g of the title compound.

- molecular formula; $C_{23}H_{21}N_5O_3ClNa$
 - yield(%); 43
 - NMR δ (DMSO- d_6);
- 1.45 (2H, m), 1.75 (2H, m), 2.12 (1H, m), 3.06 (2H, m), 3.81 (3H, s), 4.52 (2H, m), 4.58 (2H, d, J=5.6Hz), 7.07 (1H, d, J=8.8Hz), 7.24 (1H, d, J=8.4Hz), 7.32 (1H, dd, J=8.4Hz, 2.0Hz), 7.45 (1H, d, J=2.0Hz), 7.69 (1H, dd, J=8.8Hz, 2.0Hz), 8.54 (1H, d, J=2.0Hz), 8.86 (1H, brt, J=5.6Hz)

Example 230**2-[N-(3-Carboxypropyl)-N-methylaminol]-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline****[0433]**

[0434] 20 ml of ethanol and 2.61 ml of a 1N aqueous solution of sodium hydroxide were added to 389 mg of 2-[N-(3-ethoxycarbonylpropyl)-N-methoxyamino]-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline. The obtained mixture was stirred at room temperature for 4 hours and at 50°C for 10 minutes and neutralized with 1N hydrochloric acid. The crystals precipitated were recovered by filtration, purified by silica gel column chromatography (chloroform/methanol) and recrystallized from ethanol/acetone/water to give 305 mg of the title compound.

- molecular formula; $C_{22}H_{21}N_5O_4$
- yield(%); 84
- m.p.(°C); 138 ~ 140
- Mass m/e; 420 (M+1)
- NMR δ ($CDCl_3$ (+DMSO- d_6)) ;
1.96 (2H, brs), 2.31 (brs), 3.24 (3H, s), 3.76 (2H, brs), 4.67 (2H, d, J=5.6Hz), 5.94 (2H, s), 6.77 (1H, d, J=8.0Hz), 6.86 (1H, d, J=8.0Hz), 6.91 (1H, s), 7.58 (1H, brs), 7.61 (1H, d, J=8.4Hz), 8.48 (2H, m)


Examples 231 to 245

[0435] The following compounds were prepared in a similar manner to those of Examples 222 to 230.

Example 231

2-(4-Carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6,7,8-trimethoxyquinazoline


[0436]



- molecular formula; $C_{25}H_{28}N_4O_7$
- yield(%); 73
- m.p.(°C); 216 ~ 217
- Mass m/e; 297 (M+1)
- NMR δ ($CDCl_3$) ;
1.80 (2H, m), 2.05 (2H, m), 2.65 (1H, m), 3.39 (2H, dt, J=10.8Hz, 2.8Hz), 3.98 (3H, s), 4.07 (3H, s), 4.13 (3H, s), 4.26 (2H, m), 4.70 (2H, d, J=6.0Hz), 5.88 (2H, s), 6.69 (1H, d, J=7.6Hz), 6.95 (1H, dd, J=7.6Hz, 1.6Hz), 7.02 (1H, d, J=1.6Hz), 8.38 (1H, s), 9.36 (1H, s), 11.24 (1H, t, J=6.0Hz)

Example 2322-(4-Carboxypiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6,7,8-trimethoxyquinazoline

[0437]



- molecular formula; $C_{25}H_{29}N_4O_6Cl$

- yield(%); 90

- m.p.(°C); 197 ~ 198


- Mass m/e; 517 (M+1)

- NMR δ (DMSO- d_6);

1.45 (2H, brs), 1.90 (2H, brs), 2.59 (1H, brs), 3.22 (2H, brs), 3.80 (3H, s), 3.90 (6H, s), 3.92 (3H, s), 4.39 (2H, brs), 4.65 (2H, d, J=5.2Hz), 7.05 (1H, d, J=8.4Hz), 7.33 (1H, d, J=8.4Hz), 7.45 (1H, s), 7.76 (1H, brs), 10.70 (1H, brs)

Example 2332-(4-Carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline

[0438]



- molecular formula; $C_{23}H_{24}N_4O_5$ (436)

- yield(%); 79

- m.p.(°C); 263 (dec.)

- Mass; 437 (M+1)⁺


- NMR δ (DMSO- d_6);

1.51 ~ 1.59 (2H, m), 1.86 ~ 1.95 (2H, m), 2.59 ~ 2.64 (1H, m), 3.21 ~ 3.28 (2H, m), 4.39 ~ 4.44 (2H, m), 4.67 (2H, d, J=5.6Hz), 5.78 (2H, s), 6.85 (1H, d, J=7.6Hz), 6.89 (1H, d, J=7.6Hz), 6.99 (1H, s), 7.42 (1H, dd, J=9.2Hz, 1.6Hz), 7.72 (1H, d, J=9.2Hz), 7.86 (1H, d, J=1.6Hz), 10.02 (1H, br), 11.89 (1H, s)

Example 234

2-(4-Carboxypiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-methoxyquinazoline

[0439]



- molecular formula; $C_{23}H_{25}N_4O_4Cl$ (456.930)

- yield(%); 81

- m.p.(°C); 245 (dec.)

- Mass; 457 (MH⁺)


- NMR;

1.3 ~ 1.5 (2H, m), 1.79 (2H, d, J=10Hz), 2.4 ~ 2.5 (1H, m), 2.91 (2H, t, J=11Hz), 3.81 (3H, s), 4.56 (2H, d, J=13Hz), 4.60 (2H, d, J=5.7Hz), 7.09 (1H, d, J=8.6Hz), 7.18 (1H, dd, J=2.7Hz, 9.2Hz), 7.24 (1H, d, J=9.2Hz), 7.32 (1H, dd, J=2.2Hz, 8.6Hz), 7.45 (1H, d, J=2.2Hz), 7.49 (1H, d, J=2.7Hz), 8.42 (1H, t, J=5.7Hz), 12.15 (1H, brs)

Example 235

2-(4-Carboxypiperidino)-4-(3-chloro-4-methoxybenzyl)amino-6-chloroquinazoline

[0440]



- molecular formula; $C_{22}H_{22}N_4O_3Cl_2$

- yield(%); 92

- m.p. (°C) ; 280 ~ 281


- Mass m/e; 461 (M+1)

- NMR δ (DMSO- d_6);

1.59 (2H, m), 1.94 (2H, brd, J=11.6Hz), 2.62 (1H, brs), 3.32 (2H, m), 3.79 (3H, s), 4.52 (2H, d, J=13.6Hz), 4.64 (2H, d, J=4.8Hz), 6.99 (1H, d, J=8.4Hz), 7.30 (1H, d, J=8.4Hz), 7.42 (1H, s), 7.69 (1H, d, J=8.8Hz), 8.00 (1H, d, J=8.8Hz), 8.51 (1H, s), 10.24 (1H, s), 12.42 (1H, s)

Example 236**2-(4-Carboxypiperidino)-4-(benzimidazol-5-yl)methylamino-6-chloroquinazoline**

[0441]

• molecular formula; $C_{22}H_{21}N_6O_2Cl$ (436.903)

• yield(%); 99


• m.p.(°C); 230 (dec.)

• Mass; 437 (MH)⁺• NMR δ (DMSO- d_6);

1.3 ~ 1.5 (2H, m), 1.82 (2H, d, J=10Hz), 2.4 ~ 2.5 (1H, m), 2.98 (2H, t, J=11Hz), 4.60 (2H, d, J=13Hz), 4.77 (2H, d, J=5.7Hz), 7.2 ~ 7.3 (2H, m), 7.45 ~ 7.6 (3H, m), 8.16 (1H, s), 8.19 (1H, d, J=2.4Hz), 8.68 (1H, t, J=5.7Hz), 12.17 (1H, brs), 12.33 (1H, brs)

Example 237**2-(Carboxymethyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline**

[0442]

• molecular formula; $C_{18}H_{15}N_4O_4Cl$

• yield(%); 64

• m.p.(°C); 260 ~ 261 (dec.)


• Mass m/e; 387 (M+1)

• NMR δ (DMSO- d_6);

4.00 (2H, brs), 4.57 (2H, d, J=5.6Hz), 5.93 (2H, s), 6.79 (1H, d, J=8.0Hz), 6.86 (1H, d, J=8.0Hz), 6.95 (1H, s), 7.35 (1H, brs), 7.50 (1H, brs), 8.30 ~ 8.50 (2H, m)

Example 2382-(3-Carboxypropyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline


[0443]



- molecular formula; $C_{20}H_{19}N_4O_4Cl$
- yield(%); 88
- m.p.(°C); 170 ~ 172
- Mass m/e; 415 (M+1)
- NMR δ (DMSO- d_6) ;
 1.71 (2H, brs), 2.23 (2H, brs), 3.27 (2H, brs), 4.56 (2H, d, J=5.6Hz), 5.95 (2H, s), 6.82 (3H, m), 6.95 (1H, s),
 7.20 (1H, brs), 7.46 (1H, dd, J=8.8Hz, 1.6Hz), 8.12 (1H, d, J=1.6Hz)

Example 2392-(5-Carboxypentyl)amino-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline


[0444]



- molecular formula; $C_{22}H_{23}N_4O_4Cl$
- yield(%); 80
- m.p. (°C) ; 190 ~ 192
- Mass m/e; 443 (M+1)
- NMR δ (DMSO- d_6);
 1.25 (2H, brs), 1.47 (4H, brs), 2.16 (2H, brs), 3.31 (2H, brs), 4.60 (2H, brs), 5.94 (2H, s), 6.84 (2H, s), 6.96
 (1H, s), 7.33 (1H, brs), 7.60 (1H, brs), 8.25 (1H, brs)

Example 2402-[N-(3-Carboxypropyl)-N-methylamino]-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline


[0445]



- molecular formula; $C_{21}H_{21}N_4O_4Cl$
 - yield(%); 92
 - m.p.(°C); 143 ~ 144
 - Mass m/e; 429 (M+1)
 - NMR δ (DMSO- d_6 (+CD $_3$ OD));
- 1.79 (2H, brs), 2.20 (2H, brs), 3.21 (3H, s), 3.71 (2H, t, J=7.2Hz), 4.65 (2H, s), 5.95 (2H, s), 6.81 (1H, d, J=8.0Hz), 6.86 (1H, d, J=8.0Hz), 6.95 (1H, s), 7.79 (1H, d, J=8.8Hz), 7.85 (1H, d, J=8.8Hz), 8.49 (1H, s)

Example 2412-(N-Carboxymethyl-N-methylamino)-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline


[0446]



- molecular formula; $C_{20}H_{17}N_5O_4$
 - yield(%); 68
 - m.p. (°C) ; 268 ~ 270
 - Mass m/e; 392 (M+1)
 - NMR δ (DMSO- d_6) ;
- 3.11 (3H, s), 4.13 (2H, brs), 4.56 (2H, m), 5.94 (2H, s), 6.83 (2H, m), 6.93 (1H, d, J=14.4Hz), 7.20 (1H, m), 7.66 (1H, m), 8.51 (1H, s), 8.62 (1H, m)

Example 2422-[N-Ethyl-N-(3-carboxypropyl)amino]-4-(3,4-methylenedioxybenzyl)amino-6-cyanoquinazoline

[0447]



- molecular formula; $C_{23}H_{23}N_5O_4$ (433.468)

- yield(%); 96

- m.p.(°C); 186 ~ 187


- Mass; 434 (M+1)

- NMR δ (DMSO- d_6);

1.0 ~ 1.15 (3H, br 2 peaks), 1.65 ~ 1.85 (2H, br 2 peaks), 2.1 ~ 2.25 (2H, br 2 peaks), 3.57 (4H, brs), 4.58 (2H, d, J=5.7Hz), 5.96 (2H, s), 6.84 (2H, s), 6.93 (1H, s), 7.26 (1H, d, J=8.8Hz), 7.72 (1H, dd, J=1.8Hz, 8.8Hz), 8.56 (1H, d, J=1.8Hz), 8.71 (1H, brs)

Example 2432-[N-(3-Carboxypropyl)-N-methylamino]-4-(3-chloro-4-methoxybenzyl)amino-6-cyanoquinazoline

[0448]



- molecular formula; $C_{22}H_{22}N_5O_3Cl$

- yield(%); 88

- m.p.(°C); 108 ~ 109

- Mass; 440 (M+1)

- NMR δ (DMSO- d_6);


1.73 (2H, brs), 2.13 (2H, brs), 3.11 (3H, s), 3.63 (2H, brs), 3.82 (3H, s), 4.61 (2H, d, J=5.6Hz), 7.07 (1H, d, J=8.4Hz), 7.27 (1H, d, J=8.8Hz), 7.31 (1H, d, J=8.4Hz), 7.43 (1H, s), 7.72 (1H, s), 8.55 (1H, s), 8.74 (1H, brt, J=5.6Hz), 12.02 (1H, brs)

Example 2442-(4-Carboxypiperidino)-4-(benzimidazol-5-yl)methylamino-6-cyanoquinazoline

5 [0449]

10

15



20

- molecular formula; $C_{23}H_{21}N_7O_2$ (427)
- yield(%); 50
- m.p.(°C); >290
- Mass; 428 ($M^+ + 1$)
- NMR δ (DMSO- d_6);

25

1.29 ~ 1.42 (2H, m), 1.76 ~ 2.20 (2H, m), 2.39 ~ 2.51 (2H, m), 2.99 ~ 3.07 (3H, m), 4.60 ~ 4.64 (2H, m), 4.76 (2H, d, $J=5.6$ Hz), 7.23 (1H, d, $J=8.4$ Hz), 7.25 (1H, d, $J=8.8$ Hz), 7.51 (1H, d, $J=8.4$ Hz), 7.56 (1H, s), 7.71 (1H, dd, $J=8.4$ Hz, 1.6Hz), 8.14 (1H, s), 8.57 (1H, d, $J=1.6$ Hz), 8.82 (1H, brt, $J=5.6$ Hz)

Example 245

30


2-(4-Carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-carbamoylquinazoline

[0450]

35

40

45



50


- molecular formula; $C_{23}H_{23}N_5O_5$ (449)
- yield(%); 6
- m.p.(°C); 180 ~ 182 (dec.)
- Mass; 450 ($M + 1$)
- NMR δ (DMSO- d_6);

55

1.39 (2H, m), 1.81 (2H, m), 2.48 (1H, m), 2.99 (2H, m), 4.55 (2H, d, $J=5.6$ Hz), 4.62 (2H, m), 5.93 (2H, s), 6.81 (1H, d, $J=7.6$ Hz), 6.85 (1H, dd, $J=7.6$ Hz, 1.6Hz), 6.95 (1H, d, $J=1.6$ Hz), 7.20 (1H, d, $J=8.8$ Hz), 7.27 (1H, br), 7.71 (1H, br), 7.92 (1H, dd, $J=8.8$ Hz, 2.0Hz), 8.57 (1H, d, $J=2.0$ Hz), 8.59 (1H, brt, $J=5.6$ Hz), 12.09 (1H, br)

Example 2472-Benzyloxymethyl-4-(3,4-methylenedioxybenzyl)amino-6-methoxyquinazoline

[0451]



[0452] 0.74 g (2.4 mmol) of the 2-benzyloxymethyl-4-chloro-6-methoxyquinazoline prepared in Example 246, 0.55 g (3.6 mmol) of piperonylamine and 0.50 g of sodium carbonate were mixed with 20 ml of isopropyl alcohol. The obtained mixture was heated under reflux. After 6 hours, the reaction mixture was distilled under a reduced pressure to remove the solvent and the residue was purified by silica gel column chromatography (ethyl acetate/n-hexane) and recrystallized from chloroform/n-hexane to give 1.01 g of the title compound as a yellow crystal.


- molecular formula; $C_{25}H_{23}N_3O_4$
- yield(%); quantitative
- m.p. ($^{\circ}C$); 158 ~ 159
- NMR δ ($CDCl_3$);
 3.91 (3H, s), 4.69 (2H, s), 4.77 (2H, s), 4.79 (2H, d, $J=5.6Hz$), 5.94 (2H, s), 6.77 (1H, d, $J=7.6Hz$), 6.90 (1H, dd, $J=7.6Hz, 1.6Hz$), 6.94 (1H, d, $J=1.6Hz$), 7.10 (1H, brs), 7.25 ~ 7.35 (5H, m), 7.41 ~ 7.44 (2H, m), 7.81 (1H, d, $J=9.2Hz$)

Examples 281 to 291

[0453] The following compounds were prepared in a similar manner to those of Examples 88 to 94.

Example 2812-(4-Carboxypiperidino)-4-(3,5-dichloro-4-methoxybenzylamino)-6-cyanoquinazoline

[0454]




- molecular formula; $C_{23}H_{21}Cl_2N_5O_3$
- yield(%); 98
- m.p.($^{\circ}C$); 255 ~ 256 (dec.)

- Mass m/e; 486 (M+1)⁺
- NMR δ (DMSO- d_6) :
1.36(2H, brm), 1.80(2H, brm), 2.52(1H, m), 3.03(2H, m), 3.78(3H, s), 4.59(2H, d, J=6.0Hz), 4.59(2H, brm), 7.29
(1H, d, J=8.8Hz), 7.50(2H, s), 7.75(1H, dd, J=8.8Hz, 1.6Hz), 8.53(1H, d, J=1.6Hz), 8.85(1H, brt, J=6.0Hz), 12.18
(1H, brs)

Example 284**2-(4-Carboxypiperidino)-4-(3,4-dihydroxybenzyl)amino-6-chloroquinazoline**


[0455]



- molecular formula; $C_{21}H_{21}ClN_4O_4$
- yield(%); 95
- m.p. ($^{\circ}C$); 216 ~ 218 (dec.)
- Mass m/e; 429 (MH⁺)
- NMR δ (DMSO- d_6) ;
1.38~1.47(2H, m), 1.80~1.84(2H, m), 2.44~2.49(1H, m), 2.93~3.00(2H, m), 4.48(2H, d, J=5.6Hz), 4.57~4.61(2H, m), 6.60~6.65(2H, m), 6.74(1H, d, J=1.6Hz), 7.24(1H, d, J=8.8Hz), 7.46(1H, dd, J=8.8Hz, 2.0Hz), 8.15(1H, d, J=2.0Hz), 8.48(1H, brs), 8.675(1H, s), 8.75(1H, s), 12.14(1H, brs)

Example 292**2-(6-Nitroxyhexyloxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline**

[0456]



[0457] 860 mg of 2-(6-hydroxyhexyloxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline was dissolved in 15 ml of pyridine, followed by the addition of 570 mg of methyl chloride under cooling with ice. The obtained mixture was stirred for 10 hours, followed by the addition of water. The resulting mixture was extracted with ethyl acetate. The ethyl acetate layer was dried and concentrated to give 1.2 g of crude 2-(6-tosyloxyhexyloxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline.

[0458] 3 g of sodium iodide and 30 ml of dimethylformamide were added to the crude product. The obtained mixture was maintained at 60 $^{\circ}C$ by heating for one hour, followed by the addition of water. The resulting mixture was extracted

with ethyl acetate. The organic layer was washed with an aqueous solution of sodium chloride, dried and concentrated. The residue was purified by silica gel column chromatography to give 450 mg of 2-(6-iodohexyloxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline.

[0459] 410 mg of the 2-(6-iodohexyloxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline was suspended in 15 ml of acetonitrile, followed by the addition of 900 mg of silver nitrate. The obtained mixture was maintained at 60°C by heating for one hour, followed by the addition of water and ethyl acetate. The resulting mixture was filtered through Celite to remove insolubles. The organic layer was recovered, dried and subjected to silica gel column chromatography to give 340 mg of the title compound.

• molecular formula; $C_{22}H_{23}ClN_4O_6$ (474.5)

• yield(%); 95

• m.p.(°C); 121 ~ 122

• Mass; 475 (MH⁺)


• NMR δ (CDCl₃);

1.42 ~ 1.59 (4H, m), 1.70 ~ 1.89 (4H, m), 4.43 (4H, q, J=6.8Hz), 4.73 (2H, d, J=4.4Hz), 5.95 (2H, s), 6.28 (1H, br), 6.77 (1H, d, J=8.0Hz), 6.83 (1H, d, J=8.0Hz), 6.85 (1H, s), 7.54 (1H, d, J=8.8Hz), 7.58 (1H, d, J=8.8Hz), 7.66 (1H, s)

Example 293

Sodium 2-(3-sulfoxypropoxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0460]



[0461] 1 g of 2-(3-hydroxypropoxy)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline and 540 mg of sulfur trioxide/trimethylamine complex were suspended in 10 ml of pyridine. The obtained suspension was stirred at room temperature overnight, followed by the addition of ethyl acetate. The crystals thus precipitated were recovered by filtration, suspended in methanol and dissolved therein by the addition of 1N sodium hydroxide. Ether was added to the obtained solution to precipitate crystals. The crystals were recovered by filtration, whereby 400 mg (32%) of the title compound was obtained.

• molecular formula; $C_{19}H_{17}ClN_3NaO_7S$ (489.5)

• yield(%); 32

• m.p.(°C); 190 ~ 192 (dec.)

• Mass; 490 (MH⁺)


• NMR δ (DMSO-d₆);

1.90 ~ 1.95 (2H, m), 3.82 (2H, t, J=6.4Hz), 4.28 (2H, t, J=6.8Hz), 4.61 (2H, d, J=5.6Hz), 5.95 (2H, s), 6.84 (2H, s), 6.98 (1H, s), 7.50 (1H, d, J=8.8Hz), 7.64 (1H, dd, J=8.8Hz, 2.4Hz), 8.84 (1H, d, J=2.4Hz), 8.79 (1H, t, J=1.6Hz)

Example 300

2-(4-Cyanopiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline

[0462]




[0463] 75 ml of thionyl chloride and 150 ml of acetonitrile were added to 3.8 g (0.0086 mol) of 2-(4-carbamoylpiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline. The mixture thus obtained was heated under reflux for one hour. The reaction mixture was distilled under a reduced pressure to remove the solvent. A saturated aqueous solution of sodium hydrogencarbonate and triethylamine were added to the residue and the resultant mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, filtered and distilled under a reduced pressure to remove the solvent. The obtained residue was purified by a silica gel column chromatography (ethyl acetate-n-hexane) and recrystallized from chloroform-n-hexane to give 3.1 g of the title compound.

- molecular formula; $C_{22}H_{20}ClN_5O_2$
- yield(%); 85
- m.p.(°C); 169 ~ 170
- NMR δ ($CDCl_3$) ;
 1.88 (2H, m), 1.95 (2H, m), 2.87 (1H, m), 3.73 (2H, m), 4.25 (2H, m), 4.67 (2H, d, $J=5.6$ Hz), 5.65 (1H, t, $J=5.6$ Hz), 5.97 (2H, s), 6.79 (1H, d, $J=8.0$ Hz), 6.84 ((1H, dd, $J=8.0$ Hz, 1.6Hz), 6.87 (1H, d, $J=1.6$ Hz), 7.39 (1H, d, $J=8.8$ Hz), 7.44 (1H, d, $J=2.4$ Hz), 7.46 (1H, dd, $J=8.8$ Hz, 2.4Hz)

Example 301

2-[4-(1H-tetrazol-5-yl)piperidino]-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline hydrochloride

[0464]



[0465] 10 ml of toluene was added to a mixture comprising 0.50 g (0.0012 mol) of 2-(4-cyanopiperidino)-4-(3,4-meth-

EP 0 607 439 B1


ylenedioxybenzyl)amino-6-chloroquinazoline and 0.50 g (0.0024 mol) of trimethyl stannylazide. The mixture thus obtained was heated under reflux for two days. The reaction mixture was distilled under a reduced pressure to remove the solvent. The residue was suspended in 10 ml of ethanol, followed by the addition of 10 ml of 1N hydrochloric acid. The mixture thus obtained was stirred at room temperature for several hours. The mixture was filtered to recover the crystal. The crystal was washed with water and air-dried to give 0.60 g of the title compound.

- molecular formula; $C_{22}H_{21}ClN_8O_2 \cdot HCl$
- yield(%); quantitative
- m.p.(°C); 212 ~ 214
- Mass m/e; 465 (M+1)⁺
- NMR δ (DMSO- d_6) ;
1.80 (2H, m), 2.17 (2H, m), 3.45 (2H, m), 4.62 (2H, m), 4.69 (2H, d, J=5.6Hz), 5.97 (2H, s), 6.86 (1H, d, J=7.6Hz), 6.91 ((1H, dd, J=7.6Hz, 1.6Hz), 7.01 (1H, d, J=1.6Hz), 7.84 (1H, dd, J=8.8Hz, 1.6Hz), 7.88 (1H, d, J=8.8Hz), 8.51 (1H, d, J=1.6Hz), 10.13 (1H, brs), 12.28 (1H, brs)

Example 302

2-(1H-tetrazol-5-yl)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline hydrochloride

[0466]



[0467] The title compound was prepared in a similar manner to that of Example 301.


- molecular formula; $C_{17}H_{12}ClN_7O_2 \cdot HCl$
- yield(%); 37
- m.p.(°C); 201 ~ 204 (dec.)
- Mass m/e; 382 (MH)⁺
- NMR δ (DMSO- d_6);
4.90 (2H, d, J=5.6Hz), 5.97 (2H, s), 6.87 (1H, d, J=8.0Hz), 6.98 ((1H, dd, J=8.0Hz, 2.0Hz), 7.11 (1H, d, J=2.0Hz), 7.92 ~ 7.94 (2H, m), 8.60 (1H, d, J=1.6Hz), 9.53 (1H, brs)

Examples 303 to 410

[0468] The following compounds were each prepared by any method described above.


Example 3032-Chloro-4-(3,4-methylenedioxybenzyl)amino-6-methoxy-7-cyclopentyloxyquinazoline

[0469]




- molecular formula: $C_{22}H_{22}ClN_3O_4$
- yield(%): 88
- m.p.(°C): 176 ~ 177
- Mass: 428 (M+1)⁺
- NMR δ (CDCl₃) ;
 - 1.64 (2H, m), 1.82 (2H, m), 1.93 (2H, m), 2.02 (2H, m), 3.90 (3H, s), 4.74 (2H, d, J=5.6Hz), 4.85 (1H, m), 5.72 (1H, t, J=5.6Hz), 5.96 (2H, s), 6.79 (1H, d, J=7.6Hz), 6.79 ((1H, s), 6.87 (1H, dd, J=7.6Hz, 1.6Hz), 6.90 (1H, d, J=1.6Hz), 7.11 (1H, s)

Table 7




Ex.	R ³	R ³	R ⁴	m. p. (°C)	yield (%)	M a s s	NMR	note
304	Cl			264- 265	97	441 (M+1)	δ (DMSO-d ₆) : 1.70(2H, brs), 1.90(2H, m), 2.54(1H, m) 3.11(2H, m), 3.98(2H, m) 4.40(2H, d, J=6.4Hz), 5.93(2H, s) 6.80(2H, brs), 6.84(1H, brs) 7.02(1H, m), 7.28(1H, m), 7.44(1H, brs) 7.68(1H, d, J=8.8Hz), 12.24(1H, brs)	
305	Cl			258- 259	97	441 (M+1)	δ (DMSO-d ₆) : 1.36(2H, m), 1.79(2H, m), 2.47(1H, m) 2.96(2H, t, J=11.2Hz) 4.55(2H, d, J=5.6Hz), 4.58(2H, m) 5.93(2H, s), 6.82(2H, s), 6.92(1H, s) 7.05(1H, dd, J=8.8Hz, 2.4Hz) 7.23(1H, d, J=2.4Hz) 8.00(1H, d, J=8.8Hz) 8.58(1H, t, J=5.6Hz), 12.15(1H, brs)	

Table 8




Ex.	R ¹	R ³	R ⁴	m. p. (°C)	yield (%)	Mass	NMR	note
306	CN			amorphous	93	494 (M ⁺)	δ (CDCl ₃) : 1.25(3H, t, J=7.2Hz), 1.64-1.77(2H, m) 1.94-2.01(2H, m), 2.52-2.61(1H, m) 3.04-3.14(2H, m), 3.25(3H, s) 3.91(3H, s), 4.14(3H, q, J=7.2Hz) 4.72-4.81(2H, m), 4.74(2H, s) 6.93(1H, d, J=8.4Hz) 7.19(1H, dd, J=8.4Hz, 2.0Hz) 7.37(1H, d, J=2.0Hz) 7.43(1H, d, J=8.4Hz) 7.58(1H, dd, J=8.4Hz, 2.0Hz) 8.06(1H, d, J=2.0Hz)	
307	CN			196- 198	44	446 (M ⁺)	δ (DMSO-d ₆) : 1.35-1.50(2H, m), 1.79-1.86(2H, m) 2.50-2.55(1H, m), 2.99-3.08(2H, m) 3.30(3H, s), 4.54-4.62(2H, m) 4.81(2H, s), 5.98(2H, s) 6.82(1H, dd, J=8.0Hz, 1.6Hz) 6.87(1H, d, J=8.0Hz) 6.92(1H, d, J=1.6Hz) 7.33(1H, d, J=2.4Hz) 7.71(1H, dd, J=8.4Hz, 1.6Hz) 8.27(1H, d, J=1.6Hz)	

Table 9




Ex.	R ²	R ³	R ⁴	m. p. (°C)	yield (%)	Mass	NMR	note
308	Cl			180- 181	99	420(M+1)	δ (DMSO-d ₆) : 1.97(2H, quintet, J=7.4Hz) 2.26(2H, t, J=7.4Hz) 2.72(2H, t, J=7.4Hz) 3.82(3H, s), 4.67(2H, d, J=5.7Hz) 7.08(1H, d, J=8.6Hz) 7.34(1H, dd, J=8.6Hz, 2.2Hz) 7.47(1H, d, J=2.2Hz) 7.64(1H, d, J=9.0Hz) 7.74(1H, dd, J=9.0Hz, 2.4Hz) 8.37(1H, d, J=2.4Hz) 8.76(1H, t, J=5.7Hz)	

Table 1 2




Ex.	R ¹	R ²	R ³	m. p. (°C)	yield (%)	Mass	NMR	note
315	Cl			170 (decomp)	68	527(MH ⁺)	δ (DMSO) : 1.22-1.33(2H, m), 1.36-1.51(4H, m) 1.69-1.82(4H, m), 2.25-2.81(1H, m) 2.97-3.06(2H, m), 3.32-3.52(4H, m) 4.29-4.52(3H, m), 4.72(2H, brs) 5.98(2H, s), 6.80-6.92(2H, m) 7.29(1H, d, J=9.2Hz), 7.45(1H, d, J=9.2Hz, 1.2Hz) 7.60(1H, d, J=1.2Hz)	

Table 1 3




Ex.	R ¹	R ²	R ³	R ⁴	m. p. (°C)	yield (%)	M a s s	NMR	note
316	CN				oily sub- stance	quantitative	474(MH ⁺)	δ (CDCl ₃) : 1.26(3H, t, J=7.2Hz) 1.66-1.77(2H, m), 1.93-2.01(2H, m) 2.51-2.62(1H, m), 3.09-3.13(2H, m) 3.23(3H, s), 4.14(2H, q, J=7.2Hz) 4.74-4.80(2H, m), 4.79(2H, s) 5.98(2H, s), 6.80-6.84(3H, m) 7.42(1H, d, J=8.8Hz) 7.57(1H, dd, J=8.8Hz, 2.0Hz), 8.05(1H, d, J=2.0Hz)	

Table 1 4




Ex.	R ²	R ¹	R ³	m. p. (°C)	yield (%)	Mass	NMR	note
317	Cl			244- 245	quantitative	443(M+1) ⁺	δ (DMSO-d ₆) : 1.49(2H, m), 1.88(2H, m), 2.53(1H, m) 3.08(2H, m), 3.74(3H, s) 4.58(2H, d, J=5.2 Hz), 4.61(2H, m) 6.71(1H, d, J=8.0 Hz) 6.80(1H, dd, J=8.0 Hz, 2.0 Hz) 6.99(1H, d, J=2.0 Hz), 7.38(1H, brs) 7.56(1H, brs), 8.25(1H, brs) 8.86(1H, s), 12.19(1H, brs)	
318	Cl			254- 255 (decomp)	92	443(M+1) ⁺	δ (DMSO-d ₆) : 1.48(2H, m), 1.88(2H, m), 2.54(1H, m) 3.10(2H, m), 3.72(3H, s), 4.54(2H, m) 4.56(2H, d, J=5.6 Hz) 6.77(1H, dd, J=8.0 Hz, 2.0 Hz) 6.82(1H, d, J=2.0 Hz) 6.84(1H, d, J=8.0 Hz) 7.45(1H, brs), 7.60(1H, brs) 8.28(1H, brs), 8.90(1H, s) 12.21(1H, brs)	

Table 15




Ex.	R ⁴	R ⁵	R ⁶	m. p. (°C)	yield (%)	Mass	NMR	note
319	Cl	Cl		193- 194	58	350(M+1) ⁺	δ (DMSO-d ₆) : 3.71(3H, s), 4.57(2H, d, J=5.6Hz) 6.74(1H, dd, J=8.4Hz, 2.0Hz) 6.77(1H, d, J=2.0Hz) 6.84(1H, d, J=8.4Hz) 7.62(1H, d, J=8.8Hz) 7.79(1H, dd, J=8.8Hz, 2.4Hz) 8.46(1H, d, J=2.4Hz) 8.91(1H, s), 9.22(1H, t, J=5.6Hz)	

Table 16




Ex.	R ²	R ⁵	R ⁴	m. p. (°C)	yield (%)	Mass	NMR	note
320	Cl			173- 174	78	471(M+1) ⁺	δ (CDCl ₃) : 1.26(3H, t, J=7.2Hz), 1.72(2H, m) 1.98(2H, m), 2.56(1H, m), 3.05(2H, m) 3.88(3H, s), 4.15(2H, q, J=7.2Hz) 4.68(2H, d, J=5.2Hz), 4.82(2H, m) 5.56(1H, t, J=5.2Hz), 5.65(1H, brs) 6.90(3H, m), 7.39(1H, d, J=8.8Hz) 7.42(1H, d, J=2.4Hz) 7.44(1H, dd, J=8.8Hz, 2.4Hz)	
321	Cl			170- 171	91	471(M+1) ⁺	δ (CDCl ₃) : 1.26(3H, t, J=7.2Hz), 1.72(2H, m) 1.97(2H, m), 2.55(1H, m), 3.04(1H, m) 3.90(3H, s), 4.15(2H, q, J=7.2Hz) 4.66(2H, d, J=5.2Hz), 4.80(2H, m) 5.57(1H, t, J=5.2Hz), 5.68(1H, brs) 6.83(3H, m), 7.39(1H, d, J=8.8Hz) 7.42(1H, dd, J=8.8Hz, 2.4Hz) 6.97(1H, d, J=2.4Hz), 7.38(1H, d, J=8.8Hz) 7.41(1H, d, J=2.4Hz) 7.43(1H, dd, J=8.8Hz, 2.4Hz)	

Table 17




Ex.	R ²	R ³	R ⁶	m. p. (°C)	yield (%)	Mass	NMR	note
322	Cl			> 260	99	476 (M+1) ⁺	δ (DMSO-d ₆) : 1.53 (2H, m), 1.90 (2H, m), 2.62 (1H, m) 3.29 (2H, m), 4.41 (2H, m) 4.83 (2H, d, J=5.6 Hz) 7.74 (1H, d, J=8.4 Hz) 7.76 (1H, dd, J=8.4 Hz, 2.0 Hz) 7.85 (1H, d, J=8.4 Hz) 7.90 (1H, d, J=8.4 Hz) 8.15 (1H, d, J=2.0 Hz), 8.51 (1H, s) 10.34 (1H, brs), 12.28 (1H, brs)	hydro- chloride
323	Cl			> 260	65	446 (M+1) ⁺	δ (DMSO-d ₆) : 1.58 (2H, m), 1.95 (2H, m), 2.63 (1H, m) 3.32 (2H, m), 4.45 (2H, m) 4.62 (2H, d, J=5.2 Hz), 5.33 (2H, brs) 6.58 (1H, dd, J=8.0 Hz, 2.0 Hz) 6.79 (1H, d, J=2.0 Hz) 7.13 (1H, d, J=8.0 Hz) 7.85 (1H, d, J=8.8 Hz) 7.89 (1H, d, J=8.8 Hz) 8.51 (1H, s), 10.14 (1H, brs) 12.22 (1H, brs)	hydro- chloride

Table 18




Ex.	R ²	R ³	R ⁵	R ⁶	m. p. (°C)	yield (%)	Mass	NMR	note
324	Cl				218- 219 (decomp)	25	476 (M+1) ⁺	δ (DMSO-d ₆) : 1.20 (3H, t, J=7.2 Hz), 1.57 (2H, m) 1.96 (2H, m), 2.73 (1H, m), 3.31 (2H, m) 4.08 (2H, q, J=7.2 Hz), 4.49 (2H, m) 4.61 (2H, d, J=5.6 Hz) 6.59 (1H, dd, J=8.0 Hz, 2.0 Hz) 6.79 (1H, d, J=2.0 Hz) 7.13 (1H, d, J=8.0 Hz) 7.85 (1H, dd, J=9.2 Hz, 2.4 Hz) 7.93 (1H, d, J=9.2 Hz) 8.53 (1H, d, J=2.4 Hz) 10.19 (1H, br t, J=5.6 Hz) 12.31 (1H, br s)	
325	Cl				180- 187	77	350 (M+1) ⁺	δ (DMSO-d ₆) : 3.74 (3H, s), 4.58 (2H, d, J=5.6 Hz) 6.70 (1H, d, J=8.0 Hz) 6.75 (1H, d, J=8.0 Hz, 1.6 Hz) 7.00 (1H, d, J=1.6 Hz) 7.61 (1H, d, J=8.8 Hz) 7.78 (1H, dd, J=8.8 Hz, 2.4 Hz) 8.46 (1H, d, J=2.4 Hz), 8.87 (1H, s) 8.19 (1H, t, J=5.6 Hz)	

Table 19




Ex.	R ²	R ⁵	R ⁶	m. p. (°C)	yield (%)	M a s s	N M R	note
327	Cl	Cl		220- 221	71	383 (M+1) ⁺	δ (DMSO-d ₆) : 4.81 (2H, d, J=5.0 Hz) 7.67 (1H, d, J=8.4 Hz) 7.71 (1H, dd, J=8.4 Hz, 2.0 Hz) 7.74 (1H, d, J=8.4 Hz) 7.84 (1H, dd, J=8.4 Hz, 2.0 Hz) 8.11 (1H, d, J=2.0 Hz) 8.44 (1H, d, J=2.0 Hz) 9.39 (1H, t, J=5.6 Hz)	

Table 2 0




Ex.	R ^a	R ^b	R ^c	m. p. (°C)	yield (%)	M a s s	N M R	note
328	Cl			230- 231	73	504 (M+1) ⁺	δ (DMSO-d ₆) : 1.20(3H, t, J=7.2Hz), 1.51(2H, m) 1.89(2H, m), 2.72(1H, m), 3.27(2H, m) 4.08(2H, q, J=7.2Hz), 4.44(2H, m) 4.82(2H, d, J=5.6Hz) 7.73(1H, d, J=8.4Hz) 7.76(1H, dd, J=8.4Hz, 2.0Hz) 7.85(1H, dd, J=8.8Hz, 2.0Hz) 7.92(1H, d, J=8.8Hz) 8.14(1H, d, J=2.0Hz) 8.52(1H, d, J=2.0Hz), 10.35(1H, brs) 12.35(1H, brs)	hydro- chloride
329	Cl			> 260	65	446 (M+1) ⁺	δ (DMSO-d ₆) : 1.58(2H, m), 1.95(2H, m), 2.63(1H, m) 3.32(2H, m), 4.45(2H, m) 4.62(2H, d, J=5.2Hz), 5.33(2H, brs) 6.58(1H, dd, J=8.0Hz, 2.0Hz) 6.79(1H, d, J=2.0Hz) 7.13(1H, d, J=8.0Hz) 7.85(1H, d, J=8.8Hz) 7.89(1H, d, J=8.8Hz), 8.51(1H, s) 10.14(1H, brs), 12.22(1H, brs)	hydro- chloride

Table 2 3




Ex.	R ¹	R ²	R ³	R ⁴	m. p. (°C)	yield (%)	M a s s	NMR	note
334	Cl				240- 241 (decolor)	60	397(MH ⁺) ⁺	δ (DMSO-d ₆) : 1.39(2H, m), 1.80(2H, m), 2.47(1H, m) 2.96(2H, m), 4.57(2H, m) 4.66(2H, d, J=5.6 Hz) 7.15-7.45(6H, m) 7.48(1H, dd, J=9.2 Hz, 1.6 Hz) 8.17(1H, d, J=1.6 Hz), 8.64(1H, brs) 12.15(1H, brs)	
335	CN				176- 177	40	466(MH ⁺) ⁺	δ (CDCl ₃) : 1.62-1.79(2H, m), 1.96-2.03(2H, m) 1.57-1.64(1H, m), 3.08-3.18(2H, m) 3.25(3H, s), 3.91(3H, s) 4.70-4.79(2H, m), 4.80(2H, s) 6.93(1H, d, J=8.4 Hz) 7.19(1H, dd, J=8.4 Hz, 2.0 Hz) 7.36(1H, d, J=2.0 Hz) 7.45(1H, d, J=8.8 Hz) 7.58(1H, dd, J=8.8 Hz, 2.0 Hz) 8.06(1H, d, J=2.0 Hz)	

Table 2 4




Ex.	R ²	R ³	R ⁴	m. p. (°C)	yield (%)	M a s s	N M R	note
336	CN	Cl		156- 158	89	353(MH ⁺)	δ (DMSO-d ₆) : 3.42(3H, s), 4.93(2H, s), 5.99(2H, s) 6.86(1H, dd, J=8.0Hz, 1.6Hz) 6.90(1H, d, J=8.0Hz) 6.98(1H, d, J=1.6Hz) 7.73(1H, d, J=8.4Hz) 8.08(1H, dd, J=8.4Hz, 2.0Hz) 8.63(1H, d, J=2.0Hz)	
337	CN	Cl		173- 175	86	373(MH ⁺)	δ (DMSO-d ₆) : 3.44(3H, s), 3.83(3H, s), 4.95(2H, s) 7.13(1H, d, J=8.8Hz) 7.34(1H, dd, J=8.8Hz, 2.4Hz) 7.50(1H, d, J=2.4Hz) 7.74(1H, d, J=8.8Hz) 8.08(1H, dd, J=8.8Hz, 1.6Hz) 8.65(1H, d, J=1.6Hz)	

Table 2 5




Ex.	R ¹	R ²	R ³	R ⁴	m. p. (°C)	yield (%)	M a s s	NMR	note
338	Cl	-COOH			187- 188	93	378(M+1) ⁺	δ (DMSO-d ₆) : 3.83(3H, s), 4.75(2H, d, J=5.6Hz) 7.10(1H, d, J=8.4Hz) 7.38(1H, dd, J=8.4Hz, 2.4Hz) 7.53(1H, d, J=2.4Hz) 7.84(1H, d, J=8.8Hz) 7.88(1H, dd, J=8.8Hz, 2.0Hz) 8.50(1H, d, J=2.0Hz) 9.15(1H, br t, J=5.6Hz)	
339	Cl				180- 181	99	420(M+1) ⁺	δ (DMSO-d ₆) : 1.97(2H, quintet, J=7.4Hz) 2.26(2H, t, J=7.4Hz) 2.72(2H, t, J=7.4Hz), 3.82(3H, s) 4.67(2H, d, J=5.7Hz) 7.08(1H, d, J=8.6Hz) 7.34(1H, dd, J=8.6Hz, 2.2Hz) 7.47(1H, d, J=2.2Hz) 7.64(1H, d, J=9.0Hz) 7.74(1H, dd, J=9.0Hz, 2.4Hz) 8.37(1H, d, J=2.4Hz) 8.76(1H, t, J=5.7Hz)	

Table 2 6




Ex.	R ²	R ¹	R ¹	m. p. (°C)	yield (%)	Mass	NMR	note
340	Cl			173- 174	88	483(M+1) ⁺	δ (DMSO-d ₆) : 1.20(3H, t, J=7.2Hz), 1.67(2H, m) 2.01(2H, m), 2.77(1H, m) 2.89(2H, t, J=7.2Hz), 3.39(2H, m) 3.75(2H, m), 4.10(2H, q, J=7.2Hz) 4.56(2H, m), 5.96(2H, s) 6.69(1H, dd, J=8.0Hz, 1.6Hz) 6.80(1H, d, J=8.0Hz) 6.86(1H, d, J=1.6Hz) 7.83(1H, dd, J=8.8Hz, 2.4Hz) 7.95(1H, d, J=8.8Hz) 8.44(1H, d, J=2.4Hz), 9.69(1H, brs) 12.34(1H, brs)	hydro- chloride
341	Cl			186- 187	75	455(M+1) ⁺	δ (DMSO-d ₆) : 1.50(2H, m), 1.88(2H, m), 2.52(1H, m) 2.86(2H, t, J=7.4Hz), 3.03(2H, m) 3.63(2H, m), 4.65(2H, m), 5.96(2H, s) 6.69(1H, d, J=8.0Hz) 6.82(1H, d, J=8.0Hz), 6.83(1H, s) 7.27(1H, d, J=9.2Hz) 7.48(1H, dd, J=9.2Hz, 2.4Hz) 8.10(1H, d, J=2.4Hz), 8.17(1H, brs) 12.19(1H, brs)	

Table 2 7




Ex.	R ²	R ⁴	R ⁵	m. p. (°C)	yield (%)	Mass	NMR	note
342	Cl			166- 167	95	425(M+1) ⁺	δ (DMSO-d ₆) : 1.19(3H, t, J=7.2Hz), 1.57(2H, m) 1.94(2H, m), 2.73(1H, m), 3.31(2H, m) 4.08(2H, q, J=7.2Hz), 4.48(2H, m) 4.77(2H, d, J=5.6Hz) 7.25-7.45(5H, m), 7.85(2H, s) 8.52(1H, s), 10.19(1H, brs) 12.19(1H, brs)	hydro- chloride
343	Cl			212- 213	41	477(M+1) ⁺	δ (DMSO-d ₆) : 1.12(3H, t, J=7.2Hz), 1.80(2H, brs) 2.23(2H, brs), 3.24(3H, s) 3.73(2H, brs), 3.82(3H, s) 3.99(2H, q, J=7.2Hz) 4.71(2H, d, J=6.0Hz) 7.09(1H, d, J=8.8Hz) 7.35(1H, d, J=8.4Hz), 7.48(1H, s)	hydro- chloride

Table 2 8




Ex.	R ¹	R ²	R ³	R ⁴	m. p. (°C)	yield (%)	Mass	NMR	note
344	Cl				140- 141	81	449(M+) ⁺	δ (DMSO-d ₆) : 1.74(2H, brm), 1.59(2H, brm) 3.10(3H, s), 3.61(2H, t, J=7.2Hz) 3.81(3H, s), 4.61(2H, d, J=5.6Hz) 7.07(1H, d, J=8.4Hz) 7.31(1H, dd, J=8.4Hz, 2.0Hz) 7.36(1H, brs), 7.43(1H, d, J=2.0Hz) 7.55(1H, brs), 8.20(1H, brs) 12.03(1H, brs)	
345	CN		Cl		248- 249	78	393(M+) ⁺	δ (DMSO-d ₆) : 3.81(3H, s), 4.71(2H, d, J=5.6Hz) 7.55(2H, s), 7.76(1H, d, J=8.4Hz) 8.14(1H, dd, J=8.4Hz, 2.0Hz) 8.88(1H, d, J=2.0Hz) 9.49(1H, brt, J=5.6Hz)	

Table 2 9




Ex.	R ²	R ¹	R ³	m. p. (°C)	yield (%)	Mass	NMR	note
346	CN			207- 208	82	514(NH ⁺) ⁺	δ (DMSO-d ₆) : 1.17(3H, t, J=7.2Hz), 1.36(2H, brm) 1.82(2H, brm), 2.62(1H, m) 3.03(2H, m), 3.78(3H, s) 4.05(2H, q, J=7.2Hz) 4.59(2H, brd, J=5.6Hz) 4.63(2H, brm), 7.29(1H, d, J=8.8Hz) 7.50(2H, s) 7.75(1H, dd, J=8.8Hz, 2.0Hz) 8.53(1H, d, J=2.0Hz) 8.86(1H, brt, J=5.6Hz)	
347	Cl			amor- phous	19	572(MH ⁺)	δ (CDCl ₃) : 1.25-2.02(12H, m), 2.47-2.57(1H, m) 3.02-3.18(2H, m), 3.50-3.58(2H, m) 4.42(2H, t, J=6.6Hz) 4.63-4.74(2H, m), 4.75(2H, s) 5.47(2H, s), 6.80-6.81(3H, m) 7.41(1H, dd, J=8.0Hz, 2.0Hz) 7.50(1H, d, J=8.0Hz) 7.62(1H, d, J=2.0Hz)	

Table 3 0




Ex.	R ²	R ³	R ⁴	m. p. (°C)	yield (%)	M a s s	NMR	note
349	Cl			216- 218 (decomp)	95	429(MH ⁺)	δ (DMSO-d ₆) : 1.38-1.47(2H, m), 1.80-1.84(2H, m) 2.44-2.49(1H, m), 2.93-3.00(2H, m) 4.48(2H, d, J=5.6 Hz) 4.57-4.61(2H, m), 6.60-6.65(2H, m) 6.74(1H, d, J=1.6 Hz) 7.24(1H, d, J=8.8 Hz) 7.46(1H, dd, J=8.8 Hz, 2.0 Hz) 8.15(1H, d, J=2.0 Hz), 8.48(1H, brs) 8.675(1H, s), 8.75(1H, s) 12.14(1H, brs)	

Table 3 4




Ex.	R ¹	R ²	m. p. (°C)	yield (%)	M a s s	N M R	note
358	Cl		190- 192 (decomp)	32	490 (MII*)	δ (DMSO-d ₆) : 1.90-1.95(2H, m), 3.82(2H, t, J=6.4Hz) 4.28(2H, t, J=6.8Hz), 4.61(2H, d, J=5.6Hz) 5.95(2H, s), 6.04(2H, s), 6.13(1H, s) 7.50(1H, d, J=8.8Hz) 7.64(1H, dd, J=8.8Hz, 2.4Hz) 8.54(1H, d, J=2.4Hz), 8.75(1H, t, J=1.6Hz)	

Table 3 5




Ex.	R²	R³	m. p. (°C)	yield (%)	M a s s	NMR	note
359	Cl		121- 122	95	475(MH⁺)	δ (CDCl₃) : 1.42-1.59(4H, m), 1.70-1.89(4H, m), 4.43(4H, q, J=6.8Hz), 4.73(2H, d, J=4.4Hz) 5.95(2H, s), 6.28(1H, br) 6.77(1H, d, J=8.0Hz), 6.83(1H, d, J=8.0Hz) 6.85(1H, s), 7.54(1H, d, J=8.8Hz) 7.58(1H, d, J=8.8Hz), 7.66(1H, s)	
360	Cl		173- 175	98	398(M+1)	δ (DMSO-d₆) : 2.66(4H, t, J=4.8Hz), 3.66(1H, t, J=4.8Hz) 4.54(2H, d, J=6.0Hz), 5.94(2H, s) 6.83(2H, s), 6.92(1H, s), 7.22(1H, d, J=8.8Hz) 7.46(1H, dd, J=8.8Hz, 2.4Hz) 8.12(1H, d, J=2.4Hz), 8.51(1H, t, J=6.0Hz)	
361	Cl		233- 234	93	455(M+1)⁺	δ (DMSO-d₆) : 1.58(2H, m), 1.95(2H, m), 2.75(1H, m) 3.3(2H, m), 3.61(3H, s), 4.46(2H, m) 4.65(2H, d, J=5.6Hz), 5.96(2H, s) 6.84(1H, d, J=8.0Hz) 6.87(1H, dd, J=8.0Hz, 1.2Hz) 6.97(1H, d, J=1.2Hz), 7.78(1H, brd, J=8.8Hz) 7.81(1H, brd, J=8.8Hz), 8.45(1H, brs) 10.05(1H, brs), 12.05(1H, brs)	hydrochloride

Table 3 6




Ex.	R ²	R ³	m. p. (°C)	yield (%)	M a s s	NMR	note
363	H	Cl	191- 192	94	314(M+1)	δ (CDCl ₃) : 4.76(2H, d, J=5.2Hz), 5.97(2H, s) 6.15(1H, brs), 6.80(1H, d, J=8.0Hz) 6.87(1H, dd, J=8.0Hz, 1.6Hz) 6.89(1H, d, J=1.6Hz) 7.44(1H, ddd, J=8.0Hz, 6.8Hz, 1.6Hz) 7.66(1H, d, J=8.0Hz), 7.74(1H, t, J=6.8Hz) 7.78(1H, dd, J=6.8Hz, 1.6Hz)	

Table 37




Ex.	R²	R³	m. p. (°C)	yield (%)	Mass	NMR	note
364	II		159- 161	97	407 (M+1)	δ (DMSO-d ₆) : 1.38(2H, m), 1.79(2H, brd, J=12.8Hz) 2.47(1H, m), 2.94(2H, brt, J=11.2Hz) 4.56(2H, d, J=5.6Hz), 4.61(2H, m) 5.93(2H, s), 6.81(1H, d, J=8.0Hz) 6.84(1H, dd, J=8.0Hz, 1.6Hz) 6.93(1H, d, J=1.6Hz), 7.04(1H, t, J=8.4Hz) 7.24(1H, d, J=8.4Hz), 7.48(1H, t, J=8.4Hz) 7.98(1H, t, J=8.4Hz), 8.47(1H, brs) 12.13(1H, brs)	
365	CI		243- 245	81	455 (M+1)	δ (DMSO-d ₆) : 1.12(3H, s), 1.25(2H, m), 1.88(2H, m) 3.23(2H, m), 4.20(2H, m), 4.53(2H, d, J=6.0Hz) 5.94(2H, s), 6.83(2H, s), 6.92(1H, s) 7.23(1H, d, J=9.2Hz) 7.46(1H, dd, J=9.2Hz, 2.4Hz) 8.12(1H, d, J=2.4Hz), 8.53(1H, t, J=6.0Hz)	

Table 3 8




Ex.	R ²	R ³	m. p. (°C)	Yield (%)	Mass	NMR	note
366	Cl		174- 175	99	484(M+1)	δ (DMSO-d ₆) : 1.66(2H, quintet, J=7.2Hz) 2.24(2H, t, J=7.2Hz), 2.29(2H, t, J=7.2Hz) 2.35(4H, m), 3.72(4H, m), 4.55(2H, d, J=5.6Hz) 5.95(2H, s), 6.83(2H, s), 6.93(1H, s) 7.24(1H, d, J=8.8Hz) 7.47(1H, dd, J=8.8Hz, 2.4Hz) 8.14(1H, d, J=2.4Hz), 8.53(1H, t, J=5.6Hz)	
367	Cl		237- 239 (decomp)	quantitative	412(M+1) ⁺	δ (DMSO-d ₆) : 2.79(3H, s), 3.14(2H, m), 3.54(2H, m) 3.62(2H, m), 4.71(2H, d, J=5.6Hz), 4.94(2H, m) 5.99(2H, s), 6.87(1H, d, J=8.0Hz) 6.94(1H, dd, J=8.0Hz, 1.6Hz) 7.03(1H, d, J=1.6Hz), 7.87(1H, brd) 8.07(1H, brs), 8.60(1H, brs), 10.29(1H, brs) 11.36(1H, brs), 13.13(1H, brs)	dihydro- chloride

Table 3 9




Ex.	R²	R³	m. p. (°C)	yield (%)	Mass	NMR	note
368	Cl		193- 195	86	456(N+1)	δ (DMSO-d ₆) : 2.53(4H, m), 3.00(2H, brs), 3.75(4H, m) 4.53(2H, brd, J=6.0Hz), 5.94(2H, s) 6.82(2H, brs), 6.92(1H, s) 7.23(1H, d, J=8.8Hz), 7.47(1H, brd, J=8.8Hz) 8.14(1H, brs), 8.55(1H, t, J=6.0Hz)	
369	Cl		174- 176	90	470(N+1)	δ (DMSO-d ₆) : 2.39(6H, m), 2.56(2H, t, J=7.2Hz) 3.71(2H, brs), 4.55(2H, d, J=5.6Hz) 1.83(2H, s), 6.93(1H, s), 7.24(1H, d, J=8.8Hz) 7.48(1H, dd, J=8.8Hz, 2.4Hz) 8.14(1H, d, J=2.4Hz), 8.55(1H, t, J=5.6Hz)	

Table 4 I




Ex.	R²	R³	m. p. (°C)	yield (%)	M a s s	N M R	note
373	Br	Cl	213- 214	80	392(M+1)⁺	δ (DMSO-d₆) : 4.63(2H, d, J=5.6Hz), 5.99(2H, s), 6.87(2H, s) 6.97(1H, s), 7.57(1H, d, J=8.8Hz) 7.92(1H, dd, J=8.8Hz, 2.0Hz) 8.61(1H, d, J=2.0Hz), 9.26(1H, t, J=5.6Hz)	
374	F	Cl	192- 193	80	332(M+1)⁺	δ (DMSO-d₆) : 4.65(2H, d, J=5.6Hz), 5.99(2H, s), 6.87(2H, s) 6.97(1H, s), 7.71(2H, m), 8.17(1H, m) 9.14(1H, t, J=5.6Hz)	
375	Br		239- 240	80	513(M+1)⁺	δ (DMSO-d₆) : 1.17(3H, t, J=7.2Hz), 1.56(2H, m), 1.94(2H, m) 2.72(1H, m), 3.3(2H, m), 4.06(2H, q, J=7.2Hz) 4.49(2H, m), 4.64(2H, d, J=6.0Hz), 5.95(2H, s) 6.83(1H, d, J=8.0Hz) 6.87(1H, dd, J=8.0Hz, 1.6Hz) 6.97(1H, d, J=1.6Hz), 7.80(1H, d, J=8.8Hz) 7.91(1H, dd, J=8.8Hz, 2.0Hz) 8.60(1H, d, J=2.0Hz), 10.10(1H, brs) 12.22(1H, brs)	hydrochloride

Table 4 2




Ex.	R²	R³	m. p. (°C)	yield (%)	M a s s	NMR	note
376	Br		209- 210	96	485 (M+1)⁺	δ (DMSO-d₆) : 1.38 (2H, m), 1.79 (2H, m), 2.46 (1H, m) 2.95 (2H, m), 4.53 (2H, d, J=6.0 Hz), 4.58 (2H, m) 5.93 (2H, s), 6.80 (1H, d, J=8.0 Hz) 6.83 (1H, dd, J=8.0 Hz, 1.6 Hz) 6.91 (1H, d, J=1.6 Hz), 7.16 (1H, d, J=9.2 Hz) 7.55 (1H, dd, J=9.2 Hz, 2.4 Hz) 8.24 (1H, d, J=2.4 Hz), 8.52 (1H, t, J=6.0 Hz) 12.13 (1H, brs)	

Table 4 5




Ex.	R ²	R ¹	m. p. (°C)	yield (%)	Mass	NMR	note
382	Cl		233- 234	93	455(M+1) ⁺	δ (DMSO-d ₆) : 1.58(2H, m), 1.95(2H, m), 2.75(1H, m) 3.3(2H, m), 3.61(3H, s), 4.46(2H, m) 4.65(2H, d, J=5.6 Hz), 5.96(2H, s) 6.84(1H, d, J=8.0 Hz) 6.87(1H, dd, J=8.0 Hz, 1.2 Hz) 6.97(1H, d, J=1.2 Hz), 7.78(1H, brd, J=8.8 Hz) 7.81(1H, brd, J=8.8 Hz), 8.45(1H, brs) 10.05(1H, brs), 12.05(1H, brs)	hydrochloride
383	Cl		amor- phous	99	469(M+1) ⁺	δ (CDCl ₃) : 1.25(3H, t, J=7.2 Hz), 1.54(1H, m), 1.70(1H, m) 1.78(1H, m), 2.11(1H, m), 2.52(1H, m) 2.98(1H, m), 3.14(1H, m), 4.15(2H, q, J=7.2 Hz) 4.66(2H, m), 4.73(1H, m), 4.98(1H, m) 5.61(1H, br t), 5.95(2H, s) 6.78(1H, d, J=8.0 Hz) 6.85(1H, dd, J=8.0 Hz, 1.6 Hz) 6.88(1H, d, J=1.6 Hz), 7.37-7.44(3H, m)	

Table 4 6




Ex.	R ²	R ³	m. p. (°C)	yield (%)	M a s s	NMR	note
384	Cl		275- 276 (decomp)	98	441(M+) ⁺	δ (DMSO-d ₆) : 1.34(1H, m), 1.56(1H, m), 1.65(1H, m) 1.97(1H, m), 2.28(1H, m), 2.85(1H, m) 2.95(1H, m), 4.53(2H, m), 4.57(1H, m) 4.81(1H, m), 5.93(2H, s), 6.78(1H, d, J=8.0Hz) 6.84(1H, dd, J=8.0Hz, 1.6Hz) 6.91(1H, d, J=1.6Hz), 7.24(1H, d, J=8.8Hz) 7.45(1H, dd, J=8.8Hz, 2.4Hz) 8.12(1H, d, J=2.4Hz), 8.55(1H, brs)	
385	Cl	-CN	198- 199	35	339(M+) ⁺	δ (CDCl ₃) : 3.18(1H, br), 4.75(2H, d, J=5.2Hz) 5.97(2H, s), 6.17(1H, br) 6.81(1H, d, J=8.4Hz) 6.87(1H, dt, J=8.4Hz, 1.6Hz) 6.88(1H, d, J=1.6Hz), 7.72(1H, d, J=2.0Hz) 7.75(1H, dd, J=8.8Hz, 2.0Hz) 7.85(1H, d, J=2.0Hz)	

Table 4 7




Ex.	R¹	R²	m. p. (°C)	yield (%)	M a s s	NMR	note
386	MeS	H	174- 175	83	326(M+H)⁺	δ (CDCl₃) : 2.59(3H, s), 4.79(2H, d, J=5.6Hz) 5.93(2H, s), 6.77(1H, d, J=8.0Hz) 6.89(1H, d, J=8.0Hz), 6.94(1H, s) 7.62(1H, dd, J=8.8Hz, 2.0Hz) 7.75(1H, d, J=8.8Hz), 7.97(1H, d, J=2.0Hz) 8.10(1H, brs), 8.56(1H, s)	
387	0 ↑ -S-Mc	H	154- 155	80	342(M+H)⁺	δ (CDCl₃) : 2.75(3H, s), 4.80(2H, d, J=5.2Hz) 5.96(2H, s), 6.80(1H, d, J=8.0Hz) 6.89(1H, d, J=8.0Hz), 6.91(1H, s) 7.06(1H, brs), 7.64(1H, d, J=8.8Hz) 7.98(1H, d, J=8.8Hz), 8.43(1H, s), 8.74(1H, s)	
388	Cl		154- 155	71	401(M+H)⁺	δ (DMSO-d₆) : 1.68(2H, m), 3.11(3H, s), 3.40(2H, t, J=6.2Hz) 3.65(2H, t, J=7.0Hz), 4.60(2H, d, J=5.6Hz) 6.83(1H, d, J=7.6Hz) 6.87(1H, dd, J=7.6Hz, 1.2Hz) 6.95(1H, d, J=1.2Hz), 7.31(1H, br) 7.52(1H, br), 8.19(1H, br)	

Table 4 8




Ex.	R ¹	R ²	m. p. (°C)	yield (%)	M a s s	NMR	note
389	Cl	Cl	194- 195 (decomp)	48	334(MH ⁺) ⁺	δ (DMSO-d ₆) : 6.04(2H, s), 6.95(1H, d, J=8.4Hz) 7.11(1H, dd, J=8.4Hz, 2.0Hz) 7.38(1H, d, J=2.0Hz), 7.69(1H, d, J=8.8Hz) 7.86(1H, dd, J=8.8Hz, 2.4Hz) 8.66(1H, d, J=2.4Hz), 10.13(1H, s)	
390	CN		298- 300 (decomp)	29	455(MH ⁺)	δ (DMSO-d ₆) : 4.62(2H, d, J=5.6Hz), 5.47(2H, s), 5.45(2H, s) 6.81-6.82(2H, m), 6.90(1H, s) 7.51(2H, d, J=8.0Hz), 7.57(1H, d, J=8.8Hz) 7.90(2H, d, J=8.0Hz) 7.96(1H, dd, J=8.8Hz, 2.0Hz) 8.79(1H, d, J=2.0Hz), 9.10(1H, br t, J=5.1Hz)	
391	CN		176- 179	35	469(MH ⁺)	δ (CDCl ₃) : 3.92(3H, s), 4.74(2H, d, J=5.2Hz), 5.58(2H, s) 5.92-5.99(1H, m), 5.99(2H, s) 6.60-6.69(3H, m), 7.57(2H, d, J=8.0Hz) 7.70(1H, d, J=8.8Hz) 7.80(1H, dd, J=8.8Hz, 1.6Hz) 7.95(1H, d, J=1.6Hz), 8.03(2H, d, J=8.0Hz)	

Table 4 9




Ex.	R ²	R ³	m. p. (°C)	yield (%)	Mass	NMR	note
393	Cl		255- 256	96	455(N+1)	δ (DMSO-d ₆) : 1.01 (2H, m), 1.66 (2H, brd, J=13.2 Hz) 1.90 (1H, brs), 2.12 (2H, d, J=7.2 Hz) 2.79 (2H, brt, J=12.0 Hz) 4.53 (2H, d, J=5.6 Hz), 4.71 (2H, brd, J=13.2 Hz) 5.94 (2H, s), 6.82 (2H, m), 6.92 (1H, s) 7.22 (1H, d, J=8.8 Hz) 7.45 (1H, dd, J=8.8 Hz, 2.4 Hz) 8.11 (1H, d, J=2.4 Hz), 8.51 (1H, t, J=5.6 Hz)	

Table 5 0




Ex.	R ²	R ³	m. p. (°C)	yield (%)	Mass	NMR	note
395	C1		176- 177	54	463(M+1)	δ (DMSO-d ₆) : 4.39(2H, d, J=6.0Hz), 4.55(2H, d, J=5.6Hz) 5.93(4H, d, J=8.0Hz), 6.77(5H, m) 6.80(1H, br), 7.20(2H, br) 7.45(1H, dd, J=8.8Hz, 0.8Hz) 8.11(1H, d, J=2.4Hz), 8.38(1H, br)	

Table 5 1




Ex.	R²	R³	m. p. (°C)	yield (%)	M a s s	NMR	note
396	CN		176- 179	35	469(MH⁺)	δ (CDCl₃) : 3.92(3H, s), 4.74(2H, d, J=5.2Hz), 5.58(2H, s) 5.92-5.99(1H, m), 5.98(2H, s), 6.60-6.69(3H, m), 7.57(2H, d, J=8.0Hz) 7.70(1H, d, J=8.8Hz) 7.80(1H, dd, J=8.8Hz, 1.6Hz) 7.95(1H, d, J=1.6Hz), 8.03(2H, d, J=8.0Hz)	
397	CN		298- 300 (decomp)	29	455(MH⁺)	δ (DMSO-d₆) : 4.62(2H, d, J=5.6Hz), 5.47(2H, s), 5.45(2H, s) 6.81-6.82(2H, m), 6.90(1H, s) 7.51(2H, d, J=8.0Hz), 7.57(1H, d, J=8.8Hz) 7.90(2H, d, J=8.0Hz) 7.91(1H, dd, J=8.8Hz, 2.0Hz) 8.79(1H, d, J=2.0Hz), 9.10(1H, br t, J=5.1Hz)	

Table 5 2




Ex.	R ²	R ¹	m. p. (°C)	yield (%)	Mass	NMR	note
398	Cl		236- 237	27	485(M+1)	δ (DMSO-d ₆) : 1.10(6H, s), 1.11(3H, t, J=7.2Hz) 1.76(2H, brs), 3.22(3H, s), 3.64(2H, m) 3.97(2H, q, J=7.2Hz), 4.71(2H, d, J=5.6Hz) 5.97(2H, s), 6.84(2H, s), 6.95(1H, s) 7.84(1H, dd, J=9.2Hz, 2.0Hz) 7.93(1H, d, J=9.2Hz), 8.53(1H, d, J=2.0Hz) 10.10(1H, brs), 11.95(1H, brs)	hydrochloride
399	Cl		240- 241 (decomp)	78	457(M+1)	δ (DMSO-d ₆) : 1.086(6H, s), 1.66(2H, m), 3.03(3H, s) 3.54(2H, m), 4.59(2H, d, J=5.6Hz), 5.94(2H, s) 6.82(2H, s), 6.90(1H, s), 7.22(1H, d, J=9.2Hz) 7.45(1H, dd, J=9.2Hz, 2.0Hz) 8.12(1H, d, J=2.0Hz), 8.46(1H, brs)	

Table 5 3



Ex.	R ²	R ⁵	m. p. (°C)	yield (%)	M a s s	NMR	note
400	Cl		148- 150	21	443 (M+1)	δ (DMSO-d ₆) : 1.05 (3H, d, J=6.0 Hz), 1.51 (1H, m), 1.81 (1H, m) 2.26 (1H, m), 3.05 (3H, s), 3.57 (2H, m) 4.57 (2H, d, J=5.6 Hz), 5.94 (2H, s), 6.82 (2H, s) 6.91 (1H, s), 7.23 (1H, d, J=8.8 Hz) 7.46 (1H, dd, J=8.8 Hz, 1.2 Hz) 8.13 (1H, d, J=1.2 Hz), 8.49 (1H, brs)	

Table 5 5







Ex.	R ²	R ³	m. p. (°C)	yield (%)	M a s s	NMR	note
404	Cl		210 213 (decomp)		344 (MH ⁺)	δ (DMSO-d ₆) : 4.41 (2H, d, J=6.0 Hz), 4.66 (2H, d, J=5.6 Hz) 4.84 (1H, t, J=6.0 Hz), 5.95 (2H, s) 6.83 (1H, d, J=7.6 Hz) 6.86 (1H, dd, J=7.6 Hz, 1.6 Hz) 6.97 (1H, d, J=1.6 Hz), 7.67 (1H, d, J=8.8 Hz) 7.75 (1H, dd, J=8.8 Hz, 2.4 Hz) 8.40 (1H, d, J=2.4 Hz), 8.78 (1H, t, J=5.6 Hz)	
405	Cl		191- 192	97	400 (M+1)	δ (DMSO-d ₆) : 1.97 (2H, quintet, J=7.4 Hz) 2.26 (2H, t, J=7.4 Hz), 2.72 (2H, t, J=7.4 Hz) 4.65 (2H, d, J=5.7 Hz), 5.97 (2H, s) 6.83 (1H, d, J=8.0 Hz) 6.88 (1H, dd, J=8.0 Hz, 1.6 Hz) 6.96 (1H, d, J=1.6 Hz), 7.63 (1H, d, J=9.0 Hz) 7.73 (1H, dd, J=9.0 Hz, 2.2 Hz) 8.39 (1H, d, J=2.2 Hz), 8.72 (1H, t, J=5.7 Hz)	

Table 5 6




Ex.	R ²	R ¹	m. p. (°C)	yield (%)	M a s s	NMR	note
406	CN		245- 246	55	391 (M+1)	δ (DMSO-d ₆) : 1. 98(2H, quintet, J=7.4Hz) 2. 29(2H, t, J=7.4Hz), 2.75(2H, t, J=7.4Hz) 4. 68(2H, d, J=5.7Hz), 5.97(2H, s) 6. 85(1H, d, J=7.9Hz) 6. 89(1H, dd, J=7.9Hz, 1.6Hz) 6. 98(1H, d, J=8.6Hz), 7.72(1H, d, J=8.6Hz) 8. 02(1H, dd, J=8.6Hz, 1.6Hz) 8. 84(1H, d, J=1.6Hz), 8.96(1H, t, J=5.7Hz)	
407	Cl		201- 202	99	386 (M+1)	δ (DMSO-d ₆) : 2. 71(2H, t, J=7.1Hz), 2.96(2H, t, J=7.1Hz) 4. 65(2H, d, J=5.7Hz), 5.97(2H, s) 6. 85(1H, d, J=7.9Hz) 6. 89(1H, dd, J=7.9Hz, 1.6Hz) 6. 98(1H, d, J=1.6Hz), 7.62(1H, d, J=9.0Hz) 7. 73(1H, dd, J=9.0Hz, 2.2Hz) 8. 39(1H, d, J=3.2Hz), 8.73(1H, t, J=5.7Hz)	

Table 5 7



Ex.	R ²	R ⁵	m. p. (°C)	yield (%)	Mass	NMR	note
409	C1		215 (decomp)	81	505 (MHT ⁺)	δ (DMSO-d ₆) : 1.27(3H, t, J=7.0Hz), 3.21(3H, s) 4.30(2H, q, J=7.0Hz), 4.55(2H, brs) 4.97(2H, s), 5.89(2H, s), 6.52-8.42(10H, m) 12.20(1H, brs)	


Table 5 8



Ex.	R ²	R ³	m. p. (°C)	yield (%)	M a s s	NMR	note
410	Cl		279- 280 (decomp)	91	477 (MII ⁺)	δ (DMSO-d ₆) : 3.07(2H, s), 4.50(2H, brs), 4.81(2H, s) 5.89(2H, s), 6.51-6.88(3H, m) 7.22(2H, d, J=8.0Hz), 7.26(1H, d, J=9.2Hz) 7.48(1H, dd, J=9.2Hz, 2.4Hz) 7.80(2H, d, J=8.0Hz), 8.15(1H, d, J=2.4Hz) 8.58(1H, brs), 12.77(1H, brs)	

Claims


1. A nitrogenous heterocyclic compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof:



R¹, R², R³ and R⁴, which may be the same or different from one another, represent H, halogen, -C≡N, C₁₋₈-alkyl or C₁₋₈-hydroxyalkyl (in both of which a terminal C-atom may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K), acylamino (wherein one or two acyl groups are bonded to the N-atom selected from aliphatic C₁₋₅-acyl, benzoyl, toluoyl, naphthoyl, furoyl, nicotinoyl and isonicotinoyl), optionally protected carboxyl, C₁₋₈-alkoxy, a group -S(=O)_n-R⁷, wherein R⁷ is C₁₋₈-alkyl (wherein a terminal C-atom may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K), and n = 0, 1 or 2, or two of R¹, R², R³ and R⁴ may together form methylenedioxy, ethylenedioxy or a phenyl ring;

R⁵ is H, halogen, -OH, hydrazino, C₁₋₈-alkyl, C₁₋₈-hydroxyalkyl, C₂₋₈-alkenyl, optionally protected carboxyl-C₁₋₈-alkyl or carboxyl-C₂₋₈-alkenyl (in each carboxyl-C₁₋₈-alkyloxy group (wherein in the alkyl moiety a terminal C-atom may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K), a group -NR¹¹R¹² (wherein R¹¹ and R¹², which may be the same or different from each other, each represent H, C₁₋₈-alkyl, C₁₋₈-hydroxyalkyl, C₁₋₈-aminoalkyl optionally protected carboxyl-C₁₋₈-alkyl, or (C₁₋₈-alkyl)carbamoyl (in each of which a terminal C-atom of the alkyl moiety may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K), 1,3-benzoxolyalkyl or 1,4-benzodioxylalkyl, or R¹¹ and R¹², together with the nitrogen to which they are bonded, can form a ring which may contain another nitrogen or oxygen, and which may optionally be substituted with one or two substituents selected from optionally protected -OH, -C≡N, halogen, C₁₋₄-alkyl, C₁₋₄-alkoxy, optionally protected carboxyl, C₁₋₄-hydroxyalkyl, carboxyl-C₁₋₄-alkyl or tetrazolyl;

R⁶ is a group of the formula



wherein R¹⁹ is H, C₁₋₈-alkyl, C₁₋₈-hydroxyalkyl, C₁₋₂-alkoxy-C₁₋₈-alkyl, optionally protected carboxyl-C₁₋₈-alkyl (in each of which a terminal C-atom of the alkyl moiety may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K) or an acyl group selected from aliphatic C₁₋₅-acyl, benzoyl, toluoyl, naphthoyl, furoyl, nicotinoyl and isonicotinoyl; of which a terminal C-atom of the alkyl or alkenyl moiety may be replaced by -ONO₂ or -SO₃X, with X = H, Na or K), optionally protected carboxyl, or C₁₋₈-alkoxy,

a group $-S(=O)_m-R^8$, wherein R^8 is C_{1-8} -alkyl (wherein a terminal C-atom may be replaced by $-ONO_2$ or $-SO_3X$, with $X = H, Na$ or K), and $m = 0, 1$ or 2 ,

a group $-O-R^9$, wherein R^9 is optionally protected C_{1-8} -hydroxyalkyl or carboxy- C_{1-8} -alkyl (in each of which a terminal C-atom may be replaced by $-ONO_2$ or $-SO_3X$, with $X = H, Na$ or K), or benzyl which may optionally be substituted with $-OH$, nitro, halogen, C_{1-4} -alkyl, C_{1-4} -alkoxy, optionally protected carboxyl, C_{1-4} -hydroxyalkyl, carboxyl- C_{1-4} -alkyl or tetrazolyl, a phenyl group substituted with a group R^{23} , R^{23} is $-OH$, or C_{1-8} -alkyl, C_{1-8} -hydroxyalkyl or C_{1-8} -hydroxyalkyloxy (in each of which a terminal C-atom may be replaced by $-ONO_2$ or $-SO_3X$, with $X = H, Na$ or K), or C_{1-8} -alkoxy,

a 5- to 7-membered monocyclic or condensed heteroaryl group containing one or two O-, N-, or S-atom(s) as heteroatom(s) or a 1,3-benzdioxolyl, 1,4-benzdioxolyl, 1,3-benzdioxolylalkyl or 1,4-benzdioxolylalkyl group, which each may optionally be substituted with $-OH$, nitro, halogen, C_{1-4} -alkyl, C_{1-4} -alkoxy, optionally protected carboxyl, C_{1-4} -hydroxyalkyl, carboxyl- C_{1-4} -alkyl or tetrazolyl,

a group $-C(R^{24})=O$ or $-C(R^{24})=N-R^{10}$, wherein R^{24} is H or C_{1-8} -alkyl (wherein in the alkyl moiety a terminal C-atom may be replaced by $-ONO_2$ or $-SO_3X$, with $X = H, Na$ or K) and R^{10} is $-OH$ or an optionally protected R^{20} , R^{21} and R^{22} , which may be the same or different each represent H, halogen, $-OH$, $-NO_2$, amino, C_{1-8} -alkyl, C_{1-2} -alkoxy- C_{1-8} -alkyl, C_{2-8} -alkenyl C_{1-8} -alkylsulfonylamino, hydroxyimino- C_{1-8} -alkyl, mono- or di-((C_{1-8} -alkyl)oxycarbonyl) amino, (C_{1-8} -alkyl)oxycarbonyloxy (in each of which a terminal C-atom of the alkyl or alkenyl moiety may be replaced by $-ONO_2$ or $-SO_3X$, with $X = H, Na$ or K) or C_{1-8} -alkoxy,

an acyl group selected from aliphatic C_{1-5} -acyl, benzoyl, toluoyl, naphtoyl, furoyl, nicotinoyl and isonicotinoyl; an acylamino group, wherein one or two acyl groups as defined above are bonded to the N-atom of the amino group,

a 5- to 7-membered monocyclic or condensed heteroaryl group containing one or two O-, N-, or S-atom(s) as heteroatom(s), which may optionally be substituted with $-OH$, nitro, halogen, C_{1-4} -alkyl, C_{1-4} -alkoxy, optionally protected carboxyl, C_{1-4} -hydroxyalkyl, carboxyl- C_{1-4} -alkyl or tetrazolyl,

or two of R^{20} , R^{21} and R^{22} , together with the carbon atoms to which they are bonded, may form a saturated or unsaturated ring which may contain one or two heteroatom(s) independently selected from O and N, or an S-atom, and r is 0 or an integer of 1 to 8.

2. Compound according to claim 1, wherein R^1 , R^2 , R^3 and R^4 , which may be the same or different from one another, represent H, $-C\equiv N$, halogen or C_{1-8} -alkyl.

3. Compound according to claim 1 or 2, wherein one of R^1 , R^2 , R^3 and R^4 is $-C\equiv N$, chlorine or a methoxy group.

4. Compound according to any of the claims 1 to 3, wherein R^2 is $-C\equiv N$.

5. Compound according to any of the claims 1 to 3, wherein R^2 is a halogen atom.


6. Compound according to claim 5, wherein R^2 is chlorine.

7. Compound according to claim 1, wherein R^2 is a C_{1-8} -alkoxy group.

8. Compound according to claim 7, wherein R^2 is methoxy.


9. Compound according to any of the previous claims, wherein R^5 is a group of the formula $-NR^{11}R^{12}$.

10. Compound according to claim 9, wherein R^5 is a group of the formula




wherein R^{60} is selected from optionally protected $-OH$, $-C\equiv N$, halogen, C_{1-4} -alkyl, C_{1-4} -alkoxy, optionally protected carboxyl, C_{1-4} -hydroxyalkyl, carboxyl- C_{1-4} -alkyl and tetrazolyl.

11. Compound according to claim 10, wherein R^5 is a group of the formula




wherein R^{61} is an optionally protected carboxyl group or tetrazolyl.

12. Compound according to claim 9, wherein R^5 is a group of the formula




wherein R^{61} is an optionally protected carboxyl group, and $u = 3$ or 4 .


13. Compound according to any of the previous claims, wherein R^6 is a group of the formula




14. Compound according to any of the claims 1 to 12, wherein R^6 is a group of the formula




15. Compound or pharmacologically acceptable salt thereof according to claim 1 selected from





and




wherein $u = 3$ or 4 and R^{61} is optionally protected carboxyl.

16. Pharmaceutical composition comprising as the active ingredient an effective amount of a compound and/or a pharmacologically acceptable salt thereof according to any of claims 1 to 15.
17. Use of a compound and/or a pharmacologically acceptable salt thereof according to any of claims 1 to 15 for the production of a pharmaceutical composition effective as preventive or therapeutic agent for diseases against which a phosphodiesterase-inhibitory action is efficacious.
18. Use according to claim 17, wherein the phosphodiesterase-inhibitory action is a cyclic-GMP phosphodiesterase-inhibitory action.
19. Use according to claim 17 or 18, wherein the disease is selected from ischemic heart diseases, angina pectoris, hypertension, heart failure, and asthma.

Patentansprüche

1. Stickstoffhaltige heterocyclische Verbindung der folgenden allgemeinen Formel (1) oder ein pharmakologisch annehmbares Salz davon:



R¹, R², R³ und R⁴, die identisch oder voneinander verschieden sein können, repräsentieren H, Halogen, -C≡N, C₁₋₈-Alkyl oder C₁₋₈-Hydroxyalkyl (in beiden kann ein terminales C-Atom durch -ONO₂ oder -SO₃X ausgetauscht sein, wobei X = H, Na oder K ist), Acylamino (worin ein oder zwei Acylgruppen an das N-Atom gebunden sind, ausgewählt aus aliphatischem C₁₋₅-Acyl, Benzoyl, Toluoyl, Naphthoyl, Furoyl, Nicotinoyl und Isonicotinoyl), gegebenenfalls geschütztes Carboxyl, C₁₋₈-Alkoxy, eine Gruppe -S(=O)_n-R⁷, worin R⁷ C₁₋₈-Alkyl darstellt (worin ein terminales C-Atom ersetzt sein kann durch -ONO₂ oder -SO₃X, wobei X = H, Na oder K ist) und n = 0, 1 oder 2, oder zwei von R¹, R², R³ und R⁴ können miteinander Methylendioxy, Ethylendioxy oder einen Phenylring bilden;

R⁵ ist H, Halogen, -OH, Hydrazino, C₁₋₈-Alkyl, C₁₋₈-Hydroxyalkyl, C₂₋₈-Alkenyl, gegebenenfalls geschütztes Carboxyl-C₁₋₈-alkyl oder Carboxyl-C₂₋₈-alkenyl (worin ein terminales C-Atom der Alkyl- oder Alkenyleinheit ersetzt sein kann durch -ONO₂ oder -SO₃X, wobei X = H, Na oder K ist), gegebenenfalls geschütztes Carboxyl oder C₁₋₈-Alkoxy,

eine Gruppe -S(=O)_m-R⁸, worin R⁸ C₁₋₈-Alkyl ist (worin ein terminales C-Atom durch -ONO₂ oder -SO₃X ersetzt sein kann, wobei X = H, Na oder K ist) und m = 0, 1 oder 2,

eine Gruppe -O-R⁹, worin R⁹ gegebenenfalls geschütztes C₁₋₈-Hydroxyalkyl oder Carboxyl-C₁₋₈-alkyl ist (worin jeweils ein terminales C-Atom durch -ONO₂ oder -SO₃X ersetzt sein kann, wobei X = H, Na oder K ist), oder Benzyl, das gegebenenfalls substituiert sein kann mit -OH, Nitro, Halogen, C₁₋₄-Alkyl, C₁₋₄-Alkoxy, gegebenenfalls geschütztem Carboxyl, C₁₋₄-Hydroxyalkyl, Carboxyl-C₁₋₄-alkyl oder Tetrazolyl,

eine Phenylgruppe, die mit einer Gruppe R²³ substituiert ist, R²³ ist -OH oder C₁₋₈-Alkyl, C₁₋₈-Hydroxyalkyl oder C₁₋₈-Hydroxyalkyloxy (worin jeweils ein terminales C-Atom ersetzt sein kann durch -ONO₂ oder -SO₃X, wobei X = H, Na oder K ist) oder C₁₋₈-Alkoxy,


eine 5- bis 7-gliedrige monocyclische oder kondensierte Heteroarylgruppe, die ein oder zwei O-, N- oder S-Atom(e) als Heteroatom(e) enthält oder eine 1,3-Benzdioxyl-, 1,4-Benzdioxyl-, 1,3-Benzdioxylalkyl- oder 1,4-Benzdioxylalkyl-Gruppe, die jeweils gegebenenfalls substituiert sein kann mit -OH, Nitro, Halogen, C₁₋₄-Alkyl, C₁₋₄-Alkoxy, gegebenenfalls geschütztem Carboxyl, C₁₋₄-Hydroxyalkyl, Carboxyl-C₁₋₄-alkyl oder Tetrazolyl,

eine Gruppe -C(R²⁴)=O oder -C(R²⁴)-N-R¹⁰, worin R²⁴ H oder C₁₋₈-Alkyl ist (worin in der Alkyleinheit ein terminales C-Atom durch -ONO₂ oder -SO₃X ersetzt sein kann, wobei X = H, Na oder K ist), und R¹⁰ ist -OH oder eine gegebenenfalls geschützte Carboxyl-C₁₋₈-alkyloxy-Gruppe (worin in der Alkyleinheit ein terminales C-Atom ersetzt sein kann durch -ONO₂ oder -SO₃X, wobei X = H, Na oder K ist),

eine Gruppe -NR¹¹R¹² (worin R¹¹ und R¹², die identisch oder voneinander verschieden sein können, jeweils H, C₁₋₈-Alkyl, C₁₋₈-Hydroxyalkyl, C₁₋₈-Aminoalkyl, gegebenenfalls geschütztes Carboxyl-C₁₋₈-alkyl oder (C₁₋₈-Alkyl)carbamoyl repräsentieren (worin jeweils ein terminales C-Atom der Alkyleinheit durch -ONO₂ oder -SO₃X ersetzt sein kann, wobei X = H, Na oder K ist), 1,3-Benzoxolylalkyl oder 1,4-Benzdioxylalkyl,

oder R¹¹ und R¹² können zusammen mit dem Stickstoff, an den sie gebunden sind, einen Ring bilden, der einen weiteren Stickstoff oder Sauerstoff enthalten kann, und der gegebenenfalls mit einem oder zwei Substituenten substituiert sein kann, ausgewählt aus gegebenenfalls geschütztem -OH, -C≡N, Halogen, C₁₋₄-Alkyl, C₁₋₄-Alkoxy, gegebenenfalls geschütztem Carboxyl, C₁₋₄-Hydroxyalkyl, Carboxyl-C₁₋₄-alkyl oder Tetrazolyl;

R⁶ ist eine Gruppe der Formel




worin R¹⁹ H, C₁₋₈-Alkyl, C₁₋₈-Hydroxyalkyl, C₁₋₂-Alkoxy-C₁₋₈-alkyl, gegebenenfalls geschütztes Carboxyl-C₁₋₈-alkyl (worin jeweils das terminale C-Atom der Alkyleinheit durch -ONO₂ oder -SO₃X ersetzt sein kann, wobei X = H, Na oder K ist) ist, oder eine Acylgruppe, ausgewählt aus aliphatischem C₁₋₅-Acyl, Benzoyl, Toluoyl, Naphthoyl, Furoyl, Nicotinoyl und Isonicotinoyl;

R²⁰, R²¹ und R²², die identisch oder voneinander verschieden sein können, repräsentieren jeweils H, Halogen,


-OH, -NO₂, Amino, C₁₋₈-Alkyl, C_{1,2}-Alkoxy-C₁₋₈-alkyl, C₂₋₈-Alkenyl, C₁₋₈-Alkylsulfonylamino, Hydroxyimino-C₁₋₈-alkyl, Mono- oder Di-((C₁₋₈-alkyl)oxycarbonyl)amino, (C₁₋₈-Alkyl)oxycarbonyloxy (worin jeweils das terminale C-Atom der Alkyl- oder Alkenyleinheit durch -ONO₂ oder -SO₃X ersetzt sein kann, wobei X= H, Na oder K ist) oder C₁₋₈-Alkoxy,
 5 eine Acylgruppe, ausgewählt aus aliphatischem C₁₋₅-Acyl, Benzoyl, Toluoyl, Naphthoyl, Furoyl, Nicotinoyl und Isonicotinoyl; eine Acylaminogruppe, worin ein oder zwei Acylgruppen wie oben definiert an das N-Atom der Aminogruppe gebunden sind,
 eine 5- bis 7-gliedrige monocyclische oder kondensierte Heteroarylgruppe, die ein oder zwei O-, N- oder S-Atom(e) als Heteroatom(e) enthält, und die gegebenenfalls substituiert sein kann mit -OH, Nitro, Halogen,
 10 C_{1,4}-Alkyl, C_{1,4}-Alkoxy, gegebenenfalls geschütztem Carboxyl, C_{1,4}-Hydroxyalkyl, Carboxyl-C_{1,4}-alkyl oder Tetrazolyl,
 oder zwei von R²⁰, R²¹ und R²² können zusammen mit den Kohlenstoffatomen, an die sie gebunden sind, einen gesättigten oder ungesättigten Ring bilden, der ein oder zwei Heteroatom(e), unabhängig ausgewählt aus O und N, oder ein S-Atom enthalten kann,
 15 und r ist 0 oder eine ganze Zahl von 1 bis 8.

2. Verbindung gemäss Anspruch 1, worin R¹, R², R³ und R⁴, die identisch oder voneinander verschieden sein können, H, -C≡N, Halogen oder C₁₋₈-Alkyl repräsentieren.
- 20 3. Verbindung gemäss Anspruch 1 oder 2, worin eines von R¹, R², R³ und R⁴ -C≡N, Chlor oder eine Methoxygruppe ist.
4. Verbindung gemäss mindestens einem der Ansprüche 1 bis 3, worin R² -C≡N ist.
- 25 5. Verbindung gemäss mindestens einem der Ansprüche 1 bis 3, worin R² ein Halogenatom ist.
6. Verbindung gemäss Anspruch 5, worin R² Chlor ist.
7. Verbindung gemäss Anspruch 1, worin R² eine C₁₋₈-Alkoxygruppe ist.
- 30 8. Verbindung gemäss Anspruch 7, worin R² Methoxy ist.
9. Verbindung gemäss mindestens einem der vorhergehenden Ansprüche, worin R⁵ eine Gruppe der Formel -NR¹¹R¹² ist.
- 35 10. Verbindung gemäss Anspruch 9, worin R⁵ eine Gruppe der Formel




45 ist, worin R⁶⁰ ausgewählt ist aus gegebenenfalls geschütztem -OH, -C≡N, Halogen, C_{1,4}-Alkyl, C_{1,4}-Alkoxy, gegebenenfalls geschütztem Carboxyl, C_{1,4}-Hydroxyalkyl, Carboxyl-C_{1,4}-Alkyl und Tetrazolyl.

11. Verbindung gemäss Anspruch 10, worin R⁵ eine Gruppe der Formel



55 ist, worin R⁶¹ eine gegebenenfalls geschützte Carboxylgruppe oder Tetrazolyl ist.

12. Verbindung gemäss Anspruch 9, worin R⁵ eine Gruppe der Formel




5

ist, worin R^{61} eine gegebenenfalls geschützte Carboxylgruppe und $u = 3$ oder 4 ist.

10


13. Verbindung gemäss mindestens einem der vorhergehenden Ansprüche, worin R^6 eine Gruppe der folgenden Formel darstellt:



15

20


14. Verbindung gemäss mindestens einem der Ansprüche 1 bis 12, worin R^6 eine Gruppe der folgenden Formel darstellt:



25


30

15. Verbindung oder pharmakologisch annehmbares Salz davon gemäss Anspruch 1, ausgewählt aus



35


40



45

50

55




worin $u = 3$ oder 4 und R^{61} gegebenenfalls geschütztes Carboxyl ist.

16. Pharmazeutische Zusammensetzung, die als aktiven Bestandteil eine wirksame Menge einer Verbindung und/oder eines pharmakologisch annehmbaren Salzes davon gemäss mindestens einem der Ansprüche 1 bis 15 umfasst.
17. Verwendung einer Verbindung und/oder eines pharmakologisch annehmbaren Salzes davon gemäss mindestens einem der Ansprüche 1 bis 15 zur Herstellung einer pharmazeutischen Zusammensetzung, die wirksam ist als präventives oder therapeutisches Mittel gegen Krankheiten, gegen die eine Phosphodiesterase-inhibitorische Wirkung wirksam ist.
18. Verwendung gemäss Anspruch 17, worin die Phosphodiesterase-inhibitorische Wirkung eine cyclische GMP-Phosphodiesterase-inhibitorische Wirkung wirksam ist.
19. Verwendung gemäss Anspruch 17 oder 18, worin die Erkrankung ausgewählt ist aus ischämischen Herzerkrankungen, Angina pectoris, Hochdruck, Herzversagen und Asthma.

Revendications

1. Composé hétérocyclique azoté représenté par la formule générale (1) suivante ou sel pharmacologiquement acceptable de celui-ci :




R^1 , R^2 , R^3 et R^4 , qui peuvent être identiques ou différents les uns des autres, représentent H, halogène, $-C\equiv N$, alkyle en C_{1-8} ou hydroxyalkyle en C_{1-8} (dans l'un et l'autre desquels un atome C terminal peut être remplacé par $-ONO_2$ ou $-SO_3X$, avec $X = H, Na$ ou K), acylamino (où un ou deux groupes acyle sont liés à l'atome N choisis parmi acyle en C_{1-5} aliphatique, benzoyle, toluoyle, naphtoyle, furoyle, nicotinoyle et isonicotinoyle), carboxyle éventuellement protégé, alcoxy en C_{1-8} .

un groupe $-S(=O)_n-R^7$ où R^7 est alkyle en C_{1-8} (où un atome C terminal peut être remplacé par $-ONO_2$ ou $-SO_3X$, avec $X = H, Na$ ou K), et $n = 0, 1$ ou 2 , ou bien, parmi R^1 , R^2 , R^3 et R^4 , deux peuvent former ensemble méthylènedioxy, éthylènedioxy ou un cycle phényle ;

R^5 est H, halogène, $-OH$, hydrazino, alkyle en C_{1-8} , hydroxyalkyle en C_{1-8} , alcényle en C_{2-8} , carboxy-alkyle en C_{1-8} ou carboxy-alcényle en C_{2-8} éventuellement protégé (dans chacun desquels un atome C terminal de l'entité alkyle ou alcényle peut être remplacé par $-ONO_2$ ou $-SO_3X$, avec $X = H, Na$ ou K), carboxyle éventuellement protégé, ou alcoxy en C_{1-8} .

un groupe $-S(=O)_m-R^8$ où R^8 est alkyle en C_{1-8} (où un atome C terminal peut être remplacé par $-ONO_2$ ou

-SO₃X, avec X = H, Na ou K), et m = 0, 1 ou 2,
 un groupe -O-R⁹ où R⁹ est hydroxyalkyle en C₁₋₈ ou carboxy-alkyle en C₁₋₈ éventuellement protégé (dans
 chacun desquels un atome C terminal peut être remplacé par -ONO₂ ou -SO₃X, avec X = H, Na ou K), ou
 benzyle qui peut éventuellement être substitué par -OH, nitro, halogène, alkyle en C₁₋₄, alcoxy en C₁₋₄, car-
 boxyle éventuellement protégé, hydroxyalkyle en C₁₋₄, carboxy-alkyle en C₁₋₄ ou tétrazolye,
 un groupe phényle substitué par un groupe R²³, R²³ est -OH ou alkyle en C₁₋₈, hydroxyalkyle en C₁₋₈ ou
 hydroxyalkyloxy en C₁₋₈ (dans chacun desquels un atome C terminal peut être remplacé par -ONO₂ ou -SO₃X,
 avec X = H, Na ou K), ou alcoxy en C₁₋₈,
 un groupe hétéroaryle monocyclique ou condensé à 5 à 7 chaînons contenant un ou deux atomes O, N ou S
 comme hétéroatome(s) ou un groupe 1,3-benzodioxolye, 1,4-benzodioxyle, 1,3-benzodioxolylalkyle ou
 1,4-benzodioxylalkyle, qui peuvent éventuellement être substitués chacun par -OH, nitro, halogène, alkyle en
 C₁₋₄, alcoxy en C₁₋₄, carboxyle éventuellement protégé, hydroxyalkyle en C₁₋₄, carboxy-alkyle en C₁₋₄ ou
 tétrazolye,
 un groupe -C(R²⁴)=O ou C(R²⁴)=N-R¹⁰ où R²⁴ est H ou alkyle en C₁₋₈ (où, dans l'entité alkyle, un atome C
 terminal peut être remplacé par -ONO₂ ou -SO₃X, avec X = H, Na ou K) et R¹⁰ est -OH ou un groupe car-
 boxyalkyloxy en C₁₋₈ éventuellement protégé (où, dans l'entité alkyle, un atome C terminal peut être remplacé
 par -ONO₂ ou -SO₃X, avec X = H, Na ou K),
 un groupe -NR¹¹R¹² (où R¹¹ et R¹², qui peuvent être identiques ou différents l'un de l'autre, représentent
 chacun H, alkyle en C₁₋₈, hydroxyalkyle en C₁₋₈, aminoalkyle en C₁₋₈, carboxy-alkyle en C₁₋₈ éventuellement
 protégé, ou (alkyle en C₁₋₈)carbamoyle (dans chacun desquels un atome C terminal de l'entité alkyle peut
 être remplacé par -ONO₂ ou -SO₃X, avec X = H, Na ou K), 1,3-benzoxolylalkyle ou 1,4-benzodioxylalkyle,
 ou bien R¹¹ et R¹² peuvent former, avec l'azote auquel ils sont liés, un cycle qui peut contenir un autre azote
 ou oxygène, et qui peut éventuellement être substitué par un ou deux substituants choisis parmi -OH éven-
 tuellement protégé, -C≡N, halogène, alkyle en C₁₋₄, alcoxy en C₁₋₄, carboxyle éventuellement protégé, hy-
 droxyalkyle en C₁₋₄, carboxy-alkyle en C₁₋₄ ou tétrazolye ;
 R⁶ est un groupe de formule



où R¹⁹ est H, alkyle en C₁₋₈, hydroxyalkyle en C₁₋₈, alcoxy en C₁₋₂-alkyle en C₁₋₈, carboxy-alkyle en C₁₋₈
 éventuellement protégé (dans chacun desquels un atome C terminal de l'entité alkyle peut être remplacé par
 -ONO₂ ou -SO₃X, avec X = H, Na ou K) ou un groupe acyle choisi parmi acyle en C₁₋₅ aliphatique, benzoyle,
 toluoyle, naphtoyle, furoyle, nicotinoyle et isonicotinoyle ;

R²⁰, R²¹ et R²², qui peuvent être identiques ou différents, représentent chacun H, halogène, -OH, -NO₂, amino,
 alkyle en C₁₋₈, alcoxy en C₁₋₂-alkyle en C₁₋₈, alcényle en C₂₋₈, alkylsulfonylamino en C₁₋₈, hydroxyimino-alkyle
 en C₁₋₈, mono- ou di-((alkyle en C₁₋₈) oxycarbonyl)amino, (alkyle en C₁₋₈)oxycarbonyloxy (dans chacun des-
 quels un atome C terminal de l'entité alkyle ou alcényle peut être remplacé par -ONO₂ ou -SO₃X, avec X =
 H, Na ou K) ou alcoxy en C₁₋₈.

un groupe acyle choisi parmi acyle en C₁₋₅ aliphatique, benzoyle, toluoyle, naphtoyle, furoyle, nicotinoyle et
 isonicotinoyle ; un groupe acylamino, où un ou deux groupes acyle tels que définis ci-dessus sont liés à l'atome
 N du groupe amino,

un groupe hétéroaryle monocyclique ou condensé à 5 à 7 chaînons contenant un ou deux atomes O, N ou S
 comme hétéroatome(s), qui peut éventuellement être substitué par -OH, nitro, halogène, alkyle en C₁₋₄, alcoxy
 en C₁₋₄, carboxyle éventuellement protégé, hydroxyalkyle en C₁₋₄, carboxy-alkyle en C₁₋₄ ou tétrazolye,


ou bien, parmi R²⁰, R²¹ et R²², deux peuvent former, avec les atomes de carbone auxquels ils sont liés, un cycle
 saturé ou insaturé qui peut contenir un ou deux hétéroatomes choisis indépendamment parmi O et N, ou un atome
 S,

et r est 0 ou un entier de 1 à 8.

2. Composé selon la revendication 1 où R¹, R², R³ et R⁴, qui peuvent être identiques ou différents les uns des autres,
 représentent H, -C≡N, halogène ou alkyle en C₁₋₈.


EP 0 607 439 B1

3. Composé selon la revendication 1 ou 2 où, parmi R^1 , R^2 , R^3 et R^4 , l'un est $-C\equiv N$, le chlore ou un groupe méthoxy.
4. Composé selon l'une quelconque des revendications 1 à 3 où R^2 est $-C\equiv N$.
5. Composé selon l'une quelconque des revendications 1 à 3 où R^2 est un atome d'halogène.
6. Composé selon la revendication 5 où R^2 est le chlore.
7. Composé selon la revendication 1 où R^2 est un groupe alcoxy en C_{1-8} .
8. Composé selon la revendication 7 où R^2 est méthoxy.
9. Composé selon l'une quelconque des revendications précédentes où R^5 est un groupe de formule $-NR^{11}R^{12}$.
10. Composé selon la revendication 9 où R^5 est un groupe de formule




où R^{60} est choisi parmi $-OH$ éventuellement protégé, $-C\equiv N$, halogène, alkyle en C_{1-4} , alcoxy en C_{1-4} , carboxyle éventuellement protégé, hydroxyalkyle en C_{1-4} , carboxy-alkyle en C_{1-4} et tétrazolyle.

11. Composé selon la revendication 10 où R^5 est un groupe de formule




où R^{61} est un groupe carboxyle éventuellement protégé ou tétrazolyle.

12. Composé selon la revendication 9 où R^5 est un groupe de formule




où R^{61} est un groupe carboxyle éventuellement protégé, et $u = 3$ ou 4 .



13. Composé selon l'une quelconque des revendications précédentes où R^6 est un groupe de formule




14. Composé selon l'une quelconque des revendications 1 à 12 où R^6 est un groupe de formule



15. Composé ou sel pharmacologiquement acceptable de celui-ci selon la revendication 1 choisi parmi



et



où $u = 3$ ou 4 et R^{61} est carboxyle éventuellement protégé.

16. Composition pharmaceutique comprenant comme ingrédient actif une quantité efficace d'un composé et/ou d'un sel pharmacologiquement acceptable de celui-ci selon l'une quelconque des revendications 1 à 15.

17. Utilisation d'un composé et/ou d'un sel pharmacologiquement acceptable de celui-ci selon l'une quelconque des revendications 1 à 15 pour la production d'une composition pharmaceutique efficace comme agent préventif ou thérapeutique pour les maladies contre lesquelles une action d'inhibition de phosphodiesterase est efficace.

EP 0 607 439 B1

18. Utilisation selon la revendication 17 où l'action d'inhibition de phosphodiesterase est une action d'inhibition de GMP cyclique phosphodiesterase.

19. Utilisation selon la revendication 17 ou 18 où la maladie est choisie parmi les cardiopathies ischémiques, l'angine de poitrine, l'hypertension, l'insuffisance cardiaque et l'asthme.

10

15

20

25

30

35

40

45

50

55